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Abstract 
Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial 
pathogen worldwide, responsible for ~90 million new cases of disease each year, with 
asymptomatic infections giving rise to sequelae such as pelvic inflammatory disease, 
ectopic pregnancy and infertility in women. Aggressive ‘seek and treat’ public health 
measures have not stemmed the rise of Ct infections, leading to proposal of the 
‘arrested immunity’ hypothesis, where herd immunity within a population is blunted 
following earlier treatment with antibiotics. This suggests vaccination as the next key 
step in potentially eliminating Ct infections. Due to the paucity of robust clinical data, 
protective immune parameters have largely been derived from studies in mice, where 
pathogen-specific Th1-type immunity involving CD4+ T cells has been the focus of 
preclinical vaccine development. Our study represents the first preclinical 
characterization of a novel, rationally designed second-generation lipid adjuvant 
(SLA) in combination with the highly conserved recombinant Ct polymorphic 
membrane protein D (rPmpD) antigen. We demonstrate robust protection against 
urogenital Ct infection in the C57BL/6 murine model, characterized by significantly 
enhanced resistance to infection and reduction in mean bacterial load. However, 
enhanced Th1-type immunity was not found to correlate with relative protection, 
which rather coincided with the presence of robust rPmpD-specific serum and 
cervico-vaginal IgG titres. Prior to our study, the only convincing evidence of 
neutralizing antibodies effecting protection against chlamydial infection in vivo has 
emerged from studies employing the antigenically variable Ct MOMP as a vaccine 
immunogen. We propose that anti-rPmpD antibodies may play a significant role in 
vaccine-induced protection against urogenital Ct challenge, and that the role of 
antibodies warrants further investigation in future Ct vaccine development. 
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Chapter 1: General Introduction 
1.1 Chlamydia trachomatis 
Chlamydia trachomatis (Ct) is a Gram-negative obligate intracellular bacterial 
pathogen of humans, and the causative agent of sexually transmitted disease and 
blinding trachoma. Indeed, the first reliable mentions of ocular disease were 
documented in the Ebers papyrus as early as 1553-1550 BC (Clarke, 2011). However, 
despite these early records, little is known about the origins of Ct, and no evidence of 
a common ancestor has been isolated from primates, our closest living relatives. 
These observations indicate that Ct is an ancient pathogen, likely to have co-evolved 
solely with humans for millennia.  
 
Halberstaedter and von Prowazek first described these organisms in 1907 through 
examination of trachoma patient isolates (Clarke, 2011). Staining revealed that Ct 
elementary bodies (EBs) were cloaked within a membranous compartment in host 
cells. Assuming these organisms to be protozoan, the discoverers originally named 
them ‘chlamydozoa’, after the Greek word ‘χλαµύδα’ meaning ‘cloak’. However, a 
seminal breakthrough occurred in 1957, when propagation of Ct in hens’ eggs by 
T’ang and colleagues allowed for preservation and culture of the Chlamydia, when it 
was subsequently observed that Ct possessed a cell wall, and further showed 
susceptibility to antibiotics, resulting in classification as a distinct species within a 
unique bacterial phylum now known as the Chlamydiales (Moulder, 1966).  
 
1.2 Life Cycle of the Chlamydiales 
The Chlamydiales all undergo a unique biphasic developmental cycle, and nearly all 
related species possess a distinctive outer membrane complex (COMC) that differs 
	 18	
entirely in composition from all other bacteria (Everett and Hatch, 1995). Infectious 
elementary bodies (EB) are metabolically inactive (~0.3µm in diameter), and contain 
an exclusively cysteine-rich (Cys-rich) disulphide-linked COMC that is thought to 
confer extracellular osmotic stability as the functional equivalent of peptidoglycan 
(Hatch, 1996).  
 
Following internalization, the EB membrane then undergoes disulphide reduction and 
expansion within the intracellular chlamydial inclusion as the bacterium differentiates 
into metabolically active and larger (~1µm) reticulate bodies (RB) that multiply 
through binary fission (Hatch, Allan and Pearce, 1984). After replication within the 
inclusion, RBs differentiate back into EBs and egress through cell lysis or extrusion to 
infect neighboring cells (Fig.1.1). In addition to the two classical EB and RB 
morphological phenotypes, Ct RBs have also evolved to combat host defence 
strategies through development of a persistent form. These are observed in the 
presence of antibiotic treatment in vitro, and in response to the production of host 
IFN-γ that leads to intracellular tryptophan starvation (Beatty et al., 1994). Following 
removal of IFN-γ or antibiotic treatment in vitro, these persistent morphotypes re-
differentiate back in to infectious elementary bodies that can infect new cells (Skilton 
et al., 2009). 
 
Importantly, chlamydial species are also responsible for a wide range of veterinary 
and opportunistic zoonotic diseases. C.pneumoniae is associated with atherosclerosis 
and non-hospital acquired pneumonia, C.psittaci with psittacosis outbreaks and 
C.abortus with abortion in pregnant women (Longbottom and Coulter, 2003). Thus, 
given the extremely high degree of genomic synteny between Ct and many other 
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established and emerging species of pathogenic Chlamydiae (Voigt, Schofl and Saluz, 
2012), the outcomes of a wide array of independent or inter-related Ct research fields 
are also likely to have impact for the ‘One Health Initiative’ (Bidaisee and 
Macpherson, 2014). 
 
1.3 Chlamydia trachomatis disease phenotypes 
Ct strains have historically been divided into three major clades that cause radically 
different pathologies. However, despite >98% overall genomic synteny and identity 
across the entirety of the ~1.04Mbp genome, key factors that lead to distinct 
pathology and tropism remain unknown (Carlson et al., 2005). Ct serovars A-C 
primarily infect human conjunctival epithelial cells, causing inflammation of ocular 
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mucous membranes. If left untreated, repeated infections typically lead to trichiasis 
and corneal opacities, followed by subsequent blindness. Serovars D-K are 
responsible for the majority of non-invasive urogenital infections that show tropism 
for the single cell columnar epithelium of the ectocervix of women and the male 
urethra (Brunham and Rappuoli, 2013). LGV serovars are the most invasive Ct 
serotype, and sexually transmitted infections lead to systemic dissemination of 
bacteria, causing swelling and ulceration of lymph nodes; more characteristic of 
bubonic diseases such as plague (Brunham and Rappuoli, 2013). More recently 
however, an atypical outbreak of LGV has arisen in Europe, primarily in men who 
have sex with men (MSMs). This is characterized by a non-classical manifestation of 
the disease, as the associated L2b strain exhibits a predominantly rectal tropism, 
presenting clinically with proctitis (Thomson et al., 2008).  
 
Genital and LGV strains are the most common sexually transmitted bacterial 
pathogens, responsible for ~90 million new cases of disease each year (Marrazzo and 
Suchland, 2014). It is important to note that urogenital infections are asymptomatic in 
30-50% of men and 70-90% of women (Peipert, 2003). Hence, major complications 
occur predominantly in women, and arise from untreated ascending infections that 
infiltrate the endometrium and fallopian tubes causing pelvic inflammatory disease 
(PID), ectopic pregnancy and infertility (Fig.1.2). An additional complication known 
as Fitz-Hugh-Curtis syndrome may arise more rarely, involving liver capsule 
inflammation (Peter, Clark and Jaeger, 2004).  
 
In addition, because Ct is an immunizing as well as immune-sensitizing infection, and 
pathology is often immune-mediated (Rekart et al., 2013), the careful choice of 
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antigen and adjuvant are likely to be crucial factors in the successful development of 
prophylactic or therapeutic vaccines. Thus, the delineation of immune correlates of 
protection in preclinical models of Ct infection is of paramount importance. 
 
 
1.4 Immunobiology of C.trachomatis infection 
The immunobiology of genital chlamydial infection has been extensively studied 
using two closely related chlamydial species - C.muridarum and C.trachomatis. Most 
studies have been undertaken in murine models of infection, although fundamental 
differences in bacterial virulence, tropism and pathogenesis between these two species 
in their natural hosts limit direct extrapolation of some of these findings to human 
infection. Firstly, Cm is a mouse pneumonitis strain, and does not show natural 
tropism for the female reproductive tract. Secondly, when infected intra-vaginally, 
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most murine strains generally clear Cm and Ct within four weeks, whereas Ct 
infection in humans is a chronic disease (Darville et al., 1997). Thus, while insight on 
the immune response to acute Ct infection may be gained from the study of murine 
models, it is likely that observed mechanisms of pathogenesis might not be 
representative of that in humans. 
 
Animal models have clearly established that control and resolution of natural 
infection with Chlamydia spp. correlates with and is dependent upon on CD4+ effector 
T cells of the Th1 subtype. Nude mice fail to control infection, but adoptive transfer 
of CD4+ or CD8+  Chlamydia-specific T cells allows these mice to control infection 
(Ramsey and Rank, 1991; Rank, Soderberg and Barron, 1985). In the Cm infection 
model, adoptive transfer of Cm-specific CD4+ Th1- but not Th2-cell clones led to 
significant protection against genital tract infection (Hawkins, Rank and Kelly, 2002). 
Furthermore, it has become apparent that CD4+ T cells secreting IFN-γ are crucial for 
the control of Cm infection, as mice deficient in MHC Class II molecules (Morrison, 
Feilzer and Tumas, 1995), CD4 marker (Morrison et al., 2000), IL-12 (Perry, Feilzer 
and Caldwell, 1997), IFN-γ (Wang et al., 1999) or IFN-γ receptor (Johansson et al., 
1997) all fail to control Cm infection when compared to wild-type controls. 
 
The role for CD8+ T cells and B cells in the resolution of primary infection remains 
less categorical and rather more circumstantial, as mice deficient in key CD8+ T cell 
cytolytic effector molecules (perforin and FAS) show no significantly diminished 
ability to control or clear Cm infection (Perry et al., 1999). In addition, B cell 
deficient mice are also found to show similar clearance kinetics and control of Cm 
infection as wild-type controls (Ramsey, Soderberg and Rank, 1988). However, 
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studies conducted on the resolution of secondary infection have revealed an important 
role for B cells in subsequent Ct clearance following depletion of CD4+ and CD8+ T 
cells (Morrison and Morrison, 2001; Morrison et al., 2000), while in the Cm model of 
infection, Fc-receptor knockout mice display more severe secondary infection than 
their wild-type counterparts, which points to a role for B cells and antibodies in the 
promotion and enhancement of effective T cell responses (Moore et al., 2002).  
 
Taken together, in vivo studies of natural infection in the most commonly used murine 
models of Ct and Cm infection reveals a crucial role for antigen-specific CD4+ 
effector T cell function in resolution of primary infection, and a possible synergistic 
role for antibodies and B cells in control of secondary infections. These latter effects 
are likely mediated through direct neutralization of bacterial infection in the lower 
genital tract, increased antigen presentation to T cells and possible antibody-
dependent cell-mediated cytotoxicity (Igietseme et al., 2004; Moore et al., 2003). This 
is summarized in Fig.1.3. 
 
1.4.1 Cellular and immunological hypotheses of C.trachomatis pathology 
While the immune responses to natural infection have been useful in guiding the 
development of preclinical Ct vaccines, investigation of the mechanisms of 
pathogenesis are less well understood, and evidence from human studies remains 
largely correlative. However, following an array of clinical observations in humans 
and studies in mice, two theories have been proposed for the pathogenesis of Ct 
infection: the ‘immunological’ and ‘cellular’ hypotheses. However, these are not 
mutually exclusive. 
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The immunological hypothesis is founded on the premise that immune responses to 
persistent Ct infection lead to tissue damage that manifests as clinical disease (fibrosis 
and scarring). Interestingly, studies have found that HSP60, a chlamydial antigen, is 
recognized by T and B cells in humans and nonhuman primates, and predisposes 
individuals to an increased risk of PID and delayed-type hypersensitivity reactions 
(Lichtenwalner et al., 2004; Peeling et al., 1997; Yi, Yang and Brunham, 1997). A 
role for autoreactive CD4+ and CD8+ T cells that arise following Ct infection have 
been implicated in the aetiology of post-infection sequelae such as reactive arthritis, 
and are thought to be the result of molecular mimicry leading to the development of 
cross-reactive T cell clones (Goodall et al., 2001; Hassell et al., 1993). Furthermore, it 
has been observed that Th2-type responses that may develop during infection 
correlate with persistence, and may temper protective Th1-type responses, which also 
corroborate findings in IL-10 gene knockout mice that show enhanced Th1-type 
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protective immune responses following Cm infection (Holland et al., 1996; Igietseme 
et al., 2000; Yang et al., 1999).  
 
The cellular hypothesis maintains that cytokines and chemokines secreted by infected 
epithelial cells lead to the recruitment and priming of antigen-specific immune cells, 
and hence, the ensuing exacerbation of pathology following persistent or repeated 
infection (Stephens, 2003). This hypothesis was proposed following observations that 
Ct-infected epithelial cells secrete IL-8, granulocyte macrophage colony-stimulating 
factor (GM-CSF), IL-1α and IL-6 in vitro (Rasmussen et al., 1997). This further 
extends to C.pneumoniae, where infected endothelial cells are observed to secrete IL-
8, indicating similarities in chlamydial pathology at the genus level (Molestina et al., 
1999). Overall, it is thought that chlamydial infection is likely to lead to the 
development of lymphoid follicles with both antigen-specific and non-specific 
effector functions, and that persistence of infections through chlamydial immune 
evasion strategies leads to cyclical chemokine secretion and amplification of the 
immune response that exacerbates pathology. This is illustrated in Fig.1.4. 
 
This link between the immunological and cellular hypotheses may also lead to 
observed pathological phenotypes such as tissue remodeling and scarring in both 
genital and ocular disease. Studies have shown that Ct-infected epithelial cells also 
secrete IL-11, a cytokine known to be involved in tissue fibrosis (Dessus-Babus et al., 
2002), and infected mammalian cells were also found to show up-regulation of 
fibroblast growth factor, endothelial growth factor and connective tissue growth factor 
(Coombes and Mahony, 2001; Hess et al., 2001). This evidence suggests a key role 
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for cellular mechanisms of pathogenesis initiated by variable cytokine and chemokine 
secretion profiles of epithelial cells during chlamydial infection.  
 
 
 
The two paradigms have important implications for the design of future vaccines, 
especially where the selection of protective versus immunopathogenic antigens is of 
primary importance. It is also increasingly appreciated that a greater understanding of 
immunogenetics within the human population may provide clues on rational 
chlamydial vaccine design by using cohort comparison studies with isolation and high 
throughput screening of T cells from patients that show resistance or susceptibility to 
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pathology following infection. This may further inform the rational selection of 
broadly protective Ct antigens for incorporation in to multicomponent vaccines. 
 
1.5 Progress in C.trachomatis vaccinology 
Treatment of chlamydial infections is currently accomplished through administration 
of doxycycline or azithromycin (Wetten et al., 2015). While antibiotics are thought to 
be efficacious at clearance of primary infection, they are not effective at preventing 
reinfection, which exacerbates pathology (Brunham and Rey-Ladino, 2005). Although 
not widely studied, it is becoming increasingly apparent that some chlamydial 
infections are recalcitrant to antibiotic treatment, and failures have been reported in 
the clinic, particularly with regard to ano-rectal and urogenital repeat infections 
(Hocking et al., 2015; Kong et al., 2015). This has largely been attributed to factors 
such as differential drug pharmacokinetics, autoinoculation from rectum to cervix in 
women and major differences in the genital microbiome (Kong et al., 2015). 
Furthermore, although anatomically proximate, immune priming of the rectal and 
genital tracts varies during natural infection and is dependent on vaccination route 
(Mestecky, Moldoveanu and Russell, 2005). Although an obligate intracellular 
lifestyle was initially thought to prevent extensive lateral gene transfer and likely 
acquisition of antibiotic resistance, recent evidence shows that there are no absolute 
barriers to recombination within and between Ct serovars despite this intracellular 
niche (Harris et al., 2012), and that these bacteria do possess the ability for the 
transfer of tetracycline resistance in vitro (Suchland et al., 2009).  
 
Public health measures to control Ct infections since the early 1990s have largely 
promoted a ‘seek and treat’ approach at the community level. However, screening and 
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antibiotic regimens represent a substantial cost and burden to public health resources 
in both developed and developing countries. The UK National Chlamydia Screening 
Programme expenditure reached an excess of £100M between 2003-2009, while 
treatment, diagnosis and screening expenditure exceeded $2billion p.a. in the US 
(Donovan, 1997; Riha et al., 2011). Interestingly, following a study of Ct infection in 
women aged between 15-39 years in British Columbia, it has recently been proposed 
that while cases of reported PID have dropped substantially since 1995, Ct infection 
rates continue to rise (Brunham and Rekart, 2008).  
 
This led the authors to propose the hypothesis of ‘arrested immunity’, which 
postulates that early detection and treatment of Ct infection blunts the acquisition of 
naturally acquired immunity to infection within individuals, which in turn abrogates 
herd immunity within a population. Indeed, a study in mice showed that early 
treatment with doxycycline blunts the development of protective immunity (Su et al., 
1999). Epidemiological evidence supporting the acquisition of naturally acquired 
immunity in humans was obtained from clinical studies of a cohort of sex workers in 
Nairobi (Kenya), where resistance to Ct infection was found to be proportional to the 
duration of prostitution irrespective of age (Brunham et al., 1996). However, in 
humans, it has also been found that immunity takes a long time to develop (Molano et 
al., 2005), most likely due to immune evasion strategies employed by Ct. Phase 
variation of polymorphic outer membrane proteins (Pmps), chimerism of the major 
protective antigen MOMP, and a predominantly intracellular environmental niche are 
the main strategies employed by the pathogen to evade immune surveillance. This has 
led researchers to propose rationally designed vaccines as the next step in controlling 
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Ct infections. However, a greater understanding of a plethora of key components will 
be required for chlamydial vaccine development. These include:  
 
(i) An increased understanding of the applicability of commonly used animal 
models to study human chlamydial disease 
(ii) Furthering our understanding of the unique immunological properties of 
the genital tract mucosa for enhancement of vaccine-mediated mucosal 
immunity 
(iii) Prioritizing the design of a new generation of novel adjuvants to elicit T 
cell-mediated immune responses for optimum prevention or resolution of 
Ct infection 
(iv) Developing an informed knowledge of the mechanisms of attachment and 
pathogenesis of Ct, in order to facilitate antigen prioritization for vaccine 
development 
These four key areas will be discussed in the following section. 
 
1.5.1 Animal models of chlamydial infection 
The four main species employed to study genital chlamydial infection comprise the 
macaque, guinea pig, domestic pig and murine models. Each model presents with its 
individual advantages and drawbacks, although no model perfectly replicates the 
anatomical features or endocrinology of the human reproductive tract (De Clercq, 
Kalmar and Vanrompay, 2013).  
 
The pig-tailed macaque (Macaca nemestrina) is perhaps the most representative 
model for studying human Ct genital tract infections, as anatomy and physiology 
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closely mimics that of the human reproductive tract, with similar vaginal microflora 
and a 28-30 day menstrual cycle (Patton et al., 1996; Patton, Sweeney and Paul, 
2009). Furthermore, no pretreatment with progesterone to initiate a productive 
infection (as required in murine models) is necessary in this species, which shows 
natural susceptibility to Ct infection (Patton, Sweeney and Paul, 2009). Two separate 
models have been developed to study Ct infections in the pig-tailed macaque, the in 
situ model and the subcutaneous pocket model (Patton et al., 1983; Patton et al., 
1987). However, the expense, ethical approval and expertise required to work with 
nonhuman primates precludes widespread use of this model. 
 
Another very useful model for studying chlamydial infection is the guinea pig, which 
acquires C.caviae infection that manifests as inclusion conjunctivitis, and is hence 
known as the guinea pig inclusion conjunctivitis (GPIC) model (Murray, 1964). 
Easier handling, cheaper costs and maintenance of these animals allow for larger 
preclinical studies for evaluation of vaccines. Most notably, infection in guinea pigs 
can be sexually transmitted (Mount, Bigazzi and Barron, 1973), and perinatal 
infection has been observed in neonates, similar to human infections (Mount, Bigazzi 
and Barron, 1972). The female reproductive tract is also much more similar to that of 
humans than other commonly used small rodents such as mice (Vanrompay, Lyons 
and Morre, 2006). 
 
Importantly, the domestic pig (Sus scrofa domesticus) has also highlighted significant 
advantages in modeling of Ct infections, and more importantly, in addition to 
investigation of the immunobiology of Ct infection, also offers the advantage of 
studying pathogenesis of Ct infection, as urogenital Ct serovars E/Bour or E/468 lead 
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to ascending infection following intravaginal inoculation of 16-week old specific 
pathogen-free pigs (Vanrompay et al., 2005). This model has further been utilized to 
test the efficacy of preclinical recombinant subunit vaccines. Ct PmpG and SctC 
showed protective immunity against experimental genital infection, characterized by 
reduced bacterial shedding (Schautteet et al., 2011). Importantly, porcine reproductive 
tract tissue shows remarkably similar gene expression to the human genital tract 
(Dawson et al., 2013), and comparison of the porcine, murine and human immune 
systems has found that ~80% of the porcine immune system parameters investigated 
were more similar to humans than their murine equivalents. Finally, pigs are naturally 
susceptible to a wide array of chlamydial organisms including C.abortus, C.pecorum, 
C.psittaci, and C.suis. C.suis further shares a high degree of genomic identity and 
synteny with C.trachomatis (Suchland et al., 2009). However, despite the numerous 
inherent advantages of the aforementioned models, for practical reasons, which 
include the availability of specific knockout strains, a wide range of readily available 
immunological reagents, low cost, high experimental numbers and ease of 
maintenance and housing, the murine model is still most widely used to investigate Ct 
infections, and will therefore be discussed here in more detail.  
 
1.5.2 Murine model of chlamydial infection and pathogenesis 
As previously discussed, both human and murine strains (C.muridarum and 
C.trachomatis) have been used to study chlamydial immunobiology and correlates of 
immune protection in vivo. With regard to investigation of human urogenital 
infections, neither model represents all aspects of pathogenesis and infection well 
enough, although immune correlates of the resolution of acute chlamydial infection 
	 32	
may hold greater relevance to human disease for guiding preliminary design and 
investigation of vaccines.  
 
C.muridarum was originally isolated from the lungs of mice (Nigg, 1942), and when 
used to study genital infections, is employed in an anatomically distinct eco-niche that 
is physiologically quite different from the respiratory mucosa for which it shows 
natural tropism. Most Cm intravaginal infections rapidly ascend to the uterine horns 
and ovarian bursa, eliciting classic symptoms of hydrosalpinx, fibrosis, and ensuing 
infertility (de la Maza et al., 1994; Shah et al., 2005). However, mice typically clear 
infection within about 4 weeks with secondary Cm infections also much more short-
lived, indicating the acquisition of long-lived adaptive immunity that does not always 
occur in humans following primary Ct genital infection (Barron et al., 1981; 
Morrison, Feilzer and Tumas, 1995). 
 
Conversely, the human pathogen Ct elicits mostly a mild genital infection in mice, 
which is usually unable to ascend to the upper genital tract, although some strains 
have been shown to infect the endometrium and ovarian bursa (Carmichael et al., 
2013; Sturdevant et al., 2010). While typical inoculating doses for establishment of 
productive Cm infections consist of ~1500 inclusion forming units (IFU), most 
noninvasive urogenital Ct strains require both a much higher inoculating dose (~106-
108 IFU), as well as pretreatment of mice with progesterone to optimize bacterial 
infections. This limits investigation of hormonal contributions and the influence of the 
menstrual cycle on the acquisition of Ct infection in both murine models, although 
progesterone pretreatment may be dispensable for achieving productive Cm infections 
depending on inoculating dose (Ramsey et al., 1999). Because of the inability of Ct 
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infections to frequently infiltrate the upper genital tract, post-infection sequelae can 
only be studied when Ct bacteria are inoculated directly in to the uterine horns. 
 
Although confounding, it has been observed that Ct infections in mice can resolve in 
the absence of adaptive immunity, whereas adaptive immunity is indispensable for 
resolution of Cm infections (Morrison et al., 2011; Tuffrey, Falder and Taylor-
Robinson, 1982). Interestingly, although phylogenetically most closely related, subtle 
genetic differences between the two species may determine virulence in vivo. The Cm 
biovar lacks allelic variation of MOMP (a major Ct immune evasion strategy) and the 
immunological effects of the cytokine IFNγ differ between human and mouse models 
for the respective strains (O'Meara, Andrew and Beagley, 2014).  
 
In Ct, non-invasive urogenital serovars possess the trpBA operon that counteracts the 
effects of IFNγ-mediated tryptophan starvation. However, in mice, these effects are 
not observed, as IFNγ is thought to upregulate interferon regulated genes (IRGs) that 
reduce sphingolipid trafficking to the chlamydial inclusion and cause lipid starvation 
(Nelson et al., 2005). This may explain the rapid clearance and lack of ascending 
infections in the murine model of Ct infection for most serovars, as innate immunity 
may be sufficient to control lower genital tract infection. Intra-vaginal infection with 
Cm typically leads to ascending infection and pathology as bacteria infiltrate the 
endometrium and uterine horns causing hydrosalpinx (Carey et al., 2009). It has been 
suggested that in mice, Cm may have evolved to counteract disparate IFN-γ-mediated 
effects through inactivation of host cell IRGs, although this hypothesis requires 
further interrogation (Van Voorhis et al., 1997). 
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Of notable interest is the expression of three functional orthologs of the CT166 
cytotoxin in Cm, whereas noninvasive urogenital Ct strains have one functional copy, 
with ocular and LGV strains possessing truncated versions of the gene (Carlson et al., 
2004; Lo et al., 2012). Thus, the unknown role of this putative glycosyltransferase 
may also influence the observed differential outcomes of pathogenesis in mice 
between the two chlamydial biovars. However, it is still unclear as to which of the 
two murine models of infection are more representative of human infection. Indeed, it 
could be argued that the Ct model, which results in an acute self-limiting infection, is 
in fact more representative of natural primary infections in humans. Equally, the Cm 
model elicits more virulent ascending infection to the upper genital tract, with 
accompanying pathology representative of post-infection sequelae in women, but the 
infection is not chronic and usually cleared within a month. While subtle differences 
in Ct strains within mouse models can dictate infection outcome, differences in the 
genetic background of individual mouse strains further predisposes to the severity of 
disease outcomes, and this will be discussed next. 
 
1.5.3 Mouse strain variation in chlamydial infection and pathogenesis 
Differences in the course and outcome of chlamydial infections have been studied in 
three of the most commonly used mouse strains used to investigate pathogenesis 
(Darville et al., 1997; Darville et al., 2001b). These comprise C57BL/6, Balb/c and 
C3H/HeN mice. It was initially observed that differences in cytokine profiles of these 
three mouse strains was found to correlate with both duration of infection and 
incidence of pathology following primary intravaginal infection with the Cm mouse 
pneumonitis biovars (Darville et al., 1997). 
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C57BL/6 mice cleared bacteria most quickly, showing on average a 22-day course of 
infection. The Balb/c strain showed similar shedding kinetics, clearing Cm infection 
by day 25 following infection, while C3H/HeN mice showed markedly increased 
duration of shedding, with bacterial clearance achieved 38 days post challenge. 
Interestingly, the incidence of upper genital tract pathology was also markedly 
different between the three strains, with less than 50% of C57BL/6 (14/30) animals 
showing severe oviduct dilation, while 80% (24/30) and 97% (29/30) of the C3H/HeN 
and Balb/c mice (respectively) showing hydrosalpinx 42 days post infection with Cm 
(Darville et al., 2001b).  
 
Inspection of cervico-vaginal secretions revealed significantly elevated TNFα and 
IL1β in all C57BL/6 and Balb/c mouse strains when compared to C3H/HeN mice. 
Importantly, the level of murine macrophage inflammatory protein MIP-2 (the 
putative functional equivalent of human chemokine IL-8) was found to be sustained 
in C3H mice relative to the other two strains one week post-infection, most likely due 
to the increased duration of the infection, but Balb/c mice showed significantly 
elevated levels of MIP-2 compared to both other mouse strains at early time points 
during infection (days 2-5). MIP-2 is found to be responsible for recruitment and 
activation of neutrophils to the genital tract (Cacalano et al., 1994). These 
observations suggest that inter-strain variations in the kinetics of specific cytokine 
profiles dictate the course of infection and may also influence pathology that is likely 
immune-mediated.  
 
This lends credence to both the cellular and immunological paradigms of chlamydial 
pathogenesis, as prolonged infection is mirrored by secretion of MIP-2 that likely 
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leads to enhanced recruitment and sustained activation of neutrophils, with 
concomitant pathology (hydrosalpinx). Indeed, this has been shown to occur in 
Chlamydia-infected epithelial cells in vitro (Rasmussen et al., 1997). However, due to 
the pleiotropic nature of many cytokines, dissection of cytokine-specific mechanisms 
of pathogenesis are difficult to study in vivo, and other cytokines postulated to be 
involved in resolution or persistence of chlamydial infection such as IL-12, IL-10, IL-
4 and IFNγ were not investigated here.  
 
In a separate study, it has been shown that Cm utilized in a mouse pneumonitis model 
of infection caused increased mortality and prolonged infection in Balb/c mice versus 
their C57BL/6 counterparts (Yang, HayGlass and Brunham, 1996). Investigation of 
antigen-specific responses revealed a marked increase in IL-10 in Balb/c compared to 
C57BL/6 mice, with an inverse correlation observed for the IFNγ response. However, 
in the study by (Darville et al., 2001b), no mortality or significant difference in rate of 
clearance of genital Cm infection between Balb/c and C57BL/6 mice is observed. 
This not only illustrates differences in strain-specific immune responses between 
mice, but also highlights the important pathological differences when chlamydial 
organisms are deployed at sites anatomically disparate to their natural route of 
infection.  
 
Although the mechanisms governing the differential production of Th1-type cytokine 
profiles in different mouse strains remain unknown, (Jacob, Lee and Strassmann, 
1996) showed that identical numbers of macrophages obtained from different mouse 
strains also showed differential secretory levels of TNFα when stimulated with LPS 
or IFNγ. As C57BL/6, Balb/c and C3H mouse strains each contain a different 
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haplotype H-2b, H-2d, H-2k (respectively), the authors proposed that TNFα production 
might be linked to major histocompatibility complex alleles. MHC haplotypes are 
incredibly diverse within the outbred human population, and further investigation is 
required to establish whether any correlates between Ct infections and pathogenesis 
exist within patient cohorts.  
 
It is now also known that a plethora of anatomical and physiological factors may 
govern infectivity and ensuing degrees of immune-mediated pathology at sites of 
infection. These are not limited to, but may include: differential lymphocyte homing 
receptor expression in disparate tissues (Johansson et al., 1999), differential tissue-
specific abundance and type of innate immune cells such as dendritic cells and 
macrophages in respective animal models, and even the timing of infection within the 
context of the menstrual cycle and pathogen dose (Carey et al., 2009). Thus, the use 
of Cm, a mouse pneumonitis biovar to infect the murine genital or respiratory tracts (a 
non-native pathogenic niche) may lead to differential immune responses and 
mechanisms of pathogenesis in each respective environment.  
 
This is quite clearly illustrated in a recent study investigating the Cm antigen TC0582 
as a vaccine candidate for Cm infections. This immunodominant antigen was 
discovered following examination of a proteome microarray used to test sera from 
infected mice (Jacob, Lee and Strassmann, 1996). TC0582 is a highly conserved V-
type ATP synthase subunit, and possesses ~40% sequence homology to its eukaryotic 
orthologs. Moreover, TC0582 was preferentially recognized by serum from mice that 
developed hydrosalpinx when infected intravaginally with Cm, suggesting a 
correlation with immunopathology rather than protection (Zeng et al., 2012). Thus, 
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studies investigating potential protective efficacy of this antigen were conducted in 
respiratory tract Cm models of infection (Cheng et al., 2014). Here, it was found that 
mice immunized with TC0582 showed significant protection from intranasal 
challenge with Cm, evidenced by lower recoverable IFU in the lungs and percentage 
change in body weight relative to controls. Furthermore, cross-reactive autoantibodies 
directed against the murine V-type ATP synthase were not detected, indicating 
potential safety of the vaccine. Interestingly, CT308, the Ct gene ortholog of TC0582 
was not recognized by serum from women presenting with tubal factor infertility, 
showing no direct immune correlate to disease in humans (Budrys et al., 2012; 
Rodgers et al., 2011). 
 
This evidence highlights important nuances and caveats in the use of the Cm biovar 
for investigation of vaccine efficacy and pathogenesis in different environmental 
niches within the host, where an antigen may be protective in one setting, but also 
demonstrate an enhanced proclivity to initiate deleterious effects at another 
anatomically or immunologically distinct site. As previously discussed, it is likely that 
these differences may also be mediated by the genetic profiles of the host to a large 
extent. However, another major challenge that precludes effective design of vaccines 
against many sexually transmitted pathogens is the immunological uniqueness of the 
human genital tract, which is primed differently to the common mucosal immune 
system, and is thought to require combined systemic and mucosal (primarily 
intranasal) immunization to elicit optimal protection. 
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1.5.4 Immunology of the reproductive tract 
The human genital tract is anatomically and immunologically distinct from the so-
called ‘common’ mucosal immune system that comprises the oral, intestinal and 
respiratory mucosae (Mestecky, Moldoveanu and Russell, 2005). Major differences 
between reproductive tract immunology and that of anatomically disparate mucosal 
sites include: 
 
(i) The lack of immune inductive sites within male and female genital tract 
tissues such as the organized lymphoid structures known as Peyer’s 
patches in the gut mucosa (Yeaman et al., 1997) 
(ii) A predominance of IgG rather than secretory IgA within genital tract 
semen and cervico-vaginal fluid (Russell and Mestecky, 2002) 
(iii) The influence of fluctuating hormonal levels within the female 
reproductive tract during the menstrual cycle (Kozlowski et al., 2002) 
 
These features may thus influence the immune response to natural infection as well as 
vaccines designed to combat sexually transmitted infections such as HIV, 
N.gonorrhoeae and C.trachomatis. For instance, the lack of specialized lymphoid 
structures within the genital epithelium leads to weak humoral immune responses to 
natural infection or immunization at sites distal to genital infection, especially in the 
absence of potent adjuvants (Russell and Mestecky, 2002). A vaccination route that 
enables the acquisition of robust immunity within both the genital and common 
mucosal systems may be important when considering immunization strategies for 
coverage of a broad array of chlamydial infections, given the highly divergent tropism 
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of ocular, urogenital and LGV serovars, which show appetence for the conjunctival 
mucosa, genital tract and monocytes (respectively).  
 
Furthermore, with the recent emergence of the new L2b epidemic, the causative agent 
of proctitis in high-risk MSM populations, a potentially attractive experimental 
strategy that may combat a wider array of pathogenic Ct strains would be the 
development of per-rectal immunization strategies, as the lower intestinal and genital 
tracts possess shared lymphatic drainage due to their anatomical proximity (Mestecky, 
Moldoveanu and Russell, 2005). Nonhuman primate models and early clinical trials 
have further demonstrated the efficacy of this immunization route for the bacterial 
pathogen Salmonella typhi (Crowley-Nowick et al., 1997; Eriksson et al., 1998; 
Kantele et al., 1998; Nardelli-Haefliger et al., 1996) 
 
In contrast to the human genital mucosa, the presence of organized lympho-epithelial 
structures like tonsils and Peyer’s patches ensure that oral and per-rectal 
immunization lead to generalized immune responses within the common mucosal 
system characterized predominantly by antigen-specific secretory IgA (sIgA) 
responses. Interestingly, while systemic immunization leads to weak intestinal 
humoral responses, this route has been found to elicit high titres of IgG as the 
dominant immunoglobulin subtype in cervico-vaginal secretions (Bouvet et al., 1994; 
Russell and Mestecky, 2002). This is demonstrated in experimental models of HIV 
infection, where passive protection against vaginal HIV-1 or simian 
immunodeficiency virus (SIV) is conferred by systemically administered neutralizing 
monoclonal antibodies (Baba et al., 2000; Mascola et al., 2000).  
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However, intranasal vaccination remains the most effective route for eliciting high 
titre genital tract antibodies and cell-mediated immune responses (Di Tommaso et al., 
1996; Johansson et al., 1998; Russell et al., 1996). Most preclinical studies have 
employed cholera toxin B subunit (CTB) as a mucosal adjuvant, or other versions of 
this heat-labile enterotoxin, which are potent stimulants that may not be readily 
amenable for use in human vaccine development. Subsequent safety studies have 
indicated potential side effects of these ganglioside-binding toxins that may result in 
pathology following retrograde neuronal transport of antigens (Mutsch et al., 2004; 
van Ginkel et al., 2000).  
 
Another potential advantage of intranasal immunization is that high titres of vaginal 
IgA and IgG are elicited irrespective of the phase of the menstrual cycle, whereas the 
strength of local immune responses following intravaginal immunization showed 
phase-dependence during menstruation (Johansson et al., 2001; Kozlowski et al., 
2002). However, the influence of sex hormones on reproductive tract immunology 
still remains poorly understood, but may be critical for the development of future Ct 
vaccines. This further highlights the need for the development of novel antigen-
adjuvant combinations with a broad therapeutic index that elicit robust mucosal 
immunity and are safe to administer via clinically established parenteral routes. The 
role of adjuvants in the development of next-generation T cell based vaccines will be 
discussed next. 
 
1.5.5 Adjuvants  
Adjuvants are key substituents of nearly all licensed vaccines, and are defined as 
components that are capable of either enhancing or shaping the immune response to 
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specific antigens. However, even the mechanisms of action of aluminium salts, some 
of the oldest adjuvants first employed in the 1920s, still remain poorly characterized 
or entirely unknown (Marrack, McKee and Munks, 2009). Hence, to facilitate 
transition from preclinical trials to licensing, the development of new adjuvant classes 
for an array of infectious diseases seeks to both understand the mechanisms of action 
of novel immunostimulatory molecules in order to better define safety and tolerability 
profiles, while further filling crucial gaps in modern vaccinology, which include: 
 
(i) Antibody response broadening - to target pathogens such as influenza, 
HIV, Plasmodium falciparum or Chlamydia spp. which display inter-strain 
variability in key immunogens or antigenic drift  
(ii) Enhanced potency and durability of responses - which may result in 
antigen dose sparing to increase global vaccine supply 
(iii) Vaccines for the elderly to counteract senescence of the immune system 
(iv) New T cell vaccines to combat intracellular pathogens such Chlamydia 
spp., Mycobacterium tuberculosis or Leishmania spp. 
 
Clinically approved adjuvants licensed for use in human vaccines primarily comprise 
the aluminium salts, modified derivatives of bacterial lipopolysaccharide (LPS), and 
liposomal formulations. These can be formulated with various additives such as 
saponins or oils in either aqueous or oil-in-water emulsions (MF59, AS03, AF03) and 
AS04 (monophosphoryl lipid A (MPL) plus aluminium salts) (Reed, Orr and Fox, 
2013).  Thus, broadly speaking, adjuvants generally consist of two main components: 
(i) immunomodulatory molecules that interact directly with the host immune system 
(such as TLRs, or NOD- and RIG-like receptors) and (ii) delivery systems (such as 
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liposomes or virosomes) that may enhance antigen presentation to the immune 
system.  
 
Combination systems are those that incorporate a mixture of both immunomodulatory 
and delivery components, and most licensed adjuvants or those undergoing Phase III 
clinical trials represents this class. For instance, the recently licensed Cervarix 
(GlaxoSmithKline) and Fendrix (GlaxoSmithKline) vaccines, used to combat HPV 
and hepatitis B (respectively) employ the proprietary AS04 combination system 
comprising MPL (an immunostimulatory TLR4 agonist) and aluminium salts 
(putative delivery system with intrinsic adjuvanticity) (Draper et al., 2013; Levie et 
al., 2002), while the RTS,S malaria vaccine recently evaluated in a Phase III clinical 
trial is composed of the AS01 formulation containing MPL and QS21, which also 
contains a liposomal delivery vehicle (Agnandji et al., 2011).  
 
Other vaccines based on delivery systems that enhance antigen presentation include 
the virosome-based Inflexal V influenza vaccine and the hepatitis A Epaxal vaccine 
manufactured by Crucell, and likely function through encapsulating native viral 
particle structure combined with multimeric antigen presentation and fusogenic 
activity of lipids (Reed, Orr and Fox, 2013). Thus, the functionality of adjuvants is 
dependent not only on the identity of the immunostimulatory molecule, but also on 
formulation, and the intricacies of formulation-dependent effects of adjuvants in 
vaccine design will be discussed next.  
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1.5.6 Formulation-dependent effects of adjuvants in vaccine design 
Formulation-dependent variables of adjuvants and their effect on the quality of the 
immune response and vaccine efficacy are numerous, and will not be discussed in 
detail here, although several reviews highlight the importance of engineering 
constituent nanoparticles to achieve specific particle size distribution, surface charge 
and chemical structure (Bachmann and Jennings, 2010; Hubbell, Thomas and Swartz, 
2009; Oyewumi, Kumar and Cui, 2010). Several clinical and preclinical trials 
document the formulation-dependent effects of adjuvants on vaccine efficacy, 
epitomised by the recent development of the RTS,S malaria vaccine candidate (Stoute 
et al., 1997).  
 
Studies showed that formulation of the P.falciparum circumsporozoite antigen with 
AS02 (an oil-in-water emulsion plus MPL and QS21) protected 6/7 recipients from 
malarial infection, while formulation with AS04 (MPL and aluminium hydroxide) and 
AS03 (emulsion only) elicited protection in 1/8 or 2/7 recipients (respectively) 
(Mettens et al., 2008). Furthermore, in both preclinical and early phase clinical trials, 
it was subsequently realized that switching from an oil-in-water emulsion (AS02) to a 
liposomal formulation (AS01) significantly enhanced Th1-type cell-mediated 
immunity as well as antibody titres (Kester et al., 2009; Owusu-Agyei et al., 2009; 
Polhemus et al., 2009). These studies neatly illustrate the individual and 
combinatorial impact that immunostimulatory molecules (such as the TLR agonist 
MPL) and delivery vehicles (liposomes) may have on the quality of the immune 
response. 
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In addition to the AS01-AS04 formulations, MF59 is another licensed adjuvant used 
in Fluad and Pandemrix vaccines, also widely tested in preclinical studies (O'Hagan et 
al., 2012). Here, addition of TLR ligands (the TLR9 agonist CpG or TLR4 agonist 
E6020) to the MF59 emulsion has been shown to result in a Th1-skewed immune 
response, although antibody titres remained the same (Baudner et al., 2009). More 
interestingly, however, the nature of the ensuing immune response for a given 
adjuvant formulation may also be heavily dependent on the antigen incorporated in 
the vaccine. Addition of TLR ligands to adjuvant formulations show added benefit 
when the vaccine antigen is a recombinant protein (Singh et al., 2012), while limited 
benefit in magnitude or quality of the immune response is observed when inactivated 
pathogens with intrinsic immunogenicity are added (Rumke et al., 2013). In addition 
to formulation- and antigen-dependent effects on adjuvant potency, key additional 
caveats lie in the physiological disparities in preclinical animal models, which may 
result in poor efficacy or adverse effects in clinical trials. 
 
1.5.7 Animal models in adjuvant design 
General caveats are inherent when investigating the translational potential of 
adjuvants screened in preclinical animal models, particularly with regard to TLR 
agonists as used in our study. The intricacies of TLR4 signaling will be discussed in 
more detail in Chapter 5, which describes the first preclinical study of a second- 
generation lipid adjuvant (SLA). SLA is a novel, rationally designed TLR4 agonist 
used in combination with Ct rPmpD as a vaccine in a murine model of chlamydial 
infection. However, it is worth noting that murine TLR4 is more promiscuous at 
interacting with a variety of modifications on both natural and synthetic TLR4 ligands 
than is human TLR4. Importantly, expression patterns of TLRs differ substantially 
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between species. For instance, TLR8 is not expressed in murine cells, while the TLR9 
expression pattern varies between humans and rodents, thus compounding the 
significance and interpretation of the immunological effects of certain TLR agonists 
in preclinical studies (Hemmi et al., 2002; Jurk et al., 2002; Klinman et al., 2004). 
 
Differences also exist in the type of vaccination regimen employed. For instance, 
DNA immunization is far less immunogenic in humans than in mice, preexisting 
immunity to certain viral vectors within the human population limits the efficacy of 
viral-vectored vaccines that may show promise in preclinical rodent or primate 
models (Li, Saade and Petrovsky, 2012; Saxena et al., 2013). However, rare side 
effects of adjuvant-antigen combinations may still not be detectable in insufficiently 
powered preclinical or even large-scale Phase III trials in humans.  
 
This is epitomised by reports of narcolepsy in children and young people receiving 
both the Pandemrix (GSK) and Focetria (Novartis) H1N1 influenza vaccines (Miller 
et al., 2013; Partinen et al., 2012; Wijnans et al., 2013). Interestingly, both the 
adjuvants and antigens employed in each vaccine were remarkably different, 
Pandemrix consisting of an inactivated split virus vaccine with the AS03 (squalene, α-
tocopherol and polysorbate 80) adjuvant, with Focetria composed of purified 
hemagglutinin and neuraminidase subunits with MF59 (squalene, polysorbate 80 and 
sorbitan trioleate) (Reed, Orr and Fox, 2013). These studies illustrate key 
uncertainties that the field of adjuvant biology is fraught with, particularly as the 
cellular and molecular interactions of many adjuvants and their formulation 
constituents are poorly understood. 
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Nonetheless, despite these inherent drawbacks, preclinical models must form the basis 
of investigation for initial assessment of adjuvant safety and efficacy, and an 
increased understanding of physiological differences and similarities with humans is 
of paramount importance in the field. In addition to understanding their molecular 
mechanisms of action, key future requirements for next-generation adjuvants within 
the context of sexually transmitted diseases, include defining the best formulation and 
route of administration to elicit robust and durable immunity within the genital tract 
mucosa. Drawing links between measurable protective efficacy of certain adjuvants 
(such as enhanced T or B cell responses) and their initial cellular immune signatures 
through exploiting advances in transcriptional profiling, may also help to identify key 
correlates that are predictive of specific profiles of immunity. This approach has been 
adopted in the analysis of the yellow fever vaccine YF-17D, where, for instance it 
was shown that a robust CD8+ T cell response correlated with expression of 
eukaryotic translation initiation factor 2 alpha kinase 4 (Querec et al., 2009). This 
may allow for more rational screening of adjuvants at an earlier phase of 
development. 
 
Thus, in light of the potential shift away from whole cell and live-attenuated Ct 
vaccines (which possess intrinsic immunogenicity) as well as the need to enhance 
robust antigen-specific T cell priming within the genital tract to target intracellular Ct 
infections, it is likely that novel adjuvants will have a profound influence on the 
future development of Ct vaccines. While the expansion of preclinical chlamydial 
vaccine candidates has been incremental over the past few decades, it is likely to grow 
exponentially in the coming years. This is largely expedited with the advent of new 
technological approaches which enable the judicious choice of antigens primed to 
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elicit protective T cell as well as humoral responses, and the very recent development 
of a complementary genetic toolkit that has finally made this obligate intracellular 
pathogen amenable to genetic manipulation (Kari et al., 2011; Nguyen and Valdivia, 
2012; Wang et al., 2011). The repertoire of chlamydial vaccine candidates 
investigated to date will be discussed next. 
 
1.5.8 Antigens 
Vaccine development against chlamydial infections was initiated in the 1950s, where 
whole-cell inactivated EBs were used to immunize nonhuman primates in an infection 
model of ocular trachoma, and further included the first Taiwanese trachoma vaccine 
human field trial (Collier et al., 1967; Wang, Grayston and Alexander, 1967; 
Woolridge et al., 1967). However, manifestations of immuno-pathogenesis were 
detected following reinfection in some individuals, while others showed reduced 
disease and measurable short-term protection. Adverse immune events were 
categorized as delayed-type hypersensitivity reactions and the use of whole-cell 
organisms was subsequently replaced in favour of the MOMP subunit that comprised 
the mainstay of chlamydial vaccinology research for the better part of the following 
two decades. A plethora of MOMP-based immunization strategies were employed in 
a variety of animal models (Batteiger et al., 1993; Tan et al., 1990), using variations 
in administration routes (Su, Parnell and Caldwell, 1995; Taylor et al., 1988), prime-
boosting and antigen-adjuvant combinations (Dong-Ji et al., 2000). As expected, this 
diverse array of studies reported variable results of vaccine efficacy, and it was not 
until the early 21st century that technological advances in genomics have shed light on 
the intricacies and caveats of MOMP vaccination. 
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MOMP has been found to be a hotspot for genetic recombination within and between 
Ct serovars, and consists of four variable domains (VD1-VD4) (Harris et al., 2012). 
Extensive recombination of ompA (the gene encoding MOMP) within and between Ct 
strains thus confounds conventional clinical serotyping and further masks true 
phylogenetic relationships between serovars that are more clearly revealed through 
whole-genome sequencing of clinical strains (Harris et al., 2012). MOMP is the 
dominant constituent of the chlamydial outer membrane complex, comprising ~65% 
of the COMC (Hatch, Allan and Pearce, 1984). Although the function of MOMP is 
unknown, antigenic variation in MOMP may act as a major immune evasion strategy 
for Ct, as anti-MOMP antibodies have been shown to neutralize Ct infections in vivo 
(Pal et al., 2001; Tuffrey et al., 1992). However, the use of MOMP in combination 
with OmcB as a multi-subunit recombinant vaccine expressed in a Vibrio cholerae 
ghost (VCG) delivery vehicle, was found to elicit a greater population of antigen-
specific IFNγ-secreting T cells, resulting in enhanced protection against Ct serovar 
D/UW3/Cx infection, suggesting the likely importance and cooperative effect of other 
COMC proteins in eliciting chlamydial clearance through the generation of robust 
Th1-type cellular immune responses (Eko et al., 2004). 
 
Thus, the last 10-15 years have seen an increased focus on the identification and 
prioritization of novel chlamydial antigens that elicit cell-mediated immune 
responses, concomitant with technological advances in proteomics. Such novel 
approaches have examined chlamydial proteins preferentially loaded on to MHC class 
I or II molecules following pulsing of dendritic cells  (DCs) with live or UV-
inactivated Cm (Karunakaran et al., 2008; Yu et al., 2011), or employed high 
throughput screening of sera and splenocytes from infected patients or animal models 
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to identify chlamydial antigens preferentially recognized by antibodies as well as 
CD4+ T cells (Finco et al., 2011). Importantly, these methodologies hold great 
importance for the development of novel vaccines against intracellular pathogens, and 
a summary of the findings of these and other studies outlining several of the main 
chlamydial vaccine candidates in conjunction with preclinical in vivo protection data 
is presented in Table 1.1. 
Table 1.1: Chlamydial vaccine candidates (Rey-Ladino et.al, 2014) 
Antigen Chlamydial 
localisation 
Adjuvant Protection Immune response 
CT043 Membrane DNA/Protein 2.6-log 
reduction in 
lungs 
Th1 type response 
ArtJ Periplasm ND ND Neutralizing Abs in 
vitro 
CrpA Inclusion 
membrane 
Vaccinia 
virus 
Partial 
protection 
CD8+ T cell 
expansion 
CPAF Cytosol IL-12 Reduction in 
vaginal 
bacterial load 
Abs and IFNγ 
Tarp Cytosol CpG and IFA Reduction in 
vaginal 
bacterial load 
Th1-type response 
PmpG Membrane Protein 
pulsed DCs 
60% 
reduction in 
vaginal IFU 
T cells producing 
IFNγ 
PmpE Membrane Protein 
pulsed DCs 
50% 
reduction in 
vaginal IFU 
T cells producing 
IFNγ 
RplF Ribosome Protein 
pulsed DCs 
50% 
reduction in 
vaginal IFU 
T cells producing 
IFNγ 
PmpD Membrane ND ND Neutralizing Abs 
in vitro, human 
CD4+ T cell 
recognition 
MOMP Membrane FA, CpG, 
OspA, rVCGs 
70% 
reduction in 
vaginal IFU 
Th1-type response 
with IFNγ 
production 
NrdB ND Cholera 
toxin, CpG 
Partial 
protection 
CD4+ T cells 
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To account for genetic variation in MHC haplotypes, Karunakaran et al. (2008) 
utilized bone-marrow derived dendritic cells (BMDCs) from C3H and C57BL/6 mice 
with distinct MHC alleles (H2k and H2b respectively) pulsed with either live Ct or Cm 
for 12 hours, and subsequently employed cell lysis and monoclonal antibody 
purification of MHC-peptide complexes. In this study, it was found that MHC allelic 
selection is crucial in determining protein recognition, and this may play a more 
significant role in determining the outcome of infection and pathogenesis in an 
outbred human population. Peptide fragments of 17 proteins from the Cm proteome 
were purified on MHC II of C57BL/6 mice, while only 11 were isolated from the 
C3H mouse strain. Interestingly, the only overlapping peptides between the two 
mouse strains were from the PmpG and PmpF orthologs, and moreover, MOMP, and 
Pmps E, F and G generated multiple MHC class II-binding epitopes. This may 
indicate roles in immune evasion within hosts, particularly as recently identified 
hotspots for genetic variation in Pmps correspond to epitopes predicted to bind MHC 
(Gomes et al., 2007). Overall, when trialled as subunit vaccines, PmpG was found to 
elicit the greatest levels of protection, which also correlate with its immunodominance 
in the Cm model of infection (Johnson et al., 2012; Li and McSorley, 2013). 
 
Yu et.al (2011) further showed that intranasal immunization with live Cm EBs elicited 
significantly greater levels of protection than did immunization with UV-inactivated 
EBs (UVEBs), which further correlated with the number and types of peptides loaded 
on to MHC class II. The authors isolated 45 peptides from 13 different proteins 
following DC pulsing with live Cm EBs in vitro, while only 6 peptides belonging to 3 
different proteins were loaded on to MHC class II following pulsing with UVEBs. A 
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further correlate of protection was the increased number of multifunctional T cells 
elicited by live Cm infection secreting IFNγ and TNFα with or without IL-2, relative 
to UVEBs. Moreover, the antigens entering the MHC class II pathway following DC 
pulsing by live EBs included the Pmps E, F, and G, while surprisingly, none of the 
three proteins (RplF, FabG, AtpE) following UVEB pulsing of DCs consisted of outer 
membrane constituents. Preferential loading of Pmps on to MHC class II suggests 
possible targets for T cell based vaccines. Moreover, the observation that Pmps are 
preferentially processed and loaded on to MHC class II molecules during live 
infection but not following UV-inactivation, further suggests likely roles in 
pathogenesis or intracellular function. 
 
Finco et.al (2011) employed a two-pronged approach to identify chlamydial antigens 
that elicited both humoral and cellular immune responses using high throughput 
screening of 120 Ct serovar D recombinant proteins in a protein array to screen 
human sera from Ct-infected patients, and stimulate splenocytes from Ct-infected 
mice. Five antigens that were both recognized by human sera and resulted in 
significantly enhanced antigen-specific IFNγ-secretion in murine splenocytes were 
identified – IncA, CT372, OmcB, MOMP and CT823. Here again, key components of 
the COMC were identified, as well as an inclusion membrane protein expressed 
during mid-cycle development, highlighting a broader range of putative vaccine 
candidates. However, the use of recombinant proteins in immobilized arrays may 
result in non-native conformations and hence, a number of viable candidates 
containing conformational-dependent epitopes may have been overlooked in the 
screening of patient sera. However, some studies investigating the antibody signatures 
of Ct ocular infections have avoided this by using intrinsically radiolabelled 
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Chlamydiae in a radio-immunoprecipitation assay (Kari et al., 2013), and such novel 
approaches may be a way of circumventing loss of sensitivity in antibody epitope 
recognition. 
 
Thus, the surface-exposed nature of chlamydial Pmps (Crane et al., 2006), their 
postulated role as adhesins in Ct and other chlamydial species (Becker and 
Hegemann, 2014; Molleken, Becker and Hegemann, 2013), as well as the presence of 
multiple T cell epitopes on these highly immunogenic proteins (Yu et al., 2014), may 
result in robust cell-mediated immunity and neutralizing antibody responses when 
incorporated in to chlamydial vaccines. However, the precise role these proteins play 
in Ct infection and pathogenesis remains enigmatic, and no cellular interaction 
partners have been identified for any Ct Pmp. Existing knowledge on this family of 
proteins in Ct will be the subject of discussion in the following section. 
 
1.6 Secretion systems in Gram-negative bacteria 
In many bacterial pathogens, virulence and adhesion are mediated by a plethora of 
secreted or surface-exposed proteins, which are able to perform an array of diverse 
functions to manipulate host cell machinery. In order for secretion and translocation 
to occur, specialized secretory pathways are utilized. These are grouped in to seven 
major classes (Thanassi and Hultgren, 2000). Types II, IV, V and chaperone/usher 
secretion systems rely on a Sec-dependent transportation mechanism across the inner 
membrane, where recognition of a short, cleavable N-terminal signal sequence (~30 
amino acids) on the protein leads to transport from the cytoplasm across the inner 
membrane of the bacterium via the Sec apparatus - an evolutionarily conserved 
system for protein transport in bacterial and eukaryotic phyla (Stephenson, 2005). 
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Type II secretion may also be mediated through the twin-arginine translocation (Tat) 
secretory system (Sargent et al., 1998). In contrast, type I and type III secretion 
systems are Sec-independent (Beeckman and Vanrompay, 2010), and the discovery of 
a new secretion mechanism in Pseudomonas aeruginosa extended the classification to 
include a Type VI secretory system (Mougous et al., 2006), indicating a rich diversity 
of mechanisms by which virulence factors are secreted in Gram-negative bacteria. 
Types I-IV and Type VI secretion systems comprise large modular complexes that 
either span the inner and outer membranes, or contain multiple protein components 
variously associated with both membranes (Beeckman and Vanrompay, 2010). 
Chlamydiales possess a type III secretion system, of which several components and 
substrates have been identified. However, perhaps more striking is the presence of an 
expanded family of polymorphic membrane proteins (Pmps) that belong to the Type 
V autotransporter secretion system (T5ATs), and comprise roughly 13% of the total 
genomic coding capacity in Ct (Grimwood and Stephens, 1999). Ct possesses nine 
Pmps (Pmp A-I) within its genomic repertoire. The maintenance of such a large 
family of Pmps in a bacterial phylum that has undergone evolution by genomic 
reduction, suggests crucial or redundant roles for these proteins in the life cycle of the 
bacterium. However, the functional roles of Pmps during infection and biphasic 
development in Ct remain unclear. 
 
Proteins secreted by the T5AT mechanism possess a general unifying composition of 
motifs consisting of (i) an N-terminal leader sequence recognized by the Sec 
apparatus (ii) a functional passenger domain and (iii) C-terminal β–barrel pore. This is 
illustrated in Fig1.5. The extreme inter- and intra-species sequence variation of T5AT 
passenger domains is likely indicative of differing functional roles, while the β–barrel 
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pore remains largely conserved (Henderson, Navarro-Garcia and Nataro, 1998). 
Using this conserved modular structure as a template, T5ATs have been identified 
through genomic analysis in a wide range of pathogens, and are thought to comprise 
the largest family of secreted proteins in Gram-negative bacteria (Wells et al., 2007). 
However, for the majority of T5ATs, precise roles in virulence or host cell 
interactions remain putative or unknown. Selected T5ATs in key sexually transmitted 
or intracellular pathogenic Gram-negative bacteria are discussed next. 
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1.6.1 Type V autotransporters in pathogenic Gram-negative bacteria 
The IgA1 protease of Neisseria gonorrhoeae was the first identified T5AT (Pohlner et 
al., 1987). These proteins cleave secretory IgA1 at the hinge region (Kilian et al., 
1996), although IgA1 protease mutants were not defective in establishing infection in 
either the male urethra (Johannsen et al., 1999) or female genital tract (Hedges et al., 
1998). However, roles beyond IgA1 cleavage have been identified for the 
N.gonorrhoeae IgA1 protease, most notably, cleavage of the lysosomal integral 
membrane glycoprotein LAMP1 (Hauck and Meyer, 1997), (Lin et al., 1997). 
Furthermore, the ability to contribute to pathogenesis through eliciting the production 
of pro-inflammatory cytokines is another important function identified for the 
N.gonorrhoeae IgA1 protease (Lorenzen et al., 1999). Interestingly, this suggests 
multifunctional roles for a single T5AT correspondent to both extra- and intracellular 
survival, which would enable conservation of genomic space and metabolic 
requirements. 
 
Another well-studied pathogen of humans that displays T5AT toxin multi-
functionality is Helicobacter pylori, identified as a causative agent of gastritis 
(Kuipers et al., 1995), gastric adenocarcinoma (Parsonnet et al., 1991) and mucosa-
associated lymphoid tissue (MALT) lymphoma (Wotherspoon et al., 1991). H.pylori 
vacuolating toxin (VacA) is a T5AT expressed as a 140kDa pro-toxin that undergoes 
N- and C-terminal processing to an 88kDa secreted protein (Cover, Hanson and 
Heuser, 1997). This further undergoes partial proteolytic digestion to soluble 33kDa 
and 55kDa fragments (Nguyen, Caprioli and Cover, 2001). VacA is responsible for a 
panoply of effects in gastric epithelial cells including swelling of endosomal 
compartments (Pagliaccia et al., 1998), mitogen activated protein kinase activation 
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(Nakayama et al., 2004), and disruption of epithelial barrier permeability (Papini et 
al., 1998). In addition, VacA has been shown to exert both anti-proliferative effects on 
T cells (Boncristiano et al., 2003), (Gebert et al., 2003) as well as pro-inflammatory 
cytokine production in vitro (Supajatura et al., 2002). 
 
In addition to VacA, H.pylori possesses another T5AT associated with clinical 
pathology. The blood-group antigen binding adhesin (BabA) is responsible for 
epithelial attachment within the gastric mucosa, and may be a site of extensive 
recombination or mutation (Aspholm-Hurtig et al., 2004). In a German population, 
clinical isolates revealed a strong association between the babA2 gene and gastric 
adenocarcinoma (P-val=0.033), and strains triple-positive for babA2, vacAs1 and a 
Type III secretion effector-encoding gene cagA showed a significantly higher 
correlation with ulcer formation and adenocarcinoma (P-val=0.014) (Gerhard et al., 
1999).  
 
Another monophyletic group within the α-Proteobacteriaceae known to possess 
T5ATs are the Rickettsiales. Like the Chlamydiales, Rickettsiae are obligate 
intracellular bacteria, sub-divided into two groups (typhus or spotted fever) based on 
differential antigenicity, outer membrane proteins and resulting pathology (Anacker, 
Mann and Gonzales, 1987). Within the Rickettsiales, a study revealed a family of 
genes encoding surface cell antigens that were differentially fragmented or absent 
between species (Blanc et al., 2005). Four of the genes have been identified as T5ATs 
– ompA, ompB, sca1 and sca2 (Blanc et al., 2005). In R.conorii, Sca1, Sca2 and 
OmpB all have been shown to mediate adherence to host cells (Cardwell and 
Martinez, 2009; Chan et al., 2009; Riley et al., 2010), and OmpB was found to elicit 
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protective immunity (Feng et al., 2004a; Feng et al., 2004b). In addition, OmpA was 
recently shown to mediate adhesion through interaction with α2β1 integrin in non-
phagocytic human endothelial cells in vitro (Hillman, Baktash and Martinez, 2013). 
 
Given their widespread distribution and roles in adhesion and virulence in a number 
of pathogenic organisms, T5ATs are promising candidates for vaccine development. 
For instance, in addition to whole-cell vaccines against whooping cough caused by 
the pathogen Bordetella pertussis, acellular vaccines have been developed that 
include, amongst other antigens, the T5AT pertactin (Cherry et al., 1998). High-titre 
humoral responses to pertactin have been found to have the strongest correlation to 
reducing the likelihood of acquiring pertussis disease (Hewlett and Halperin, 1998; 
Storsaeter et al., 1998). However, the physiological role pertactin plays in 
pathogenesis remains contentious, while conflicting studies on adhesion to various 
cell types is reported (Everest et al., 1996; van den Berg et al., 1999), an 
immunoprotective epitope comprising the C-terminal (PQP)5 motif has been 
identified (Charles et al., 1991). In addition, pertactin was the first T5AT for which 
the 3D-structure was obtained, which revealed a 16-stranded parallel β-helix (Emsley 
et al., 1996). This enables detailed inspection of the molecular nature of putative 
binding motifs and immunoprotective epitopes. 
 
Most recently, the Bexsero vaccine (Novartis), developed to combat Neisseria 
meningitidis serogroup B infections, was the first clinically approved vaccine to be 
developed by reverse vaccinology. Bexsero contains the Neisseria adhesin A (NadA) 
T5AT as one of the three recombinant protein antigens (Serruto et al., 2012). Large-
scale genomic comparisons were used to identify virulence factors and potential 
	 59	
vaccine candidates in silico, across a broad range of strains. Preclinical in vivo studies 
identified NadA as a protective antigen in rats, able to induce bactericidal antibodies 
(Comanducci et al., 2002), while in vitro studies using heterologous expression in 
non-invasive Yersinia enterocolitica indicate a putative role for NadA as a bacterial 
adhesin (Capecchi et al., 2005; Nagele et al., 2011). Thus, T5ATs are an important 
class of proteins present in a wide range of Proteobacteria that are able to exert a 
plethora of distinct and often multifunctional effects to manipulate a variety of host 
cell types. Importantly, the range of oligomeric or monomeric states exhibited may 
exert distinct functional roles, which may in turn vary depending on the 
environmental niche of the pathogen. Interestingly, despite adaptation to an 
intracellular lifestyle through ‘evolution by reduction’, the Chlamydiaceae preserve a 
large number of T5ATs within their genomic repertoire. However, the structural and 
functional characterization of these proteins still remains rudimentary. 
 
1.7 The polymorphic membrane proteins (Pmps) of Chlamydia trachomatis 
By 2012, completion of the genome sequences of all known pathogenic and zoonotic 
Chlamydiaceae revealed an expanded family of Pmps within this diverse family. 
C.pneumoniae (21 Pmps), C.pecorum (16 Pmps), C.abortus (18 Pmps), C.caviae (17 
Pmps), C.psittaci (21 Pmps), C.felis (20 Pmps). Ct possesses a family of nine 
polymorphic membrane proteins (Pmps A-I) which all belong to the T5AT family. 
These proteins comprise roughly 13.6% of the total genomic coding capacity 
(Grimwood and Stephens, 1999). However, the precise role of this large family of 
proteins within the context of chlamydial infection is yet to be fully established, 
although certain clues are emerging through studies of small patient cohorts and 
recent advances in genetic manipulation of Ct. 
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The expression profiles of Ct Pmps have been extensively studied at both the mRNA 
and protein levels in the 18 laboratory reference strains that comprise ocular, 
urogenital and LGV serovars (Gomes et al., 2006; Nunes et al., 2007). Six out of the 
nine pmp genes clustered according to tissue tropism (Gomes et al., 2006). The study 
showed that degrees of polymorphism between Ct Pmps were highly variable, 
although this did not necessarily reflect changes in amino acids, evidenced by the 
ratio of non-synonymous to synonymous mutations (dN/dS). pmpF and pmpH were 
the most polymorphic but remained conserved at the protein level (dN/dS = 0.23 and 
0.14 respectively), indicating possible conserved function. In contrast, pmpB 
possessed the highest level of protein variation (dN/dS=1.59) that may be suggestive 
of horizontal gene transfer or host immune pressure. This is also reflected in pmpE, 
pmpF and pmpH genes, which showed a non-random distribution of polymorphisms, 
and in a separate study, pmpF was found to have a cluster of non-synonymous 
mutations at locations of predicted MHC epitopes (Carlson et al., 2005).  
 
Polymorphic variation in these regions may be a strategy to affect MHC-T cell 
interactions and antigen presentation. Of note, the two most clinically prevalent Ct 
serovars E and F phylogenetically diverged from the other urogenital serovars for 
Pmps B, C, D, H and I, which was distinct from a comparison of interrelatedness 
using the ompA gene encoding the chimeric MOMP protein, where serovars E and F 
were more closely related to other serovars (Millman, Tavare and Dean, 2001). This 
points to a possible role for polymorphisms in Pmps conferring selective ecological 
advantages in certain strains, as well as in mediating tissue specific tropism. 
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A subsequent study by the same group sought to compare pmp expression between 
clinical (E and L2) and reference (E/Bour and L2/434) strains (Nunes et al., 2007). 
All pmp genes were expressed at 2 hours post infection, with pmpF showing the 
highest peak levels of gene expression in all strains, and pmpA the lowest. 
Subsequently, sera from 39 female adolescents presenting with Ct infection in clinics 
in Oakland were used to assess reactivity to recombinant Pmps D and F, where mixed 
infections were ruled out apriori using sequencing of ompA in cervical samples. 
Interestingly, 57.7% of sera reacted to rPmpD, while no patient serum was reactive to 
rPmpF in immunoblots. Furthermore, sera from patients infected with serovars E, F, 
Ba and K all recognized rPmpD, while those infected with serovars D, Ia, J, and G 
were non-reactive. Importantly, this may reflect differing levels of in vivo expression 
or immunodominance of MOMP or Pmps in different Ct serovars within the context 
of human infection, and further work is required to elucidate whether any correlations 
may be drawn with regard to serovar-specific Pmp immunogenicity and infection 
clearance or pathology. 
 
To investigate the heterogeneity in humoral responses to the nine-member Ct Pmp 
family, four separate patient cohorts were selected representing sexually, 
pathologically and geographically distinct populations (Tan et al., 2009). Women 
presenting with PID from Pittsburgh, adult male patients from Baltimore and 
adolescent females from Oakland and Little Rock with confirmed Ct infection were 
included. Pmps B, C, D and I were the major Pmps recognized by immune sera, 
indicating that these may be likely surfaced-exposed or expressed in abundance 
during Ct infection. Expression of Pmps may also be highly regulated during genital 
infection, and host-specific differences in epitope recognition may also play a part in 
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preferential recognition. In addition, geographical disparity of patient groups may 
mask epidemiological variations in serovar distribution that in turn may influence 
specific anti-Pmp serological profiles. However, in this study, 73% of patient sera 
recognized rPmpD, a highly immunogenic Ct antigen. 
 
To complement genomic profiling of pmp expression in Ct, Pmp expression was 
investigated using a panel of highly cross-adsorbed polyclonal antibodies directed 
against Ct Pmps A-I (Tan et al., 2010). Here, it was found that all Pmps are surface-
exposed, and that varying numbers of inclusions within a single infection do not 
express a given Pmp subtype. An ‘off rate’ for a given Pmp was defined as the 
percentage of inclusions that were homogenously negative for Pmp staining relative 
to those that were positive. Fixing and staining was conducted 42 hours post infection. 
Pmps A and D had the lowest ‘off’ rate (<1%), which may indicate important roles in 
RB development or RB to EB transition. Pmps F and H showed slightly elevated off 
rates (1-2%), while Pmps B, C and E displayed ‘off’ rates of 5-10%. 
 
Interestingly, two types of PmpF were recognized in differential staining patterns 
(homogenous and punctate) by two separate anti-PmpF pAbs, which also reacted 
differently in immunoblotting, reflecting different epitope recognition. This suggests 
that PmpF polymorphism may also be occurring in vitro. Interestingly, a single cell 
harbouring two distinct inclusions displayed PmpB expressing inclusions at one pole 
but not at the other, indicating the on-/off-rates of Pmps are not likely governed by the 
metabolic or developmental state of the infected cell. Co-immunofluorescence for 
Pmps revealed that expression of a given Pmp was found to be shut off independently 
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of Pmps that were both genetically linked (i.e. in the same operon) or genetically 
disparate. 
 
The presence of such a large family of orthologous genes in the Chlamydiales is 
indicative of a trait common to several obligate intracellular pathogens that have 
evolved to adapt to an intracellular lifestyle through genomic reduction. These 
bacterial pathogens comprise the Rickettsiae, Ehrlichiae and spirochetes, whose entire 
genomes are about one third the size of E.coli (Palmer, 2002). The Ct genome was 
found to contain ~859 genes, with ~28% showing no similarity to proteins deposited 
in GenBank (Stephens et al., 1998). Adaptation to an intracellular lifestyle precludes 
the need for many genes involved in metabolic pathways, and gene deletion often 
occurs through progressive loss-of-function mutations. In the sexually transmitted 
pathogen Treponema pallidum, the causative agent of syphilis, more than 50% of the 
open reading frames encode proteins of no known function (Fraser et al., 1998), and 
the loss of genes involved in metabolic pathways has also been observed in the 
genomes of Rickettsia prowazekii and C.trachomatis (Andersson et al., 1998; 
Stephens et al., 1998). 
 
Interestingly, it has further been postulated that paralogous gene families encoding 
outer membrane proteins (such as the chlamydial Pmps) may play a role in immune 
evasion (Palmer, 2002). Studies conducted on the animal pathogen Anaplasma 
marginale identified and addressed the putative function of an expanded family of 
gene paralogs in this species termed major surface proteins (msp2) (Palmer et al., 
1994). It is known that A.marginale can replicate for years within immunocompetent 
hosts to facilitate the likelihood of transmission (Eriks et al., 1989; Kieser, Eriks and 
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Palmer, 1990). This is accomplished by MSP-2 variants that arise cyclically to cause 
waves of bacteremia (Palmer, Brown and Rurangirwa, 2000).  
 
Variants are generated by recombination of multiple pseudogenes with hypervariable 
central regions in to the msp2 expression site (Brayton et al., 2001). Orthologs of the 
msp2 family are also found and expressed in A.phagocytophila, the causative agent of 
human granulocytic ehrlichiosis (Zhi, Ohashi and Rikihisa, 1999). The strategy of 
antigenic phase variation to evade the host immune system is also employed by a 
protozoan eukaryotic pathogen of humans – Trypanosoma brucei (El-Sayed et al., 
2000), where waves of undulating parasitemia are observed following changes in the 
variant surface glycoproteins. That a number of bacterial pathogens with 
comparatively small genomes such as the Chlamydiaceae may also implement this 
strategy to facilitate survival and transmission, may be of significant importance when 
considering vaccine development in tandem with the immune evasion strategies of Ct, 
especially in light of its elaborate repertoire of Pmps. Furthermore, it is now well-
established that Ct possesses the ability to undergo genomic recombination and 
antigenic polymorphism, particularly within the ompA gene and certain Pmps, but 
also within the cryptic plasmid which can also be exchanged between serovars 
(Gomes et al., 2006; Harris et al., 2012). These surface-exposed antigens represent 
both challenges and opportunities for the future development of prophylactic or 
therapeutic chlamydial vaccines. 
 
1.8 Concluding remarks 
To date, chlamydial vaccine development has focused on the prioritization of 
vaccination strategies that elicit robust pathogen-specific CD4+ Th1-type responses, 
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usually quantified by monitoring of splenic lymphocyte populations secreting IFNγ. 
However, the role of antibodies is becoming increasingly important as a correlate of 
vaccine-induced protection against infection, and so far, the only robust evidence 
documenting the in vivo efficacy of neutralizing antibodies has arisen from employing 
the antigenically variable chlamydial MOMP as an immunogen (Olsen et al., 2015; 
Pal et al., 2001). Thus, given the limited application of chimeric antigens such as 
MOMP, there is a need for broadening preclinical vaccine studies towards assessing 
an array of other chlamydial outer membrane proteins that may act as targets for 
neutralizing antibodies due to their surface-exposed nature. The Pmp family of 
proteins comprises a judicious choice of candidates. 
 
Pmps have been regarded as promising vaccine candidates due to a high number of 
predicted T cell epitopes, and immunoproteomics approaches using tandem mass 
spectrometry have also found these proteins to be preferentially loaded on to MHC 
class II (Karunakaran et al., 2008; Karunakaran et al., 2015; Yu et al., 2014). Based 
on these findings, preclinical vaccine studies incorporating Pmps E, F, G and H have 
been conducted in vivo in heterologous mouse strains (Yu et al., 2014), demonstrating 
differential haplotype-dependent immunodominance, correlating with the variable 
humoral responses to Pmps in clinical studies (Tan et al., 2009). However, a recent 
bioinformatics analysis of these Pmps show that Pmps E and F are highly 
polymorphic between LGV and noninvasive urogenital strains, with differences in the 
number of GGA(I,L,V) and FXXN motifs and Cys residues, likely indicating 
differences in adhesion profiles or functionality. Indeed, polymorphisms in these 
Pmps have also been shown to reside in regions of the proteins corresponding to 
predicted T cell epitopes, suggesting a role in immune evasion (Gomes et al., 2007; 
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Nunes et al., 2015). Interestingly, the pmpG gene has also been implicated in phase 
variation, following the identification of regulatory sequences within the gene (Nunes 
et al., 2015). 
 
Thus, we have chosen to employ the Ct PmpD as a preclinical vaccine candidate. 
PmpD is the most highly conserved Pmp across all known Ct serovars (>99.15%), is 
surface-exposed, and is known to contain a broad array of T cell epitopes (Crane et 
al., 2006; Swanson et al., 2009). This fulfills key prerequisites in the development of 
an effective chlamydial vaccine, which include: (i) coverage of a broad array of 
circulating strains (ii) ability to provide heterotypic antibody-mediated neutralization 
against Ct infection (iii) ability to elicit robust CD4+ Th1-type cellular immunity.  
 
In addition to the judicious choice of antigen, it is likely that adjuvants will play a key 
role in the success of future chlamydial vaccines, particularly due to the previously 
outlined regulatory and safety requirements for well-defined molecular mechanisms 
of action, the ability to demonstrate effective translational potential from preclinical 
models to clinical trials (in view of anatomical and physiological disparities between 
humans and mice), and the need to elicit robust pathogen-specific cell-mediated 
immunity predominantly reliant on memory and effector CD4+  T cells (Reed, Orr and 
Fox, 2013; Su and Caldwell, 1995). To this end, we have performed the first 
preclinical study using a novel, rationally designed TLR4-based second-generation 
lipid adjuvant (SLA), that has previously undergone evaluation of potency and 
efficacy on both human and murine primary and cultured cell lines in vitro, and has 
been documented to elicit a robust Th1-biased immune response evidenced by 
cytokine and chemokine profiles (Darrick Carter, personal communication). 
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Moreover, given the deployment of MPL in the licensed Cervarix vaccine (GSK) for 
the prophylaxis of prevalent HPV transmission and infection, the wealth of 
information describing the safety and efficacy of TLR4 agonists would expedite the 
translation of this molecule to early phase clinical trials (Draper et al., 2013).  
 
1.9 Aims of the project 
Several inter-related areas were addressed in this project, with the primary aim of 
assessing and documenting the efficacy of rPmpD and SLA in the development of 
future chlamydial vaccines. In addition, we conduct the first biophysical 
characterization studies of rPmpD and the T3SS virulence factor CT694, two 
important effector proteins implicated in Ct adhesion and invasion. Biophysical 
characterization of CT694 will be discussed first, as this investigation was a 
subsidiary objective conducted as an adjunct to the main focus of the thesis, which 
comprises a more detailed investigation of rPmpD as a chlamydial adhesin and a 
highly efficacious vaccine immunogen. 
 
1.9.1 Biophysical characterization of Ct CT694 
CT694 is a putative T3SS early effector protein unique to Ct, with no genetic paralogs 
present in closely related chlamydial species, or any significant sequence homology to 
genes in phylogenetically distinct bacterial genomes. To facilitate functional 
annotation for this protein, we have initiated early biophysical characterization studies 
with the eventual goal of obtaining a 3D molecular representation of the structure 
using X-ray crystallography. This is the focus of Chapter 3. 
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1.9.2 Biophysical characterization of Ct rPmpD 
In light of the requirement for the preservation of native protein structure in vaccine 
development and future structural studies, we provide the first biophysical 
characterization of a chlamydial Pmp using an array of biochemical and analytical 
techniques, and propose a model that illustrates a likely role for PmpD during 
biphasic chlamydial development within the context of our own and others’ previous 
work. This is presented in Chapter 4. 
 
1.9.3 In vitro investigation of Ct rPmpD as a chlamydial adhesin 
The second area of study comprises a preliminary investigation of the putative 
function of Ct rPmpD as a chlamydial adhesin. Neutralization and competitive 
inhibition assays are employed, providing preliminary evidence implicating Ct 
rPmpD as a chlamydial adhesin. This implies a functional role for PmpD in mediating 
chlamydial attachment to host cells, suggesting that this highly conserved chlamydial 
antigen may be a judicious target for incorporation in to future chlamydial vaccines. 
These findings are discussed in Chapter 5. 
 
1.9.4 In vivo efficacy of rPmpD in combination with a novel, rationally 
designed TLR4 agonist for use in preclinical Ct vaccines 
Finally, we characterize the efficacy of Ct rPmpD as a chlamydial vaccine candidate, 
and conduct the first preclinical investigation on the immunogenicity and efficacy of a 
novel, rationally designed TLR4 agonist in combination with rPmpD. This study 
demonstrates the protective efficacy of vaccines incorporating rPmpD in both the 
presence and absence of SLA in a murine model of Ct lower genital tract infection, 
and has further implications for the design of next-generation adjuvants in shaping 
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ensuing immune responses. In addition, we highlight an important role for pathogen-
specific antibodies at eliciting protection against sexually transmitted Ct infections. 
These data are presented in Chapter 6. 
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Chapter 2: Materials and Methods 
2.1  Protein production and biophysical characterisation 
This section describes the procedures used in cloning, expression, purification and 
biophysical characterization studies of recombinant Ct PmpD and CT694 proteins 
described in Chapters 3 and 4. 
 
2.1.1 Polymerase Chain Reaction (PCR) 
Prior to PCR, Ct serovar E/Bour genomic DNA (ATCC) was amplified using the 
GenomiPhi DNA amplification kit (GE Healthcare). All Ct genes were subsequently 
amplified using PCR from resulting DNA. Primer sequences are listed in Table 2.1. 
The PCR cycle conditions employed for amplification of each gene fragment are 
listed in Table 2.2, and the composition of each PCR mix in Table 2.3. Phusion 
High-Fidelity DNA Polymerase (NEB) was used to perform PCR reactions. Reactions 
were incubated in a BIOER LifeEco Thermocycler in 200µl thin-walled PCR tubes. 
After addition of loading dye, 20µl reactions were run on a 1% agarose gel and 
purified using the QIAQuick Gel Extraction Kit (QIAGEN) according to the 
manufacturer’s protocol. Each PCR product was eluted in 50µl of nuclease-free water 
and the concentration (ng/µl) determined using a NanoDrop ND-1000 
Spectrophotometer. PCR products were stored at -20°C until use.  
 
2.1.2 Cloning and generation of plasmids using restriction enzymes 
All reagents were purchased from New England Biolabs (NEB). Gel-purified PCR 
products of the target genes and vector backbones (Fig.2.1) were digested using the 
respective restriction enzymes overnight at 37°C. (Table 2.5). Antarctic shrimp 
phosphatase was added to vector digests to de-phosphorylate the 5’-end of the vector 
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to minimize spontaneous re-ligation. After addition of loading dye, 25µl of the vector  
Table 2.1: Forward and reverse primers 
Gene 
Name 
Forward primer (F) and Reverse primer (R) 
pmpD 
(F1) 
F:AGTTGCCATGGTAGATCTTCATGCTGGAGGACAGTCTGTAAATGAGC    
R:ATCTACTCGAGTTCCATACGCTGAGCAGTGAGATTATGAGC 
pmpD 
(F2) 
F:ATCTTCCATGGATAGTCAGGCTGAAGGACAGTATAGG 
R:ATTGACTCGAGTTTAAAACCATAACTACATAATGTAGCTCC 
pmpD 
(F3) 
F:ATCTTCCATGGATAGTCAGGCTGAAGGACAGTATAGG    
R:ATCGTCTCGAGACGTAAGCAAGAAATAGCACC 
ct694 F:ATCGTCCATGGCAAGTATTCGACCTACTAATGGGAGTGG 
R:CGCGGGTCGACGTCTAAGAAAACAGAAGAAGTTATGACAGTTAGTGTTTGG 
ΔN-
ct694 
F:ACGCGCCATGGATATTTATCATCCGACTATTTCTGGACAAGG                
R:GCCGTCTCGAGGTCTAAGAAAACAGAAGAAGTTATGACAGTTAGTGTTTGG 
T7 
Primers 
F:TAATACGACTCACTATAGGG                                                                                     
R:GCTAGTTATTGCTCAGCGG 
 
Table 2.2: Polymerase chain reaction (PCR) cycle conditions 
PCR 
Cycle 
Initial 
Denaturation 
Denaturation Annealing Extension No. 
Cycles 
Final Extension 
pmpD 98°C, 30s 98°C, 30s 55°C-
75°C, 30s 
72°C, 
3mins and 
30s 
30 72°C, 6mins 
ct694 98°C, 30s 98°C, 30s 55°C-
75°C, 30s 
72°C, 
2mins and 
40s 
30 72°C, 6mins 
          
Table 2.3: Polymerase chain reaction mix 
Component Volume (µl) 
5x Phusion polymerase buffer 5 
10mM dNTPs 0.5 
10mM 5’F primer 1.25 
10mM 5’R primer 1.25 
Phusion DNA polymerase 0.5 
Template DNA 2 
Nuclease-free water 14.5 
 
double digest reactions were run on a 1% agarose gel and purified using the 
QIAQuick Gel Extraction Kit (QIAGEN) according to the manufacturer’s protocol. 
Table 2.4: Ligation Reactions 
Component Volume (µl) 
10x ligase buffer 2 
100mM DTT 2 
10mM ATP 1 
Insert:Vector 
(Molar Ratio) 
(3:1) 
T4 DNA ligase 1 
Nuclease-free water to 20µl 
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Ligation reaction conditions are listed in Table 2.4. Prior to ligation with gene inserts, 
inactivation of Antarctic Shrimp Phosphatase contained in the vector digest reaction 
was achieved by heating at 65°C for 15 minutes. Following isolation of digested 
insert DNA using the QIAquick PCR Purification Kit (QIAGEN), insert was added to 
the vector in 3:1 molar excess and incubated at 16°C overnight. All genes inserted 
into the multiple cloning site of all pET-vectors possessed a non-cleavable C-terminal 
His6-tag (Fig.2.2). 
 
 
 
 
 
 
 
 
 
 
2.1.3 Plasmid transformation and amplification 
2-5µl of ligation reaction mixture was added to 50µl of chemically competent 
NovaBlue Single E.coli cells (Novagen) and transformed via heat shock. The mixture 
was incubated for 5mins on ice, transferred to a heating block at 42°C for 30s and 
immediately placed back on ice for 10mins. 250µl of sterile SOC Media (Novagen) 
was added to the cells and incubated with gentle shaking at 37°C for 1-2hrs, and then 
plated on to LB agar containing 50µg/ml kanamycin sulphate (Sigma Aldrich). 
Colonies were obtained after incubating the agar plates at 37°C overnight. 
Table 2.5: Restriction Enzyme Double Digest Reactions 
Insert pET Vector 
Component Volume 
(µl) 
Component Volume 
(µl) 
NcoI (ct694, ΔN-ct694 
and pmpD) 
1 NcoI 1 
XhoI (ΔN-ct694 and 
pmpD) 
1 XhoI 1 
SalI (ct694) 1 10x  Buffer 4 3 
10x NEB Buffer 4 3 pET vector 10 
Gene Insert 10 Antarctic Shrimp Phosphatase 1 
Nuclease-free water 15 10x Antarctic Shrimp 
Phosphatase Buffer 
3 
  Nuclease-free water 11 
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Verification of plasmid uptake was conducted using colony PCR with the same 
primers used for initial gene amplification, and relevant colonies were picked and 
grown in 5-10ml LB media containing kanamycin (50µg/ml) at 37°C for 5-8hrs. 
Plasmids were isolated using the QIAprep Spin Miniprep Kit (QIAGEN), eluted in 
50µl of nuclease-free water and stored at -20°C. The fragments were resolved by 
agarose gel electrophoresis and visualised using SybrSafe DNA gel stain (Sigma 
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Aldrich) under UV-light. All plasmids were sequenced to screen for correct in-frame 
ligation and potential mutations using primers recognizing the T7-promoter and T7-
terminator regions in the multiple cloning site of the pET-vector. Where feasible, 
successful cloning of respective genes was also confirmed by restriction enzyme 
double digest analysis. 
 
LB-medium (volume = 1L): 10g tryptone (Fisher Scientific), 5g yeast extract (Fisher 
Scientific), 10g NaCl (Fisher Scientific), deionised water 
LB-agar (volume = 1L): 10g tryptone (Fisher Scientific), 5g yeast extract (Fisher 
Scientific), 10g NaCl, 15g agar (LAB M Ltd), deionised water 
 
2.1.4 Analysis of the plasmids by nucleotide sequencing 
The correct sequence of the recombinant plasmids was confirmed by nucleotide 
sequencing. T7-promoter and terminator primers, as well as internal primers 
complementary to the target genes were used to verify correct sequences. Plasmid 
sequencing reactions were performed by the Bioscience Technology Facility (York, 
UK) with an Applied Biosystems 3130XL sequencer. Analysis of sequence 
chromatograms was performed using the ABI Vector NTI program. All genes were 
amplified correctly from genomic DNA as verified by Clustal Omega sequence 
alignments.  
 
2.1.5 Over-expression of the recombinant PmpD and CT694 protein fragments 
For small scale expression tests, competent E.coli BL21 (DE3), Origami 2 (DE3), 
Rosetta 2 (DE3) and C41(DE3) cells were transformed and induced. The recombinant 
genes from Chlamydia trachomatis serovar E/Bour DNA (ATCC) were 
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overexpressed in the BL21 (DE3) E.coli strain (Novagen). For large scale expression, 
strain E. coli BL21 (DE3) (Novagen) was used for the production of all recombinant 
proteins used in this study. In each case, transformed cells were grown at 37°C in 
lysogeny broth supplemented with kanamycin sulphate antibiotic (50µg/ml) to an 
optical density of 0.6, induced with 1mM isopropyl β-d-1-thiogalactopyranoside and 
then cultured overnight at 37°C. To purify rPmpD and CT694, cells were harvested 
by centrifugation, resuspended in extraction buffer consisting of 20mM TrisHCl pH 
8.0, 50mM NaCl, 10mM imidazole, to which an EDTA-free protease-inhibitor 
cocktail tablet (Roche Diagnostics, USA) had been added, and lysed by sonication. 
For recombinant CT694, cell lysate supernatants containing soluble protein were 
carried forward for affinity purification. For rPmpD, inclusion body isolation, 
denaturation and refolding was carried out prior to purification. 
 
2.1.6 Inclusion body preparation 
For preparation of inclusion bodies, bacteria were induced at OD of between 0.6-1.0, 
as protein yield can often be enhanced at higher OD. Following expression overnight 
at 37°C, bacteria were lysed by sonication in the following lysate buffer: 20mM Tris-
HCl, pH 8.0 50mM NaCl,  5mM EDTA , 0.5% Triton-X100 and 0.1mM PMSF. 
Reducing agents were avoided so as to not interfere with potential intramolecular 
disulphide bonding. Cells from 4 litres of culture were lysed in 250ml of lysate and 
sonicated for a total of 10-15 minutes on ice in 10s bursts with 10s intervals. 
Following sonication, 10mM MgSO4 was added to chelate EDTA, and lysozyme 
(0.1mg/ml) subsequently added to the lysate and incubated at RT for 20min to 
facilitate cell lysis. The lysate was centrifuged (6000 rpm for 15 minutes) to collect 
inclusion bodies, and the pellet resuspended completely once more by sonication in 
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the lysate buffer. The final wash step was conducted using lysate buffer without 
Triton-X100: 20mM Tris-HCl, pH 8.0 50mM NaCl , 5mM EDTA.  The washed 
inclusion body pellets were dispersed completely by sonication and then dissolved 
overnight at 4°C by stirring vigorously, in 20mM Tris buffer (pH 8.0) containing 6M 
GdHCl. 100 mL for 2 L of culture was used at this dissolution stage. The following 
day, the solution was centrifuged (6000 rpm for 20 minutes) to remove any insoluble 
particulates, and refolding of the rPmpD was conducted using step-wise dialysis by 
altering the concentration of GdHCl from 6M to 4M to 2M to 1M over the course of 3 
days at 4°C. 
 
2.1.7 Protein purification 
Recombinant CT694 or rPmpD were purified using a nickel-affinity chromatography 
column (GE Healthcare) pre-equilibrated with binding buffer (20mM TrisHCl pH 8.0, 
50mM NaCl, 10mM imidazole), and protein was eluted under a linear imidazole 
gradient (10–500mM). Eluted fractions were analysed by SDS–PAGE and those 
containing overexpressed protein (approximately 90% pure) were pooled and 
concentrated and then applied onto a 16/60 S75 Superdex gel-filtration column (GE 
Healthcare) which was pre-equilibrated with 20mM TrisHCl pH 8.0, 50mM NaCl. 
Eluted fractions containing pure CT694 protein (appearing as a single band on SDS–
PAGE) were concentrated to approximately 20–40 mg/ml protein and stored at 
−80°C. 
 
2.1.8 Circular Dichroism 
Circular-dichroism (CD) spectra were recorded at 20°C with a Jasco J-180 CD 
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spectrophotometer using a 0.1 cm path-length quartz cell. Experiments were carried 
out in 20mM Tris/HCl buffer pH 8.0. The protein concentrations in the samples were 
0.2 mg ml−1. Random error and noise were reduced for each spectrum by averaging 
three scans in the wavelength range 260–195 nm. The signal acquired for the buffer 
used for dilution of the proteins was subtracted from the spectra acquired for the 
proteins. 
 
2.1.9 Dynamic Light Scattering 
The polydispersity of rPmpD oligomeric and monomeric fractions was analysed using 
dynamic light scattering (DLS). Measurements were carried out at 20˚C with the 
protein at 1 mg/ml in size exclusion buffer using the DynaPro Dynamic Light 
Scattering system (Protein Solutions). 
 
2.1.10 Protein Crystallization Screening 
Crystallization was carried out in nandroplet sitting-drop vapour-diffusion format in 
96-well low-profile Greiner plates and Mosquito liquid handling robot (TTP Labtech, 
UK). Plates were placed at 277K using sitting drops formed by mixing equal volumes 
(150nl) of protein and reservoir solution. All high-throughput 96-well crystallization 
screens were purchased from Hampton Research. These included the Hampton 1 and 
2, Index, PACT, CSS 1 and 2, Peg Ion 1 and Peg Ion 2 screens. In addition, due to the 
likely association of both CT694 and PmpD with host and bacterial cell membranes, 
specialized 96-well high-throughput MemPlus and MemGold membrane protein 
screens (Molecular Dimensions) were also utilized. For rPmpD and CT694 proteins, 
concentrations of 5-20mg/ml or 10-80mg/ml were used (respectively). 
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2.1.11 Agarose Gel Electrophoresis 
DNA was analysed using agarose gel electrophoresis. Agarose and SybrSafe DNA gel 
stain were purchased from Invitrogen. 1kb DNA ladder and 6× loading dye were 
purchased from New England Biolabs (NEB). A 1% (w/v) agarose gel consisted of 
0.7g of agarose in 70ml Tris-base, acetic acid and EDTA (TAE) buffer and 1µl of 
10000× SybrSafe DNA gel stain. 20µl-loading samples consisted of 83% (v/v) DNA 
solution and 17% (v/v) loading dye. Electrophoresis with 1% agarose gels was carried 
out at 100V for 40 minutes in 1× TAE buffer. DNA fragment length was estimated 
using 1kb DNA ladder (NEB). Detection, photography and excision of amplified 
DNA fragments were visualized under a Safe Lamp and excision of bands of 
corresponding molecular weights carried out using a scalpel.  
 
1x Gel Loading Dye: 2.5% Ficoll-400, 11mM EDTA, 3.3mM Tris-HCl (pH 8.0), 
0.017% SDS, 0.015% bromophenol blue 
TAE buffer: 40mM Tris, 20mM acetic acid, 5mM EDTA, pH 8.0 
 
2.1.12 SDS- and Native PAGE 
Acrylamide solution was purchased from National Diagnostics. All running and 
loading buffers for Native PAGE contained no SDS. SDS-PAGE samples were 
denatured for 5mins in sample loading buffer at 95°C prior to gel loading. ‘Broad 
Range Molecular Weight Marker’ (BioRad) was used as a standard to estimate 
protein molecular weights. The marker contained myosin (200kDa), β-galactosidase 
(116kDa), phosphorylase B (97.4kDa), serum albumin (66.2kDa), ovalbumin 
(45kDa), carbonic anhydrase (31kDa), trypsin inhibitor (21.5kDa), lysozyme 
(14.4kDa) and aprotinin (6.5kDa). 
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Protein samples were analysed by loading on to 10% SDS gels and 5% native gels. A 
10% resolving gel consisted of 2ml deionized water, 1.5ml buffer (1.5M Tris/HCl, 
0,4% (w/v) SDS, pH 8.8), 1.65ml acrylamide solution, 25µl of 10% (w/v) APS, 4µl 
TEMED and 4µl bromophenol blue. A 5% native gel consisted of 2ml of deionized 
water, 1.5ml buffer (1.5M Tris/HCl, pH 6.8), 0.825ml acrylamide solution, 25µl of 
10% (w/v) APS and 4µl TEMED. Following electrophoresis, the gels were immersed 
overnight in staining and then destaining solutions (see below) and photographed 
using the SynGene INGENIUS apparatus with GeneSnap software. 
 
Loading buffer: 0.5M Tris, 10% (w/v) glycerol, 2% (w/v) SDS, 0.005% 
Bromophenol Blue, 5% (v/v) β-mercaptoethanol, pH 6.8 
Running Buffer: 25mM Tris, 250mM glycine, 0.1% (w/v) SDS, pH 8.4 
Staining solution: 25% (v/v) propan-2-ol, 10% glacial acetic acid, 0,2% (w/v) 
Coomassie Brilliant Blue 
De-staining solution: 5% (v/v) propane-2-ol and 7% (v/v) glacial acetic acid 
 
2.2 In vitro cell adhesion studies 
This section describes the procedures used in cell adhesion experiments with rPmpD-
coated polystyrene beads described in Chapter 5. 
 
2.2.1 Bradford Assay 
Eight dilutions of BSA standard (2000µg/ml, 1500µg/ml, 1000µg/ml, 750µg/ml, 
500µg/ml, 250µg/ml, 125µg/ml, 25µg/ml and 0µg/ml) were prepared. Buffer 
containing 20mM Tris/HCl, 50mM NaCl was used as the diluent for BSA standards. 
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1x dye reagent was equilibrated to room temperature, and 1ml of this solution 
pipetted in to a disposable cuvette. 20µl of standard or protein sample of unknown 
concentration was pipetted in to the cuvette, mixed well, and left for 5mins at room 
temperature before absorbance was measured at 595nm on a UV Eppendorf 
Biophotometer. Unknown protein concentrations were determined from the standard 
curve. 
Coomassie (Bradford) Protein Assay Reagent: Coomassie G-250 dye, methanol, 
phosphoric acid and solubilizing agents in water.  
 
2.2.2 Endotoxin Removal and Quantification 
To remove LPS from rPmpD prior to use in immunisations and adhesion assays, 1ml 
of rPmpD was sealed with parafilm in a sterile Eppendorf tube and incubated with 
10µl of Triton-X 114 detergent (1:100 dilution) with stirring in a water bath at 4°C 
overnight. Sample was then incubated at 37°C for 10mins to form detergent micelles 
with LPS followed by immediate centrifugation at 13,300rpm and separation of 
supernatant aqueous (rPmpD-containing) from detergent (LPS-containing) phases. 
Supernatants were then analysed for endotoxin concentration using the LAL 
Endotoxin Chromogenic substrate kit according to the manufacturer’s protocol. 
All reagents were equilibrated to room temperature before use. Four vials containing 
endotoxin standards (1EU/ml, 0.5EU/ml, 0.25EU/ml, 0.1EU/ml) were prepared, and 
50µL of each standard or unknown sample replicate into the appropriate microplate 
well, cover the plate with the lid and incubate for 5 minutes at 37°C. Each series of 
determinations included duplicate runs of rPmpD supernatant, blanks (50µL of 
endotoxin-free protein buffer or endotoxin-free water) and four endotoxin standards. 
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50µL of LAL was added to each well using a pipette and incubated at 37°C for 10 
mins. 100µL of substrate solution to each well and mixed thoroughly, followed by 
incubation of the plate at 37°C for 6 minutes. 50µL of Stop Reagent (25% acetic acid) 
was added and gently shaken on a plate mixer for 10 seconds. Absorbance was read at 
405nm on a plate reader VersaMax microplate reader in conjunction with the 
SoftMax Pro v.5.3 software (Molecular Devices, USA).  
After subtraction of the average absorbance of the blank replicates from the average 
absorbance of all individual standard and unknown sample replicates, a standard 
curve was plotted with average blank-corrected absorbance for each standard versus 
concentration in EU/mL.  Endotoxin concentration of each unknown sample was 
estimated using the equation for the line of best fit.   
Pierce LAL Chromogenic Endotoxin Quantitation Kit, sufficient reagents to 
perform 50 assays of standards and samples in a microplate (i.e., 50 wells total)  
Kit Contents: Escherichia coli (E. coli) Endotoxin Standard (011:B4), lyophilized, 
1 vial, 15-40 endotoxin units (EU)/mL upon reconstitution Limulus Amebocyte 
Lysate (LAL), lyophilized, 2 vials, 1.4mL/vial upon reconstitution Chromogenic 
Substrate, lyophilized, 1 vial, 6.5mL/vial upon reconstitution Endotoxin-free 
Water, 1 vial, 30mL  
 
2.2.3 Bead adhesion experiments 
1 mL of 1% bead suspension in 50 mM MES pH 6.1 containing a final protein 
concentration of 0.25μg/ml - 50μg/ml rPmpD or BSA was used for coating the beads. 
A final concentration of 1mM EDAC was used to covalently link rPmpD directly to 
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the beads through primary amine groups on the ligand. 50μg/ml, 25μg/ml, 2.5μg/ml 
and 0.25μg/ml concentrations of rPmpD were used for coating beads. The mixture 
was incubated at 20°C with gentle shaking for 1hr and the reaction was stopped by 
centrifugation of the suspension, discarding the supernatant, and washing the pellet 
twice in in binding buffer to remove all traces of EDAC. Coupling of rPmpD protein 
to the beads was verified on SDS-PAGE by inspection of the reaction supernatant and 
boiling of coated beads at 95°C for 5mins.  
 
2.2.4 Bead binding  
Initial adhesion assays using 2µm L4530 fluorescent beads (Sigma Aldrich) were 
performed on layers of Hak cells (70-80% confluent) in 96-well plates. Serial 
dilutions of beads (1:20, 1:50 and 1:100) were added to Hak cells which were 
incubated for 1 h at 4°C to initiate binding. Unattached beads were removed by twice 
washing with PBS, and cells were fixed with methanol. Binding was quantified 
following Giemsa staining, by counting the number of attached beads per 50 cells in 
triplicate fields of view under phase microscopy. Naked (uncoated) or BSA-coated 
beads were used as controls. 
 
2.2.5 Antibody neutralisation assay 
Three dilutions (1:20, 1:50 and 1:100) of a 1% solution of L4530 fluorescent beads 
were separately pre-incubated with three dilutions (1:50, 1:100, 1:200) of heat-
inactivated pre-immune or anti-rPmpD immune serum (obtained from immunized 
C57BL/6 mice) for 1h at 37°C with gentle shaking to enable binding of antibodies to 
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the beads. Bead-serum mixtures were then added to layers of Hak cells (70-80% 
confluent) in 96-well plates, and incubated for 2h at 4°C to allow for binding. 
Unattached beads were removed by twice washing with PBS, and cells were fixed 
with methanol. Binding was quantified following Giemsa staining, by counting the 
number of attached beads per 50 cells in triplicate fields of view under phase 
microscopy. Naked (uncoated) or BSA-coated beads were used as controls. 
 
2.2.6 Competitive inhibition assay 
Monolayers of Hak cells (70-80% confluent) in 96-well plates were pre-incubated 
with four dilutions (50μg/ml, 25μg/ml, 2.5μg/ml and 0.25μg/ml) of soluble rPmpD 
for 1hr at 4°C to allow for binding. Following two washes in PBS to remove unbound 
protein, three dilutions (1:20, 1:50 and 1:100) of a 1% solution of L4530 fluorescent 
beads were added and incubated for 2h at 4°C to allow for binding. Unattached beads 
were removed by twice washing with PBS, and cells were fixed with methanol. 
Binding was quantified following Giemsa staining, by counting the number of 
attached beads per 50 cells in triplicate fields of view under phase microscopy. Naked 
(uncoated) or BSA-coated beads were used as controls. 
Beads: Fluorescent carboxylate-modified beads of several mean particle size 
distributions were purchased from Sigma Aldrich - L3210 (0.5µm), L4655 (1µm) or 
L4530 (2µm). 
Coupling buffer: Covalent coupling to carboxylate-modified beads was performed 
by reaction with 1mM N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDAC) (Sigma Aldrich) in 50 mM MES pH 6.1. 
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Binding buffer: 100mL of binding buffer was composed of 10mL (10x RPMI), 10% 
BSA (w/v), 1mL 1M HEPES (pH7.5) and 89mL deionized water. Buffer was sterile-
filtered prior to use. 
Giemsa stain solution 
Giemsa stain solution consisted of 3.6ml Sorensen A [9.5g/l NaHPO4 (Sigma)], 1.4ml 
Sorensen B [9.07g/l KH2PO4 (Sigma)], 45ml de-ionized water and 5.55ml Giemsa 
stain (VWR International). 
 
2.3 In vivo vaccinology studies 
This section describes the procedures used in in vivo vaccinology studies (described 
in Chapter 6) using monomeric 65kDa rPmpD (Fig.4.2) in combination with three 
different formulations of a second-generation lipid adjuvant (SLA) in a mouse model 
of Ct infection. 
 
Buffers and Solutions 
Phosphate buffered saline 
1x phosphate buffer saline (PBS) consisted of 10mM PO43−, 137 mM NaCl, and 2.7 
mM KCl made up in distilled water. 
Gey’s solution 
Individual solutions consisted of: 
Solution A (1L): 35g NH4Cl (Sigma-Aldrich), 1.85g KCl (VWR International), 0.63g 
Na2HPO4 (Sigma-Aldrich), 0.12g KH2PO4, 5g Glucose 
Solution B (100mL): 0.42g MgCl2.6H2O (Sigma-Aldrich), 0.14g MgSO4.7H20 
(Sigma-Aldrich), 0.34g CaCl2 (Sigma-Aldrich) 
Solution C (100mL): 2.25g NaHCO3 (Sigma-Aldrich) 
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Gey’s working stock (1x): Solution A: 20 parts, Solution B: 5 parts, Solution C: 5 
parts, Distilled water: 70 parts 
 
Buffers for Enzyme-Linked Immunosorbent Assay (ELISA)  
Coating buffer consisted of 0.1M Na2CO3, 0.1M NaHCO3, pH 9.6. Blocking buffer 
and diluent consisted of 1x PBS with 0.05% Tween-20 (Sigma-Aldrich) and 0.1% 
BSA (Sigma-Aldrich). 0.01% sodium azide (Sigma-Aldrich) was added to blocking 
buffer only. Wash buffer consisted of 1x PBS with 0.05% Tween-20 (Sigma-Aldrich). 
 
2.3.1 Animals 
Female C57BL/6 mice were obtained from a locally maintained colony (University of 
York, York, UK). Female Balb/c mice were obtained from Harlan Laboratories 
(Wisconsin). Both mouse strains were used from 6-8 weeks of age and housed under 
specific pathogen-free conditions. Experimental procedures were administered in 
accordance with the UK Home Office regulations. 
 
2.3.2 Animal Samples 
Blood samples were obtained by tail snip. Up to 50µl of blood was stored in 
Eppendorf vials on ice or at 4°C until processing. Total blood volume was taken via 
cardiac puncture using a 25G needle after death. Mice were killed by carbon dioxide 
asphyxiation followed by cervical dislocation. The spleen was dissected and kept at 
4°C. in 1x RPMI (Gibco) until processing. Each spleen was homogenized using a 
50µm cell strainer. 10ml of sterile 1x RPMI medium (Sigma Aldrich) was used to 
wash splenocytes through the strainer into the Falcon tube. These were centrifuged at 
1300rpm for 10mins at 4°C. 
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2.3.3 Chlamydia trachomatis strains 
C.trachomatis E/Bour strain and genomic DNA were obtained from ATCC. Clinical 
isolates E9/Soton and F1/Soton were obtained from Professor Ian Clarke (University 
of Southampton) and serovar D/UW3/Cx from Imperial College, London (propagated 
in the Shattock Laboratory, originally from Rey Carabeo). 
 
2.3.4 Cell culture and propagation of Chlamydia trachomatis strains 
C.trachomatis isolates were propagated in mycoplasma-free McCoy cells (ATCC) in 
96-well, 24-well, 6-well plates (Sigma) or 75-cm2 polystyrene culture flasks 
(Corning). McCoy cells were grown in Dulbecco’s modified Eagles’ medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). Cell seeding densities were 
determined using Tryphan Blue staining and haemocytometer counts. Cells were 
infected with C.trachomatis strains by centrifugation of the inoculum at 1800rpm for 
30mins-1hour at room temperature or 37°C in DMEM containing cycloheximide 
(1µg/ml) and gentamicin (25µg/ml). After completion of the biphasic developmental 
cycle, cells were harvested using a cell scraper and centrifuged at 3500rpm. For 
storage, the C.trachomatis-infected pellet was resuspended in a 1ml solution of ice-
cold 4-sucrose phosphate buffer (16mM Na2HPO4, pH 7.1 and 0.4M sucrose, 
abbreviated as 4SP) and 10% PBS (mixed in a 1:1 ratio). The cells were transferred 
into a bijoux tube with sterile glass beads and lysed by vortexing for 2 mins. Cell 
debris was removed by centrifugation at 1500rpm for 5 mins and the supernatant 
collected and stored at -80°C. 
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2.3.5 Chlamydia trachomatis UV-inactivation 
C.trachomatis serovars E9/Soton or E/Bour elementary bodies were inactivated by 
UV irradiation at a distance of 15cm under a UV-lamp for 60 minutes. Viability was 
validated by inoculation on to McCoy cell monolayers and immunofluorescence 
staining 48 hrs post infection. 
 
2.3.6 Second Generation Lipid Adjuvant Formulations 
Second-generation lipid adjuvant (SLA) was synthesised by Avanti Polar Lipids 
(Alabaster, AL), Corden Pharma (Liestal, Switzerland), or in collaboration with Dr. 
Robert William’s lab at Colorado State University. Squalene and cholesterol were 
purchased from Sigma-Aldrich (St. Louis, MO). Poloxamer 188 and glycerol were 
obtained from Spectrum Chemical (Gardena, CA). Buffer components purchased 
from J.T. Baker (San Francisco, CA). Dioleoyl phosphatidylcholine (DOPC) was 
obtained from Lipoid LLC (Newark, NJ). Dimyristoyl phosphatidylcholine (DMPC) 
and dipalmitoyl phosphatidylcholine (DPPC) were obtained from Avanti Polar Lipids 
or Lipoid. 
  
Aqueous suspensions of SLA (SLA-AF) were manufactured by mixing DPPC and the 
TLR4 ligand at a 2:1 DPPC:SLA molar ratio in chloroform, which was then 
evaporated. Ultra pure water was added to the resulting dried film, and the mixture 
was sonicated in a VWR 75D (West Chester, PA) or Crest Powersonic CP230D 
(Trenton, NJ) sonicating water bath at 60°C until the formulation was translucent. 
  
Oil-in-water emulsion formulations of SLA (SLA-SE) were manufactured by high-
speed mixing a buffered aqueous phase (containing poloxamer 188, glycerol, and 
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ammonium phosphate buffer) and an oil phase (containing squalene, DMPC, and 
SLA) at 7,000-10,000 rpm for 10 minutes followed by microfluidization for 10-12 
passes at 30,000 psi as described previously with minor modifications (Misquith et 
al., 2014). 
  
The liposome formulation (SLA-LSQ) was manufactured by the thin film technique, 
with the lipid excipients (DOPC:cholesterol 4:1 weight ratio) together with SLA were 
initially mixed in chloroform. Following evaporation of the solvent, the lipid film is 
hydrated in 25 mM ammonium phosphate buffer (pH ~5.7) and briefly sonicated in a 
water bath to remove the film from the glass flask. This crude liposome mixture is 
then processed by high-pressure homogenization at 20,000 psi for five cycles to 
achieve a monodisperse particle size ~80 nm, which is then mixed with aqueous 
QS21 solution and sterile-filtered through a 0.2 µm membrane. 
 
2.3.7 Mouse immunisations 
Six-eight week old C57BL/6 mice were obtained from local colonies (York BSF) and 
housed in specific pathogen-free conditions. Animals were immunised 
subcutaneously (s.c.) at the base of the tail on day 0 with 100µl of sterile PBS 
containing 5µg/dose SLA adjuvant (SLA-AF, SLA-SE SLA-LSQ) with 5µg/dose 
rPmpD or 2x107 IFU of UV-inactivated Ct serovar E/Bour EBs. Mice were boosted 
s.c. with the same doses on days 21 and 42. Additional groups of mice received 
rPmpD or PBS alone as controls. 
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2.3.8 Chlamydia trachomatis intra-vaginal challenge, bacterial swabbing and 
quantification 
Mice were anaesthetised with isofluorane (Abbott, Maidenhead, UK) in a dedicated 
inhalation chamber prior to Depo-Provera administration and challenge. All animals 
received a subcutaneous injection of 2.5mg of medroxyprogesterone acetate (Depo-
Provera, Pfizer) in the scruff of the neck one week prior to challenge. After testing for 
lack of a reflex, when in a light sleep, the animals were held upwards from the base of 
the tail and 10µl of Chlamydia trachomatis urogenital serovar D/UW3/Cx containing 
4.5×108 IFU (obtained from Prof. Rey Carabeo) was pipetted into the vaginal vault 
using a Microman Precision Microliter Pipette with rounded-tip capillary pistons 
(Gilson). 
 
Cervicovaginal swabs were obtained on days 1, 3, 7, 14 and 22 post-challenge. Swabs 
were vortexed in 500µl sterile PBS with glass beads and stored at -80°C until 
titration. Enumeration of recoverable Ct bacteria was conducted in Hak cells (ATCC) 
using serial dilutions of swab samples centrifuged on to cell monolayers by 
immunofluorescence 48hrs post infection. The total number of inclusions per well 
were counted at 10x magnification using fluorescence microscopy, and quantified as 
inclusion forming units per ml (IFU/ml). 
 
2.3.9 Cervico-vaginal washes 
Cervico-vaginal washes were carried out under the same conditions of anaesthesia. 
100µl of sterile-filtered 1x PBS was pipetted up-and-down the vaginal cavity ten 
times using a Microman Precision Microliter Pipette with rounded-tip capillary 
pistons. To prevent protein degradation, 25x Protease Inhibitor Cocktail (Sigma-
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Aldrich) was added to the PBS. Cervico-vaginal washes were stored at -80°C until 
use. 
 
2.3.10 ELISA 
Serum was obtained on days 0, 14, 35, 56 and 105. Cervico-vaginal washes were 
obtained on days 34 and 55 post initial immunization. Blood samples were left at 4°C 
overnight to facilitate clotting. The following day, samples were centrifuged at 24,000 
x g at 4°C for 15 minutes to separate serum from cells. Sera and washes were stored 
at -20°C until required. 96-well Assay plates (Costar) were coated with 50µl rPmpD 
(1µg/ml) or UV-inactivated Ct E/Bour UVEBs (5.8x106 IFU/ml) at 4°C overnight in 
coating buffer (0.1M Na2CO3, 0.1M NaHCO3, pH 9.6).  Plates were washed four 
times with wash buffer (300µl/well). All subsequent washing steps were carried out 
using the same number of washes and volume of wash buffer per well with a 
SkanWasher 400 (Molecular Devices, USA). Blocking buffer was added (200µl/well) 
and plates incubated for 2hr at room temperature prior to addition of serial dilutions 
of serum (100µl/well) in diluent from (1/10 to 1/10,000,000) and serial dilutions of 
cervico-vaginal wash (neat to 1/625). After incubation for 2 hours at 37°C, plates 
were washed and then incubated with HRP-conjugated goat anti-mouse IgG, IgG1 or 
IgG2c antibodies (AbD Serotec) at 37°C for 30 minutes. After the final wash step, 
50µl/well of ,3’,5,5’-tetramethylbenzidine (TMB) substrate solution (Sigma-Aldrich) 
was added. Colour development was stopped after 5 minutes with 1M H2SO4 (KPL, 
USA) and plates were read immediately at 450nm (OD450) with a VersaMax 
microplate reader in conjunction with the SoftMax Pro v.5.3 software (Molecular 
Devices, USA). Reciprocal serum dilutions corresponding to 50% maximal binding 
were used to obtain titres. 
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2.3.11 ELISpot 
For initial immunogenicity studies, animals were euthanized 15 days after the final 
immunization, spleens collected, and single cell suspensions made. For the challenge 
study, animals were euthanized 8 weeks following final immunization (5 weeks post 
challenge). Enzyme-linked immunospot (ELISpot) assays were performed 
immediately following splenic harvest. Briefly, 96-well MultiScreen plates filtration 
plates (Millipore) were coated overnight at 4°C with IFNγ, IL-2, IL-5 or IL-10 
monoclonal capture antibodies (Mabtech). Splenocytes (2.5x105) were added to the 
plate in the presence of 1µg/ml rPmpD. After incubation at 37°C with 5% CO2 for 
20h, plates were washed and incubated with respective biotinylated detection 
antibodies according to manufacturer’s protocol (Mabtech). This was followed by 
incubation with streptavidin-alkaline phosphatase (1hr, RT) and addition of 
BCIP/NBT-plus substrate until distinct spots emerged. Plates were washed and dried 
overnight and spot forming units enumerated by eye. 
 
2.3.12 Western Blot 
Whole cell lysates of Ct serovar D/UW3/Cx were fractionated by SDS-PAGE and 
transferred to a polyvinylidene difluoride (PVDF) membrane using a transfer 
apparatus according to the manufacturer’s protocols (Bio-Rad). After incubation with 
5% BSA in Tris-buffered saline and Tween-20 (TBST - 10mM Tris, pH 8.0, 150mM 
NaCl, 0.5% Tween 20) for 60 min, the membrane was washed once with TBST and 
incubated with either preimmune serum, or d56 serum obtained from C57BL/6 mice 
immunized with rPmpD or UVEBs at 4°C overnight. Membranes were washed three 
times in TBST for 10 min and incubated with a 1:1000 dilution of HRP-conjugated 
anti-mouse antibody for 2h. Blots were washed with TBST three times and developed 
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with the ECL reagents (Amersham Biosciences) according to the manufacturer’s 
protocols. 
 
2.3.13 Immunofluorescence 
Cells were fixed by incubating in 100% methanol (chilled at -20°C) at room 
temperature for 5 min. After decanting the methanol, blocking buffer was added for 
30 min at room temperature to prevent unspecific binding of the antibodies. Cells 
were subsequently incubated with primary antibody (1:50) in dilution buffer for 1hr at 
room temperature and washed three times in PBS (5 min per wash) prior to addition 
of corresponding secondary antibodies (1:300) in the dark. After two 5mins washes, 
DAPI solution diluted (1:5000) in blocking buffer was added for 5mins and coverslips 
were subsequently dipped in deionized water and mounted in mounting medium on 
glass slides (ThermoFisher). 
 
Immunofluorescence antibodies and buffers 
1× Phosphate Buffered Saline (Sigma-Aldrich), Methanol (Fluka), Blocking and 
Dilution Buffer (1x PBS/0.2% BSA), Primary antibodies: Mouse anti-Ct LPS 
(ab54377 - abcam), Mouse anti-Ct MOMP (sc51837 - Santa Cruz), Secondary 
Antibodies: Donkey anti-mouse Alexa-Fluor 555 (Invitrogen), Goat anti-rabbit 
Alexa-Fluor 488 (Invitrogen), 4',6-diamidino-2-phenylindole – DAPI (Invitrogen), 
Mounting medium: Add 2.4 g of Mowiol 4-88 was added to 6 g of glycerol. 18 mL 
of 0.2 M Tris-Cl (pH 8.5) was added and heated to 50°C for 10min with occasional 
mixing. Following dissolution of the Mowiol, DABCO was added to 2.5% (w/v) to 
reduce fading. 1mL aliquots were stored at −20°C. 
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2.4 Statistical Analysis 
Unless otherwise stated, groups were compared using an unpaired t-test assuming 
non-uniform variance, and all statistical analyses performed using the GraphPad 
Prism5 software. For vaccinology studies measuring resistance to infection and mean 
bacterial load, Professor Martin Bland performed the statistical analysis using the 
Stata data analysis and statistical software package. Groups were compared using 
one-way analysis of variance (ANOVA). If the data did not fit the model of normal 
distributions with uniform variance, a transformation was used. Visual inspection of 
the transformed data and Bartlett’s test for equal variances were used to verify the 
assumptions.  Following one-way ANOVA, pairs of groups were compared using 
Sidak’s multiple comparison method. P-values ≤ 0.05 were considered significant. 
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Chapter 3: Biophysical characterization CT694, an early type-three 
secretion system effector of Chlamydia trachomatis 
 
3.1 Introduction 
In addition to the Type V autotransporter secretion system (T5AT) that comprises the 
nine Pmps, C.trachomatis also possesses a Type III secretion system (T3SS), of 
which several substrates have been identified, and shown to interact with an array of 
host proteins. These include members of Inc family of proteins which associate with 
the Ct inclusion membrane (Rockey et al., 2002), and the well studied effector known 
as Tarp (translocated actin-recruiting phosphoprotein). Tarp is an early Ct effector 
known to be involved in remodelling of the host cytoskeleton and interactions with 
cell signaling proteins (Jewett et al., 2008; Jewett et al., 2006). Manipulation of the 
cytoskeletal machinery and signaling pathways is often a key prerequisite in the 
successful invasion of non-phagocytic cells by pathogenic bacteria (Dautry-Varsat, 
Subtil and Hackstadt, 2005).  
 
Genomic transcriptional analysis during the Ct developmental cycle has been 
conducted (Belland et al., 2003). Here, microarrays were used to determine 
upregulation of genes associated with early (EB to RB) and late (RB to EB) stages of 
chlamydial development. Typically, it was found that immediate-early genes are 
associated with metabolism, and one gene was discovered to be a homolog of human 
early endosomal antigen-1 (CT147), associated with the chlamydial inclusion. Genes 
transcribed later in development typically encoded proteins involved in membrane 
assembly such as the cysteine-rich outer membrane proteins OmcA and OmcB 
(CT444 and CT443), Pmps G and H (CT871 and CT872) and aforementioned 
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thioredoxin disulphide isomerases (CT780 and CT783), are likely associated with 
correct disulphide bond formation in the COMC.  
 
Interestingly, a predicted T3SS effector unique to C.trachomatis (CT694) was also 
found highly upregulated late in development. Genes transcribed late in development 
during RB to EB transition are hypothesized to be packaged away as effector proteins 
primed for invasion (Fields et al., 2003). Until very recently, due to the lack of a 
tractable genetic manipulation system for Ct, several T3SS substrates have been 
identified through the use of chemical inhibitors and heterologous expression systems 
in Yersinia and Salmonella (Fields and Hackstadt, 2000; Muschiol et al., 2006; Subtil, 
Parsot and Dautry-Varsat, 2001; Wolf et al., 2006).  
 
CT694 and the adjacent CT695 gene were secreted by Yersinia pseudotuberculosis, 
but not by the T3SS null mutant (ΔyscS) Yersinia pseudotuberculosis (Hower, Wolf 
and Fields, 2009). Interaction partners for CT694 were identified using a 
Saccharomyces cerevisiae yeast-two-hybrid screen, with full-length CT694 fused to 
the gal4 binding domain and expressed in an AH109 strain, which was mated with a 
Y187 strain expressing a HeLa cell cDNA library fused to the gal4 activation domain. 
Recovered plasmids revealed interaction with residues 891-1055 of human AHNAK, 
a 700kDa protein known to bind actin (Haase et al., 2004;Hohaus et al., 2002). 
Further experiments also revealed that a CT694 ΔC-terminal truncated protein 
(CT694ΔC) failed to interact with AHNAK indicating involvement of this region in 
host cell interactions. 
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Ectopic expression of CT694 in HeLa cells revealed colocalization of GFP:CT694 
with endogenous AHNAK. In contrast, GFP:CT694ΔC was found to associate with 
the plasma membrane, but failed to associated with AHNAK. Furthermore, ectopic 
expression of GFP:CT694 in HeLa cells resulted in decreased abundance of actin 
fibres stained by phalloidin, indicating possible effects on cytoskeletal remodeling by 
CT694 (Hower, Wolf and Fields, 2009). To investigate the hypothesis that the N-
terminus of the protein contains a domain that may be involved in membrane 
localization, subsequent studies generated a range of GFP-fusion constructs to 
identify protein localization and binding partners during ectopic expression and yeast-
two-hybrid (Y2H) screens (Bullock, Hower and Fields, 2012). 
 
Fig.3.1 (reproduced from Bullock, Hower and Fields (2012)), shows the different 
truncations used to study the subcellular localization of the N- and C-terminal 
domains of CT694. The authors found that full-length CT694 associated with 
AHNAK as well as plasma membranes, but that a construct deficient in the N-
terminal region corresponding to amino acid residues 40-80 is deficient for membrane 
localization. CT694 has thus been classified as a multi-domain T3SS effector, and is 
postulated to function in concert with Tarp during the invasion process, most likely in 
cytoskeletal remodeling. The presence of an N-terminal membrane localization 
domain may be important in targeting effector molecules to specific host cell 
compartments, while the distal C-terminal domain involved in AHNAK interaction 
and morphological changes may confer effector function. 
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Recently, a Ct molecular chaperone Slc1 has been identified in complex with both 
CT694 and CT695, suggesting that CT695 is also a Ct effector, the function of which 
is yet to be fully elucidated (Pais et al., 2013). In addition, CT694 has been used as a 
diagnostic antigen in the monitoring of trachoma programs (Goodhew et al., 2012; 
Martin et al., 2015), suggesting immunogenicity during the course of natural 
infection, and its implied effector function may warrant its use as an antigen in future 
multicomponent Ct vaccines. Our investigations aim to elucidate the biophysical 
characteristics of this Ct-specific T3SS effector, using a range of methodologies 
similar to those employed for the study of rPmpD.  
 
3.2 Results 
3.2.1 Generation of the plasmids encoding CT694  
Ct serovar E/Bour genomic DNA (ATCC) was amplified using the GenomiPhi DNA 
amplification kit (GE Healthcare) to generate increased amount of DNA for PCR 
reactions. This resulted in a range of DNA fragments of varying molecular weights 
(Fig.3.2).  
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3.2.2 Analysis of plasmids for correct gene insertion using PCR and DNA 
sequencing 
Following ligation, transformation and plasmid amplification in NovaGigaSingle 
cells, PCR amplification of the isolated plasmids was conducted using initial primers 
used for gene amplification (Table.2.2). DNA fragments were resolved using agarose 
gel electrophoresis and visualization with SybrSafe stain under UV-light (Fig.3.3). 
This revealed the expected fragment size for ligated inserts. DNA sequencing was 
used to verify the correct sequence of all plasmids following cloning (Appendix). 
Due to the presence of a XhoI restriction enzyme site (CTCGAG) within the CT694 
gene, plasmids encoding the full-length gene were generated from the pET-28 (b) 
vector backbone using NcoI and XhoI restriction enzyme digest of the vector, and 
NcoI and SalI restriction enzyme digest of the gene fragment amplified from Ct 
serovar E/Bour DNA (Fig.3.3). SalI possesses the same complementary overhang 
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[TCGA] as XhoI, so ligation can still be carried out using the T4-DNA-ligase. For 
cloning of the ΔN-CT694 gene, both vector and fragment were cloned and ligated 
using NcoI and XhoI restriction enzyme digests followed by incubation with T4 
DNA-ligase. Genes cloned using this restriction enzyme combination result in a C-
terminal His6 tag. After ligation of the vector and insert, gene fragments were located 
between the ribosome binding sequence and the His6 tag (Fig.2.2).  
 
3.2.3 Overexpression of Chlamydia trachomatis recombinant CT694 full-length 
protein  
Full-length (~35kDa) CT694 was overexpressed and purified in the soluble cytosolic 
fraction in E.coli BL21 (DE3) cells. Overexpressed full-length protein was purified 
using a three-step Ni-MAC, SEC and IEC procedure and analysed using both 5% 
native gel electrophoresis and 12% SDS-PAGE. Representative Akta traces are shown 
for typical purification steps (Fig.3.4-3.5). CT694 elutes as two well-defined peaks, 
with a mixture of oligomers eluting at the void volume of the column, and monomeric 
35kDa CT694 protein eluting as the second peak. Purity was confirmed using SDS-
PAGE and native gel electrophoresis. 
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SDS gels show significant proteolysis of full-length recombinant CT694 over time. 
This breakdown pattern is shown in Fig.3.6(A), as full-length protein degrades to a 
well-defined fragment after four months at 4°C. N-terminal sequencing of this 
breakdown product revealed the sequence: DIYHPTIFGQGAQPIVSTGDKKLD 
(Fig.3.6(B)), although no data were obtained for the C-terminal sequencing. 
Interestingly, the N-terminal sequence begins at amino acid residue 80 of the protein, 
suggesting the putative membrane localization domain identified in the study by 
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(Bullock, Hower and Fields, 2012) is labile or auto-catalytically cleaved. We have 
named this ~27kDa fragment ΔN-CT694.  
 
3.2.4 Overexpression of Chlamydia trachomatis recombinant ΔN-CT694 
fragments 
ΔN-CT694 was successfully cloned in to the pET-28 (b) vector for cytosolic 
expression (Fig.3.7) using primers designed as described in Materials and Methods 
(Table 2.1). 
 
Overexpression of ΔN-CT694 reveals a similar SEC elution profile as full-length 
CT694 (Fig.3.5). Manual annotation of the N-terminal sequencing data following 
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MALDI-MS is shown in Fig.3.8. This is confirms the three most prevalent N-terminal 
sequences observed in the sample. 
 
ΔN-CT694 is found to be stable at 4°C at the 6 week time point, but shows 
proteolysis when incubated for the same time period at 17°C and 20°C (Fig.3.9(A)). 
This may be due to slight contamination and increased activity of cytosolic E.coli 
proteases at higher temperatures, and the diminishing effects of protease inhibitor 
cocktails used in protein purification over time. ΔN-CT694 was retrieved from 
crystallization drops form Greiner plates incubated at 4°C for 6 weeks in native and 
SDS gels under both reducing and non-reducing conditions. No indications of 
disulphide-mediated intermolecular interactions are observed here, as ΔN-CT694 
enters and migrates to the predicted molecular weight irrespective of the presence of 
β–ME in 12% SDS-PAGE (Fig. 3.9 B and C). Likewise, there is no evidence for 
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differential migration in native gels with or without the presence of reducing agents. 
This indicates the likelihood of an intramolecular disulphide bond formed between the 
two Cys residues contained within this fragment that stabilize the protein fold. All 
further crystallization experiments were thus carried out at 4°C. 
To assess the likely secondary structure of ΔN-CT694, circular dichroism was 
conducted. This shows likely structured, folded protein, and a characteristically α–
helical profile (Fig.3.10), as predicted by secondary structural prediction algorithm 
PSIPRED (Fig.3.11).  
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3.2.5 I-TASSER tertiary structural modeling of CT694  
As an adjunct to ongoing crystallisation screens, an attempt was made to gain likely 
insight in to ΔN-CT694 tertiary structure and topology by ab initio modeling using 
the iterative threading assembly refinement (I-TASSER) server (Roy, Kucukural and 
Zhang, 2010). This methodology has previously been employed and validated for the 
modeling of hypothetical Ct protein CT296 (Kemege et al., 2011). Interestingly, the I-
TASSER predicted model very closely matched the experimentally verified structure 
of CT296 solved by X-ray crystallography (RMSD of Cα atoms ~2.72-angstroms). 
Furthermore, these structural descriptions challenged previous experimental findings 
within the field, and validated the efficacy of ab initio modeling in predicting the 
structure, and hence function of a hypothetical protein (Kemege et al., 2011). 
 
Because CT694 shows no primary sequence homology to any known protein outside 
Ct or the closely related Cm biovars, it was decided to employ I-TASSER modeling to 
deduce likely secondary structure (Fig.3.12). Importantly, the predicted α–helical 
structure corresponds to experimentally validated secondary structure using circular 
dichroism (Fig.3.10). The majority of solved protein structures within the PDB that 
possessed most significant homology to the predicted CT694 model as generated by I-
TASSER belonged to the karyopherin superfamily of nuclear importins. Karyopherins 
are responsible for binding to specific cytosolic proteins bearing a classic nuclear 
localization sequence (NLS) (Lee et al., 2006), followed by translocation across the 
nuclear membrane (Kobayashi and Matsuura, 2013).  
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Furthermore, the stable proteolytic product observed following expression of full-
length CT694 corresponds with complete cleavage of the membrane localization 
domain (MLD) between residues 79/80 (Bullock, Hower and Fields, 2012). 
Given that CT694 does not fractionate with membranes during late-cycle 
development (Bullock, Hower and Fields, 2012), it may be likely that the MLD is 
required only for interaction with host cell membranes during Ct adhesion and 
invasion, but is subsequently cleaved off during later stages, suggesting possible 
alternative cytosolic effector functions for the CT694 C-terminal domain in RBs. 
 
Hower, Wolf and Fields (2009) do not rule out the possibility of GTPase activating 
protein (GAP) activity for CT694 directed towards a plethora of host cell proteins. 
However, if CT694 is indeed a karyopherin-like protein as predicted by I-TASSER 
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modeling, it is tempting to speculate that it may be responsible for nuclear 
translocation of certain host cell or injected Ct proteins during the early stages of 
infection, and during biphasic development. For instance, PmpD possesses a nuclear 
localization sequence, and the passenger domain is co-purified with host cell cytosolic 
proteins (Swanson et al., 2009). Other Ct effectors may also possess characteristic 
NLS.  
 
Furthermore, following carboxymethylation of CT694, we have identified at least one 
of the four Cys residues (Cys50) at the N-terminus of the protein is unpaired and hence 
able to partake in intermolecular interactions. The ΔN-CT694 domain contains two of 
the four Cys residues (Cys167 and Cys261) (assumed to be paired), given that no 
intermolecular aggregation is observed in non-reducing SDS gels. Native gels run 
under reducing and non-reducing conditions also indicate no changes in biophysical 
state (Fig.3.9 (B), (C)). 
 
3.3 Discussion 
Ct has only very recently become readily amenable to genetic manipulation (Nguyen 
and Valdivia, 2012; Wang et al., 2011). Prior to this, over the last 6-8 years, insight in 
to mechanisms of pathogenesis of Ct infections has been obtained through advances 
in pharmacological or genetic manipulation of host cell pathways and observation of 
the effects of these modifications on cellular phenotypes. However, the temporal, 
spatial and functional roles that specific Ct proteins play in orchestrating cellular 
phenotypes or cell signaling pathways is much less clear during the course of Ct 
infection of host cells. Many observable phenotypes are likely due to the ~80 or so 
predicted T3SS effectors, most of which have unknown function.  
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A problem that has become endemic within the field of intracellular pathogen biology 
in the absence of tractable genetic manipulation is models derived from correlative 
data, where an observed cellular effect due to (e.g. ectopic expression) has been 
directly correlated with an observed cellular phenotype. While advances in cell 
biology techniques such as ectopic expression and yeast-two-hybrid screens may 
provide a good starting point from which to probe effector protein function, they are 
by no means definitive, as cell signaling events are usually context-dependent and 
part of a complex network of interacting pathways that may provide negative or 
positive feedback loops which are not well represented by overexpression in vitro. 
Furthermore, whether these proteins are actually translocated in to the host cell in 
vitro remains to be confirmed for many effectors. The most concrete means of 
directly correlating observed T3SS effector function with a cellular phenotype has 
been through microinjection of antibodies in to cells, where anti-Tarp antibodies have 
been shown to lead to a reduction in infection, and anti-IncA antibodies result in a 
fragmented inclusion phenotype (Hackstadt et al., 1999; Jewett et al., 2010).  
 
In the latter case, this also reflects the observed phenotype in a clinical strain 
defective for incA expression (Johnson and Fisher, 2013), indicating the importance 
of future whole genome sequencing to represent a variety of clinical strains and its 
potential utility in elucidating genotype-phenotype relationships. T3SS effectors act 
throughout the developmental cycle of Ct, and have also been observed to play a role 
in the acquisition of lipid precursors and in bacterial exit pathways. A Y2H screen for 
interaction partners of the Inc protein CT228 revealed an interaction with the myosin 
light chain phosphatase (MYPT1), which is heavily regulated by phosphorylation, and 
	 109	
is thought to play a role in myosin-dependent extrusion of inclusions late in the 
infectious cycle (Lutter et al., 2013). Here again, genetic validation of a likely role for 
this interaction is provided by a naturally occurring clinical strain Ct B/Jali20 serovar 
(Lutter et al., 2013). This serovar has a truncated CT228 gene, which fails to recruit 
MYPT1 to the inclusion membrane. 
 
Crucially, the advent of genetic manipulation of Ct has allowed more rigorous 
analysis of T3SS effectors, and this has helped to interrogate the function of specific 
genes at different stages of Ct development (Saka et al., 2011). Recently, a mutant 
strain lacking the T3SS effector Tepp, enabled the delineation of phosphorylation 
events on host protein recruitment, and these effects were importantly validated by 
plasmid transformation of the mutant strain that showed restoration of Tepp function 
(Chen et al., 2014). Most recently, the function of CPAF has been elucidated using 
advances in genetic manipulation (Snavely et al., 2014). 
 
Although CT694 has been identified to interact with human AHNAK, the functional 
consequence of this interaction remains circumstantial (Hower, Wolf and Fields, 
2009), and will most likely require complementation of a CT694 null mutant to verify 
purported interactions. With the required toolkit now available to manipulate 
endogenous proteins in Ct, experimental validation of observed cellular phenotypes 
can be rigorously tested in vitro. However, a caveat of this approach is that if the gene 
is essential for bacterial survival, it may not be possible to observe a cellular 
phenotype, although an observed reduction in infection is most likely, given the 
presumed role of CT694 as early T3SS effector (Belland et al., 2003). Thus, structural 
approaches hold significant advantages in functional annotation of hypothetical 
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chlamydial proteins that may be integral to bacterial invasion or intracellular 
replication. The biophysical characterization of PmpD, a putative chlamydial adhesin 
subsequently employed as a candidate vaccine immunogen in our study, will be 
discussed in the following chapter. Structural integrity of recombinant vaccine 
antigens may play an important role in the ensuing immune response, particularly 
with regard to recognition of native antigenic epitopes, but is also crucial for 
downstream structural studies and protein crystallization. 
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Chapter 4: Biophysical characterization of Chlamydia trachomatis 
polymorphic membrane protein D – a candidate vaccine antigen 
 
4.1 Introduction - PmpD 
Purification of the Ct outer membrane complex was first carried out in 1981 following 
treatment of isolated EBs with an array of non-ionic, dipolar and anionic detergents 
(Caldwell, Kromhout and Schachter, 1981). Early studies on the COMC showed that 
Ct EBs and RBs from both C.psittaci and C.trachomatis LGV-434 species were not 
solubilised by the anionic detergent SDS, unless reducing agents were present (Hatch, 
Allan and Pearce, 1984). Ct EBs consist primarily of MOMP and two major cysteine-
rich outer membrane proteins (CRPs) - known as OmcA (12kDa) and OmcB (60kDa) 
in C.trachomatis (Hatch, Allan and Pearce, 1984). In addition, COMCs in chlamydial 
species have been shown to harbor varying numbers of polymorphic membrane 
proteins (Pmps) (Tanzer, Longbottom and Hatch, 2001). The Pmps comprise a large 
and diverse family of Type V autotransporter (T5ATs) proteins within the 
Chlamydiaceae. While the total number of pmp genes varies between species, all 
possess a single pmpD ortholog (Wheelhouse et al., 2012). In addition, PmpD is the 
most highly conserved Pmp in Ct, with 99.15% sequence identity between the 18 Ct 
reference serovars (Carlson et al., 2005). This suggests a likely crucial or conserved 
role for pmpD in the life cycle of Ct.  
 
Early studies using convalescent sera from patients with trachoma, lymphogranuloma 
venereum (LGV), cervicitis and urethritis all recognized a ~155kDa species-specific 
antigen (Caldwell, Kuo and Kenny, 1975). Several years later, this immunogenic 
protein was subsequently identified as PmpD, and shown to be surface-exposed on Ct 
elementary bodies (Crane et al., 2006). Furthermore, polyclonal anti-PmpD serum 
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demonstrated pan-neutralising activity against ocular, genital and LGV strains in 
vitro, and the authors further postulated that pre-existing antibodies to Ct MOMP or 
LPS blocked the ability of anti-PmpD antibodies to neutralise Ct infection (Crane et 
al., 2006). Examination of the PmpD protein sequence reveals 26 cysteine residues 
(the highest of any Ct Pmp), with 17 GGA(I,L,V) and 19 FXXN tetrapeptide repeat 
motifs – a feature shown to be characteristic of the chlamydial autotransporter 
passenger domains, and markedly over-represented in Pmps relative to the rest of the 
chlamydial proteome (Fig.4.1) (Craneet al., 2006).  
 
The chlamydial outer membrane is unique when compared to all other known Gram-
negative phyla, due to the presence of an extensively oxidized disulphide-linked outer 
membrane complex (COMC) in EBs, which shows increased fluidity, plasticity and 
differential protein composition and function as the infective forms transform in to 
metabolically active RBs through reduction of outer membrane proteins (Bavoil, 
Ohlin and Schachter, 1984; Hatch, Allan and Pearce, 1984). Although the cues for 
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regulation of biphasic development are not known, this reduction and re-oxidation of 
the COMC is thought to be crucial to enable vital infectious and metabolic processes 
which are key to intracellular survival, such as the initiation of entry and attachment 
(Abromaitis and Stephens, 2009), the insertion of the T3SS apparatus (Betts-
Hampikian and Fields, 2011), and porin function of the chlamydial major outer 
membrane porin (MOMP) that comprises  ~65% of the COMC, and is thought to be 
responsible for nutrient acquisition (Bavoil, Ohlin and Schachter, 1984; Sun et al., 
2007). Given their uncharacteristic abundance within the chlamydial genome, it is 
highly likely that Pmps play pivotal roles in this biological transformation both 
extracellularly and possibly during intracellular metabolic activity. 
 
During biphasic development, membrane composition has been shown to alter 
substantially, with RBs possessing little or no cysteine-rich proteins (CRPs) (Hatch, 
Allan and Pearce, 1984). In addition, most of the MOMP protein was shown to exist 
in monomeric form within RBs, with membranes more readily dissociable using 
anionic detergents, while EBs possess a large proportion of disulphide-linked trimeric 
MOMP (Sun et al., 2007). Earlier studies also employed the use of exogenous 
reducing agents to address the biological properties of both C.psittaci and 
C.trachomatis LGV-434 EBs (Hackstadt, Todd and Caldwell, 1985). It was observed 
that treatment of EBs with DTT resulted in decreased infectivity, increased glutamate 
oxidation and changes in Machiavello staining properties. However, reducing agents 
alone were not able to elicit a true RB transition, as electron microscopy revealed no 
changes in bacterial size or electron density, indicating irreversible disruption of key 
structural motifs required for membrane remodeling. These observations indicate that 
reduction of outer membrane proteins within the COMC may elicit metabolic and 
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structural changes, likely due to conformational changes in MOMP, although the 
contribution of other proteins (such as Pmps) to these morphological changes cannot 
be excluded. 
 
Bavoil, Ohlin and Schachter (1984) used reduction and alkylation of MOMP within 
EBs to implicate the involvement of MOMP in pore-forming activity in the Ct 
COMC. Retention of carbol fuchsin dye suggested increased membrane permeability, 
and the abrogation of infectivity may reflect the disruption of key inter- and 
intramolecular bonding in extensively cysteine-rich outer membrane proteins that may 
function as adhesins, yielding a disordered and sub-optimal membrane structure. The 
mechanisms of reductive cleavage or re-oxidation of the COMC in vivo are still not 
understood, although MOMP has been shown to be reduced to its monomeric form 
within 1hr of EB entry in to host cells and CRPs are detected 20-22hrs post infection 
(Hatch, Miceli and Sublett, 1986). This suggests that changes in either the oxido-
reductive states within the host cell inclusion or metabolism of the bacterium may 
effect transformation. 
 
Of note is the presence of an RGD motif (aa698-700), (also shared by PmpF) and 
hypothesized to partake in adhesion via integrin binding, as well as a putative nuclear 
localization sequence (aa783-aa798). Two recent studies investigating PmpD 
processing reveal a variety of proteolytic species using antibodies generated against 
peptide fragments from the N-terminal, passenger and C-terminal domains (Kiselev, 
Skinner and Lampe, 2009; Swanson et al., 2009). Swanson et al. (2009) report a 
variety of membrane-associated and soluble forms of PmpD. Flower-like oligomeric 
structures (~23nm) are observed on EBs (Fig.4.2), and comprise full length (155kDa) 
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and processed (73kDa and 82kDa) forms of PmpD. A secondary, late-stage 
processing step results in a soluble 111kDa proteolytic fragment that subsequently 
undergoes cleavage to 73kDa and 30kDa soluble products that remain localized 
within the inclusion lumen (Swanson et al., 2009). However, this does not necessarily 
preclude potential cytosolic effects of PmpD, as proteins secreted in to the host cell 
cytosol at low levels may be difficult to detect by immunofluorescence. 
 
 
In contrast, Kiselev et.al (2009) reported earlier processing of the 157kDa passenger 
domain (24hpi) to 65kDa and 80kDa fragments, the latter remaining attached to the 
chlamydial cell wall, with the former secreted within the inclusion lumen (Fig.4.3) 
(Kiselev, Skinner and Lampe, 2009). The study also revealed similar temporal 
expression of the pmpD gene for ocular, urogenital and LGV (A, D and L2) strains, 
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and a proteolytic breakdown pattern similar to that for the PmpD ortholog (Pmp21) in 
C.pneumoniae (Wehrl et al., 2004). It was found that Pmp21 in C.pneumoniae is 
surface-exposed as well as cleaved from the mature 170kDa protein to 70kDa and 
55kDa fragments. These observations are also consistent with earlier reports 
investigating the processing of C.pneumoniae outer membrane proteins (Vandahl et 
al., 2002). 
 
 
Furthermore, post-translational proteolysis of another PmpD ortholog has been 
investigated in Chlamydia abortus, designated Pmp18D in this species (Wheelhouse 
et al., 2012). C.abortus is the causative agent of ovine enzootic abortion (OEA), and 
infections comprise a substantial economic burden to the livestock industry, as well as 
a significant threat to pregnant women (Wheelhouse et al., 2010). Pmp18D was found 
to undergo processing to a 104kDa passenger domain fragment and a 48kDa protein 
comprising the β–barrel that remained associated with the chlamydial outer 
membrane (Wheelhouse et al., 2012). Akin to the proteolytic pattern of Ct PmpD 
observed by Swanson et al. (2009), the C.abortus Pmp18D 104kDa passenger domain 
fragment undergoes further cleavage to molecular weights corresponding to 84kDa, 
76kDa and 73kDa, indicative of an array of putative soluble effector molecules within 
the inclusion lumen. These studies indicate that PmpD is expressed and undergoes 
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post-translational processing in a range of chlamydial species and may play a role in 
the extracellular as well as intracellular environmental niches of Chlamydiaceae.  
 
This chapter provides the first biophysical and biochemical characterization of the 
Chlamydia trachomatis 65kDa recombinant PmpD passenger domain fragment. 
Evidence for the existence of rPmpD in a variety of oligomeric species is presented 
by conducting dynamic light scattering (DLS) on purified rPmpD fractions separated 
by size exclusion chromatography. In accordance with the prediction algorithm 
PSIPRED, we provide experimental evidence for the secondary structure of rPmpD 
using circular dichroism, and demonstrate that oligomeric and monomeric rPmpD 
display predominantly pleated β–sheet structure, further consistent with the 3D 
molecular descriptions of the majority of T5AT proteins from an array of Gram-
negative pathogenic bacteria solved by X-ray crystallography (Henderson, Navarro-
Garcia and Nataro, 1998).    
 
In addition to differences in the relative proteolytic lability of monomeric and 
oligomeric rPmpD, we employ conventional redox techniques to delineate putative 
differences in the biochemistry of the protein. We demonstrate that oligomeric rPmpD 
is composed of an extensively disulphide-bonded network, as the absence of high 
concentrations of reducing agents fails to elicit dissociation and migration in to native 
and SDS gels. Anionic detergents are insufficient to cause complete dissociation into 
monomeric constituents. Conversely, monomeric rPmpD is very sensitive to the 
effects of even very low quantities of reducing agents, and increasing concentrations 
of TCEP, DTT, glutathione and β–ME rapidly cause intermolecular aggregation. This 
is suggestive of key intramolecular disulphide bonding important for tertiary 
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structural integrity, that when disrupted may cause exposure of hydrophobic patches 
that lead to intermolecular aggregation. In light of these findings, a model for PmpD 
within the context of chlamydial outer membrane biology and the unique biphasic 
developmental cycle of the Chlamydiaceae is proposed. 
 
4.2 Results 
4.2.1 Cloning of pmpd passenger domain gene truncations 
Genes encoding truncated PmpD passenger domain fragments F1-F3 (Fig.4.4) were 
PCR-amplified from Ct serovar E/Bour genomic DNA (ATCC) using primers 
encoding the respective restriction enzyme sites prior to cloning in to the pET-26 (b) 
and pET-28 (b) vectors (Fig.2.1). The pET-26 (b) vector containing the pelB leader 
sequence was utilized to initiate translocation of rPmpD across the inner membrane to 
the bacterial periplasm, a typical secretory route for autotransporter proteins. 
 
Following ligation, transformation and plasmid amplification in NovaGigaSingle 
cells, double digests of transformed plasmids were conducted using NcoI and XhoI 
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enzymes. DNA fragments were resolved using agarose gel electrophoresis and 
visualization with SybrSafe stain under UV-light (Fig.4.5). This revealed the expected 
fragment size for all genes cloned. DNA sequencing was used to verify the correct 
sequence of all three plasmids following cloning. 
 
4.2.2 Overexpression of Chlamydia trachomatis recombinant PmpD passenger 
domain fragments 
For overexpression of the recombinant PmpD passenger domain fragments pmpD F1 
(120kDa) and F3 (65kDa) gene fragments were cloned and expressed in a variety of 
E.coli strains at 16°C and 37°C in order to determine optimal conditions for soluble 
protein expression. BL21 (DE3), Origami 2 (DE3) and Rosetta 2 (DE3) strains were 
transformed with the relevant plasmids. To circumvent the likelihood of ribosomal 
translational arrest due to the presence of 52 interspersed rare codons within the 
rPmpD passenger domain, an E.coli Rosetta 2 (DE3) strain encoding eight additional 
rare tRNAs was also utilized. Given the cysteine-rich content of the PmpD protein (26 
Cys residues), Origami 2 (DE3) strains with mutations in glutathione and thioredoxin 
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reductases were transformed in the attempt to facilitate cytoplasmic disulphide 
bonding. Expression was induced using 1mM IPTG when cultures had reached an 
OD600 of 0.6. Cell lysates were analysed using 12% SDS-PAGE. 
 
Soluble cytoplasmic and insoluble fractions were analysed for F1 (120kDa) and F3 
(65kDa) PmpD fragments. Higher expression levels were obtained in all cell types for 
the F3 fragment, while lower yields of F1 (full length passenger domain) and F2 
(98kDa proteolytic fragment) were obtained and also purified (not shown). As an 
alternative approach to confinement of the Cys-rich rPmpD in a primarily reducing 
cytosolic environment, a pelB leader sequence was appended to the N-terminus of the 
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F1-F3-encoding pmpd gene fragments using the pET-26 (b) vector, in order to effect 
rPmpD translocation across the inner membrane into the oxidizing environment of the 
periplasm, a typical transportation route for T5ATs. However, no soluble periplasmic 
protein was obtained in any strain or growth temperature tested in small-scale 
expression tests with constructs harboring the pelB leader sequence, with the majority 
sequestered in insoluble inclusion bodies (Fig.4.7).  
 
Because fragment F3 (Fig.4.3) was expressed in high abundance, this was taken 
forward for all subsequent in vitro studies and investigation of rPmpD 
immunogenicity and in vivo. BL21 (DE3) cells were used for rPmpD production, as 
these also resulted in highest levels of expression (Fig.4.5). The partition of rPmpD 
almost exclusively in the insoluble fraction of cell lysates necessitated the use of 
inclusion body solubilization and refolding by dialysis.  
 
4.2.3 Purification of rPmpD 65kDa passenger domain 
Inclusion bodies were solubilised in 6M guanidinium hydrochloride (GdHCl) 
dissolved in elution buffer (20mM Tris HCl, 50mM NaCl), and refolded by step-wise 
dialysis (6M, 3M, 1.5M) over 3 days. Insoluble aggregated protein was removed by 
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centrifugation, and soluble material applied to a Ni-column. The remaining GdHCl 
was gradually washed out following protein immobilization, and a two-step 
purification involving imidazole gradient elution from the Ni-column (Fig.4.8) and 
fast protein liquid chromatography (FPLC) on an S200 16/60 Superdex gel filtration 
column was conducted. rPmpD elutes as a broad peak consisting of a mixture of 
higher order oligomers, with a smaller peak comprising monomeric protein (Fig.4.9). 
The presence of oligomers is consistent with previously published electron 
micrograph images reported by Swanson et al. (2009) (Fig.4.2), where PmpD is 
observed to exist in clusters and rosettes of varying dimensions indicative of a broad 
range of oligomeric states. 
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MALDI-MS was further utilized to determine the identity of the 65kDa fragment 
eluted (Fig.4.9). As expected, spectral analysis confirmed this protein as PmpD from 
Ct serovar E/Bour (Fig.4.10). 
 
 
4.2.4 Dynamic light scattering 
To assess the size distribution of species within the two fractions prior to 
crystallisation, dynamic light scattering was implemented. Polydispersity index (PDI) 
was used as a measure of sample homogeneity, and defined as the ratio of the average 
molecular mass to the number average molecular mass, with a PDI of 1 indicating 
monodispersity. Histograms plotting hydrodynamic radius (nm) against particle size 
distribution calculate a PDI of 0.34 for Peak ‘O’, indicating a complex mixture of 
oligomeric species, while Peak ‘M’ shows a PDI of 0.9, reflecting nearly complete 
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monodispersity, with possible slight contamination from oligomeric fractions 
(Fig.4.11).  
 
 
 
4.2.5 Circular dichroism 
As rPmpD was refolded from inclusion bodies following denaturation, the yield of 
soluble protein was fairly low (0.2mg/ml). Furthermore, it was necessary to gain 
insight in to the secondary structure of the protein. This was implemented using 
circular dichroism. Peaks ‘O’ and ‘M’ both showed profiles characteristic of 
predominantly β–sheet structure (Fig.4.12). This is consistent with predicted 
secondary structures obtained using PSIPRED (Fig.4.13), and indeed with numerous 
other structures of Gram-negative T5ATs (Nishimura et al., 2010). In addition, 
rPmpD is found to partition almost exclusively in to the aqueous rather than the 
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detergent phase during TX-114 extraction of LPS from purified E.coli inclusion body 
pellets (Fig.4.14), indicating predominantly hydrophilic properties. 
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4.2.6 Crystallisation screens of monomeric rPmpD 
The crystallization of monomeric PmpD was conducted using a range of protein 
concentrations and crystallization screens. These included the Hampton 1 and 2, 
Index, PACT, CSS 1 and 2, Peg Ion 1 and Peg Ion 2 screens. In addition, specialized 
96-well high-throughput MemPlus and MemGold membrane protein screens 
(Molecular Dimensions) were also purchased. For rPmpD proteins, concentrations of 
5mg/ml-20mg/ml were employed. Fig.4.15 shows typical microcrystalline precipitate 
observed under a range of conditions in both customized and commercial screens. 
However, no crystals amenable to diffraction studies were obtained in our study. 
 
 
 
4.2.7 Redox biochemistry of rPmpD 
To determine the biochemical nature of oligomeric and monomeric rPmpD, and to 
address the role of potential differences in disulphide bonding and ionic interactions 
in rPmpD, native and SDS gels were run under a variety of redox conditions 
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(Fig.4.16-4.17). Fig.4.16 shows a 10% SDS gel with rPmpD monomer and oligomer. 
Monomeric rPmpD migrates alongside the 65kDa molecular weight marker under all 
conditions (Lanes 5-8). However, oligomeric rPmpD, a mixture of species, fails to 
dissociate and enter the gel completely in the absence of 0.5M β–ME in the loading 
buffer (Lane 4), indicating intermolecular disulphide-mediated bonding in the 
majority of species present within the mixture. SDS, an ionic detergent is insufficient 
to disrupt these intermolecular interactions. 
 
 
 
Monomeric and oligomeric rPmpD species also behave differently in the absence of 
reducing agents and detergent. Under native conditions, migration of monomeric 
rPmpD occurs, whereas the oligomeric fraction fails to enter and migrate in to the 5% 
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acrylamide gel, likely due to its high molecular weight (Fig.4.17). Interestingly, the 
three different reducing agents also differentially influence the behavior of rPmpD 
monomer under native conditions. It was anticipated that addition of reducing agents 
would disrupt oligomers into their constitutive subunits, but even the addition of 0.5M 
β–ME fails to cause entry in to the gel. Increasing concentrations of reducing agents 
to recombinant monomeric rPmpD lead to a change in charge:size ratio and reduced 
mobility of the protein.  
 
 
 
Taken together, these data suggest that rPmpD exists in an array of distinct molecular 
species with secondary, tertiary and quaternary structures governed by a complex 
mixture of biochemical interactions most likely involving Cys residues. Monomeric 
rPmpD is sensitive to the effects of reducing agents, and it is tempting to propose that 
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this may be due to the disruption of key intramolecular disulphide bonds, which, 
when disrupted, may lead to denatured protein and subsequent aggregation through 
non-specific hydrophobic interactions, evidenced by upward shifts under native 
conditions (Fig.4.17). rPmpD oligomers are held together by intermolecular 
disulphide interactions, although intramolecular disulphide interactions are likely 
present as well.  
 
Currently, carboxymethylation of rPmpD to dissect the positions of exposed and 
paired Cys residues in monomeric and oligomeric rPmpD has been carried out. It is 
anticipated that the use of mass spectrometry following selected proteolytic digests of 
the protein will enable elucidation of Cys-Cys interactions within each biochemical 
species, and inform rational site mutagenesis of exposed residues to prevent 
intermolecular aggregation and enhance the yield of a stable, monodisperse rPmpD 
species more amenable to crystallization optimization. 
 
4.2.8 Proteolytic digestion 
Both rPmpD monomer and oligomers were subjected to proteolytic digest using a 
panel of four different enzymes: clostripain, elastase, trypsin and chymotrypsin. 
Proteolysis was carried out at room temperature for 0.5mins, 2mins, 5mins and 
30mins, and the samples immediately denatured and run on a 12% SDS gel. 
Clostripain and chymotrypsin failed to cause proteolysis even after 30mins. Elastase 
caused similar breakdown patterns for both oligomeric and monomeric rPmpD, but 
notable differences were observed in the presence of trypsin. The 65kDa rPmpD 
monomer was almost completely degraded to smaller fragments ~22kDa and ~35kDa 
after 30 minutes (Fig.4.18). In contrast, rPmpD oligomer showed a different 
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proteolytic pattern; with a wider range of digest fragments and some ‘full length’ 
protein still observed indicating some degree of proteolytic recalcitrance. These 
observations are in contrast to those observed for chlamydial MOMP, where it was 
found that the 67kDa MOMP trimer was completely recalcitrant to trypsin digestion 
even when incubated at 37°C for 20h, whereas the MOMP monomer was susceptible 
to cleavage by the enzyme (Sun et al., 2007). 
 
 
 
Moreover, trimeric MOMP only became amenable to proteolytic cleavage following 
boiling, indicating that intermolecular disulphide-mediated bonding may be 
responsible for providing proteolytic recalcitrance. This is consistent with the 
properties for other outer membrane porins, and previous studies have observed that 
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both E.coli and N.meningitidis porins display similar proteolytic resistance (Jansen et 
al., 2000; Rosenbusch, 1974). However, proteolytic studies have not previously been 
conducted on chlamydial Pmps, and the relative lability of rPmpD may be 
correspondent with findings and postulated roles of PmpD passenger domain 
fragments of variable molecular weights during biphasic development, including 
secretion in to the inclusion lumen or host cell cytosol (Kiselev, Skinner and Lampe, 
2009; Swansonet al., 2009). 
 
4.2.9 Effect of pH on rPmpD dissociation 
The effect of pH on dissociation of oligomeric rPmpD was also investigated under 
non-reducing conditions in SDS-PAGE (Fig.4.19). No difference in migration or 
dissociation was observed for rPmpD oligomer at a range of different pH levels (pH 
3-10). This is in contrast to the MOMP trimer that dissociates at low (pH 3) and high 
(pH 10) levels. Importantly, such observations may have implications for the 
detection of conformational-sensitive epitopes in certain immunological assays such 
as ELISAs, where the pH of bicarbonate coating buffers is usually around pH 9.6, as 
this facilitates binding to assay plates.  
 
However, a loss in sensitivity may be observed for native oligomeric proteins that 
dissociate at high pH, particularly with regard to monoclonal antibody epitope 
recognition. Indeed, this has been observed in vitro following dissociation of MOMP 
trimers at high pH (Sun et al., 2007). We have shown here, that rPmpD is stable at 
both high and low pH levels, thus mitigating loss of detection of conformational-
dependent epitopes in ELISA assays. This enhanced stability may also have 
physiological implications for in vivo Ct infections. In C.pneumoniae infections in 
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vitro, abrogation of infectivity was demonstrated at high pH levels (Theunissen et al., 
1992). 
 
 
4.3 Discussion 
This study is the first to investigate the biophysical properties of a chlamydial Pmp. 
Purification of recombinant Pmps in E.coli in previous studies has been conducted 
through recovery of insoluble protein from inclusion bodies by denaturation in 
chaotropic agents followed by subsequent protein refolding (Becker and Hegemann, 
2014; Crane et al., 2006; Molleken, Schmidt and Hegemann, 2010). However, no 
study has characterized the biophysical or biochemical nature of the protein species 
used in subsequent immunological or in vitro assays. This is important, as the 
preservation of native structure is likely to influence sensitivity of binding assays as 
well as antibody recognition of native protein epitopes. Moreover, in some studies, 
truncated rPmpD passenger domain fragments that have not been shown to be present 
during the natural life cycle of Ct have been expressed and utilised in adhesion assays 
(Becker and Hegemann, 2014), making direct relevance to described physiological 
function slightly unrepresentative. Here, we have characterized the biochemical 
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properties of the 65kDa rPmpD passenger domain, a proteolytic fragment identified 
by mass spectrometry that is shown to be present in the soluble fractions of Ct cell 
lysates (Kiselev, Skinner and Lampe, 2009). We show that: 
 
(i) rPmpD purifies as a complex mixture of extensively disulphide-linked 
oligomers and soluble monomeric protein, in which key intramolecular 
disulphides may be important in maintaining native secondary structure 
(ii) Oligomeric and monomeric rPmpD consist primarily of β–sheet pleated 
structure, as evidenced by circular dichroism, consistent with secondary 
structural predictions and observed 3D molecular structures of solved 
T5AT proteins 
(iii) Oligomeric rPmpD is more recalcitrant to proteolysis by trypsin than 
monomeric 65kDa rPmpD, a property likely consistent with its 
physiological role as a membrane protein designed to maintain Ct COMC 
structural integrity 
(iv) Monomeric 65kDa rPmpD passenger domain partitions in to the aqueous 
phase following incubation with LPS-extraction detergent TX114, 
demonstrating predominantly hydrophilic properties 
 
As previously alluded to, proteins comprising the chlamydial COMC undergo 
substantial changes in redox states that facilitate EB to RB transition and protein 
function (Hatch, Allan and Pearce, 1984). Although the precise mechanisms 
governing biphasic development and reduction of chlamydial membrane proteins are 
unknown, an alternative mechanism has been proposed for the modification of 
disulphides within the COMC at the host-pathogen interface. This involves active 
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modification through the activity of host cell protein disulphide isomerase (PDI) 
(Davis, Raulston and Wyrick, 2002). Biotinylated Ct serovar E (UW5-Cx) EBs were 
incubated with an endometrial epithelial cell line (HEC-1B), and matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) was used to identify protein 
complexes coupled to EBs following affinity purification. The 55kDa PDI protein 
was repeatedly identified in complex with EBs in addition to heat shock protein 60 
(hsp60), actin and ATP synthase.  
 
The significance of PDI in thiol-disulphide exchange reactions is epitomized by the 
cleavage of diphtheria toxin, which is an essential step for mediating host cell 
cytotoxicity (Ryser, Mandel and Ghani, 1991). Thiol/disulphide exchange at the host 
cell interface is also involved in the internalization of important viral pathogens such 
as HIV and Newcastle disease virus (Jain, McGinnes and Morrison, 2007; Ou and 
Silver, 2006). Although most PDI is located within the endoplasmic reticulum, it is 
also present at the cell surface, often associated with host cell receptors (Couet et al., 
1996; Feener, Shen and Ryser, 1990; Klappa, Hawkins and Freedman, 1997; Landel, 
Kushner and Greene, 1995). To further confirm the role of PDI in facilitating 
productive Ct infection, three methodologies were used to modify chlamydial and 
host disulphides in addition to PDI activity (Davis, Raulston and Wyrick, 2002): 
 
(i) Pre-incubation with anti-PDI antibodies ~69% caused a reduction in 
chlamydial infectivity relative to control IgG in HEC-1B cells 
(ii) Reduction in chlamydial infectivity by ~22% was observed following 
addition of bacitracin, a membrane-impermeable inhibitor of PDI, 
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previously shown to be instrumental in inhibiting attachment of human 
immunodeficiency virus (Ryser et al., 1994)  
(iii) Reduction in Ct infectivity by ~30% was observed following addition of 
DTNB (5,5’-dithiobis[2-nitrobenzoic acid]), a membrane-impermeable 
thiol-alkylating agent also shown to reduce Sindbis virus entry in BHK-1 
cells through interference with viral capsomere disulphide binding (Abell 
and Brown, 1993). 
 
These data suggest an important role for correct disulphide bonding within the COMC 
in addition to the requirement for a functional host PDI in the chlamydial infection 
process. Furthermore, two subsequent studies using a CHO6 cell line with a defect in 
PDI N-terminal signal sequence processing have implicated PDI to be essential in 
chlamydial entry and attachment, and further demonstrate that bacitracin, when 
present throughout EB incubation with host cells, almost completely abrogated 
infection in contrast to the modest decrease in previously reported results by (Davis, 
Raulston and Wyrick, 2002) when the inhibitor was washed off prior to infection 
(Abromaitis and Stephens, 2009; Conant and Stephens, 2007). The authors attribute 
this difference to constitutive expression and recycling of PDI to the cell surface in 
CHO6 cells ectopically expressing functional PDI, and further report that enzymatic 
activity of PDI was found to be essential for entry. It is likely that Ct may bind to a 
receptor closely associated with PDI.  
 
However, despite these observations, it is difficult to address experimentally whether 
PDI acts to modify host or bacterial surface proteins. Conventional biochemical 
techniques such as the pretreatment of membranes with reducing or alkylating agents 
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in the study of host-pathogen interactions in vitro may confound interpretation of 
results on infectivity due to rapid re-oxidation or mismatched disulphides. Hence, the 
use of stably transfected cell lines may be a more robust way to study interactions at 
the Ct-host cell interface. However, with the very recent advances in genetic 
manipulation of Ct, the field of research will be dramatically transformed in the near 
future, with the ability to interrogate the contribution of specific genes to adhesion 
both in vitro and in vivo (Kari et al., 2014; Nguyen and Valdivia, 2012). 
 
Taken together, these data indicate a role for active host cell modification of COMC 
disulphides during the Ct infection process, although it is likely that several other 
redundant mechanisms may be involved that result in outer membrane modification. 
The Ct serovar D genome has been found to contain two PDI-encoding genes (CT780 
and CT783), which contain thioredoxin domains, but bear little homology to 
eukaryotic PDIs (Davis, Raulston and Wyrick, 2002;Stephenset al., 1998). In 
addition, recent studies have also linked disulphide bonding within the chlamydial 
T3SS apparatus to biphasic development, detecting significant alterations in the 
cysteine-rich needle protein CdsF (Betts-Hampikian and Fields, 2011). Reduction of 
the rigid EB COMC is necessary for insertion of the T3SS apparatus into the outer 
membrane. The T3SS is essential for delivery of key virulence factors in Ct invasion, 
many of which initiate cytoskeletal remodeling and bacterial internalization (Hower, 
Wolf and Fields, 2009;Jewett et al., 2006). Cys-rich membrane proteins such as 
PmpD may act as a scaffold for such effector systems, particularly given the 
disulphide-rich nature of both PmpD and Ct needle proteins such as CdsF (Betts-
Hampikian and Fields, 2011). It is thus tempting to speculate that a complex array of 
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bacterial and host cell effectors may facilitate chlamydial invasion during the early 
stages of infection. 
 
Of particular relevance in chlamydial species when compared to other Gram-negative 
bacteria is the unique capacity to maintain a number of free thiols within periplasmic 
or membrane-associated proteins. The formation of disulphide bonds is usually 
restricted to non-cytoplasmic compartments, mainly occurring within the bacterial 
periplasm, and is crucial for protein stability and folding (Nakamoto and Bardwell, 
2004). In E.coli and the majority of other Gram-negative bacterial species, disulphide 
bonding is mediated mainly by the oxidative folding pathway that comprises the 
periplasmic enzymes DsbA and DsbB that each possess a characteristic CXXC motif 
(Dutton et al., 2008). In addition, several species from bacteria to eukaryotes also 
possess enzymes that form part of a different pathway known as the disulphide 
isomerization pathway that is used to rectify incorrectly matched disulphides 
(Nakamoto and Bardwell, 2004). 
 
Using a cysteine counting method for predicted cell envelope proteins, in combination 
with homology searches of DsbA and DsbB enzymes in 375 diverse bacterial 
genomes, (Dutton et al., 2008) found a significant bias towards even numbers of Cys 
residues in predicted transmembrane proteins across diverse bacterial phyla. This may 
be an evolutionary adaptation to avoid likely mismatching of disulphides within the 
periplasm. Interestingly, bacteria predicted to lack disulphide bonds consisted mainly 
of obligate intracellular and anaerobic organisms, including Chlamydiae, 
Deltaproteobacteria, Firmicutes and Spirochetes (Dutton et al., 2008). It was 
postulated that in these bacteria, intracellular redox conditions may prohibit 
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extensively disulphide-bonded proteins, while fermenting organisms such as 
Lactobacilli within the Firmicute phylum lack an electron transport chain, which is 
key to catalysis of disulphide bond formation (Dutton et al., 2008). Thus, novel 
mechanisms of protein folding may occur in these unique bacterial phyla. Indeed, the 
structural biology has elucidated the existence of a novel isopeptide mechanism of 
stabilization in a pilin protein of the Lactobacillus bacterium Streptococcus pyogenes 
(Kang et al., 2007). 
 
However, the findings by Dutton et.al (2008) are clearly not representative of the 
Chlamydiaceae, as previous studies have clearly demonstrated the presence of at least 
one intra-molecular disulphide-bonded protein MOMP (Yen, Pal and de la Maza, 
2005). Thus, it is apparent that Chlamydiaceae may employ a more diverse range of 
mechanisms to modify the disulphide bonding status of membrane-associated 
proteins. In addition to possessing homologs of DsbA and DsbB (CT176 and CT177), 
the recent discovery, structural and functional characterization of DsbH in 
C.pneumoniae has shown that this enzyme functions as a disulphide reductase, and 
may be responsible for maintaining reduced Cys residues within the chlamydial 
periplasm (Mac et al., 2008).  
 
Given the extreme phylogenetic distance from well-characterized bacteria such as 
E.coli and B.subtilis (Pace, 1997), as well as their unique adaptation to intracellular 
environments, such discoveries are important in elucidating potential links between 
plasticity of the Cys-rich outer membrane and the biphasic developmental cycle of 
Chlamydiales. Indeed, it has recently been discovered that following transition to 
metabolically active RBs, a role for functional peptidoglycan becomes apparent 
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(Liechti et al., 2014; McCoy and Maurelli, 2006). DsbH is likely important in either 
maintaining the chlamydial periplasm in a generally reducing state depending on the 
metabolic stage of the bacterium, or for initiating host-pathogen interaction by 
reducing a subset of proteins in the supramolecular disulphide complex. Analysis of 
the C.pneumoniae and E.coli genomes also reveal a fourfold higher proportional 
representation of oxidoreductases in C.pneumoniae than E.coli (Inaba et al., 2006; 
Kalman et al., 1999). Interestingly, structural comparison of the active site of 
C.pneumoniae DsbH to solved structures of E.coli thioredoxins has revealed critical 
importance of the central two residues in the CXXC motif in dictating substrate 
specificity. 
 
The role of disulphide reductases such as DsbH may also play even more crucial and 
specific roles within the context of T5AT secretion. A recent study investigated the 
size and conformational limits of the presence of disulphide-bonded loops in the 
secretion of T5AT proteins (Leyton et al., 2011). By conducting systematic site 
mutagenesis, increasing the distance between the Cys residues in the E.coli plasmid-
encoded toxin (Pet), a member of the serine protease ATs of the Enterobacteriaceae 
(SPATEs), the authors were able to determine the maximum length of the disulphide-
bonded loop that does not interfere with translocation of the passenger domain. This 
was found to be a gap of 18 amino acid residues between consecutive cysteines. 
 
Examination of over 30 different T5ATs from a diverse range of bacterial species 
including (among others) E.coli, S.flexneri, H.pylori, N.meningitidis, P.aeruginosa 
and H.influenzae revealed a paucity of Cys residues within these proteins, with an 
average of 2.5 Cys residues per protein. This is in stark contrast to the 26 Cys residues 
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in C.trachomatis PmpD and 14 Cys residues in the C.pneumoniae ortholog Pmp20. 
Overall, the nine C.trachomatis Pmps A-I possess an average of 16 Cys residues. In 
addition, the average distance between Cys residues in all 31 T5ATs examined from 
bacterial species outside the Chlamydiaceae is 7.5 amino acids. This proximity, 
coupled with the even number of Cys residues (2 or 4) observed in all but two ATs 
(E.coli EspC and S.flexneri IcsA) would likely facilitate both intramolecular 
disulphide binding within the periplasm by the aforementioned oxidative pathway 
involving DsbA and DsbB enzymes, as well as enable transport through the β–barrel 
pore by preventing large loops from forming that may block translocation (Fig.4.20). 
 
 
 
In Ct PmpD, 2 Cys residues reside in the cleavable N-terminal signal sequence, and 1 
Cys residue in the C-terminal β–barrel domain, with an odd number of 23 Cys 
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residues present in the passenger domain of the protein. This would either necessitate 
the maintenance of free thiols within the periplasm or intermolecular disulphide 
linkage within the Ct outer membrane. Furthermore, the average distance between 
successive Cys residues contained within the passenger domain of PmpD is 39 amino 
acid residues. In light of the findings of (Leyton et al., 2011), transport of the full-
length passenger domain through the β–barrel autotransporter domain via a proposed 
hairpin mechanism would be impossible under typical oxidative bacterial periplasmic 
environments. The fact that PmpD is secreted into the chlamydial inclusion lumen and 
is found in the soluble cytosolic fractions of infected cell lysates (Crane et al., 2006) 
suggests that inhibition of translocation does not occur, and lends further credence to 
the likelihood of an actively controlled redox environment within Chlamydiaceae, 
especially following the discovery of thiol-reductases DsbH (CT780) and DsbJ 
(CT783) (Mac et al., 2008).  
 
Biophysical characterization of Ct rPmpD suggests that this protein exists in an array 
of oligomeric and monomeric states. This is also observed for the extensively studied 
H.pylori virulence factor VacA, which is viewed as a paradigm for toxin 
multifunctionality (Cover and Blanke, 2005), although a plethora of other toxins in 
pathogenic bacteria from Staphylococcus aureus alpha toxin (Bantel et al., 2001) to 
the A and B subunits of cholera and pertussis toxins that mediate ADP 
ribosyltransferase activity and host cell binding (respectively) also display 
multifunctionality (De Haan and Hirst, 2004; Tamura et al., 1983).  
 
A hallmark of toxin multifunctionality is the ability to cause distinct effects in an 
array of different environmental niches in a temporally and spatially variable manner 
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both intracellularly and at the extracellular host-pathogen interface. In addition to 
cellular vacuolation, VacA has been implicated in cell adhesion (Garner and Cover, 
1996), immune modulation (Gebert et al., 2003), mitochondrial transmembrane 
potential alteration (Willhite and Blanke, 2004), and cellular signal transduction 
pathways (Fujikawa et al., 2003). Ct is responsible for a diverse array of disease 
phenotypes, ranging from ocular trachoma, urogenital infections and 
lymphogranuloma venereum (LGV). PmpD is 99.15% conserved between all 18 
reference serovars (A-L3) that encompass ocular, genital and LGV strains, suggesting 
a conserved function despite a wide range of cell tropisms from conjunctival and 
ectocervical epithelial cells to monocytes. In addition, PmpD has an ortholog in all 
other known Chlamydiaceae (Wheelhouse et al., 2012). 
 
Furthermore, the ability to consolidate multiple functions within a single protein 
would be a likely outcome of evolution by genomic reduction exhibited by obligate 
intracellulars, as this results in greater conservation of genome coding capacity and 
metabolic resources. Oligomerisation of PmpD on the Ct bacterial surface may be a 
means of enhancing adhesion through the incorporation of a greater concentration of 
binding sites (Fig.4.2). Structural characterisation of pentameric Shiga toxin has 
revealed three different binding sites on each of the subunits that interact with cellular 
receptors, giving a total of 15 binding sites per oligomer (Ling et al., 1998). Pmps in 
Ct may employ a similar strategy. 
 
It is also interesting to note that Ct PmpD has almost twice the average amount of Cys 
residues than all other 8 Ct T5ATs, and is the most Cys-rich T5AT in C.trachomatis, 
constitutively expressed throughout development (Crane et al., 2006; Tan et al., 
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2010). Based on the assumptions of size and conformational restraints of passenger 
domain translocation proposed by (Leyton et al., 2011), using a maximum spacing of 
17 amino acids between consecutive Cys residues required to form an intramolecular 
disulphide bond that can still fit through the β–barrel AT pore, inspection of the linear 
primary sequence indicates that PmpD may need to maintain as many as 11 reduced 
Cys residues within the entirety of the passenger domain for translocation, after which 
homo- or hetero-oligomerisation may occur. This relatively large number of free Cys 
residues suggests that PmpD may act as a scaffold for maintaining the structural 
integrity of the COMC through cross-linking with other Cys-rich membrane proteins 
(e.g. OmcB, Pmps and MOMP) as well as supporting other key effector proteins such 
as the T3SS apparatus during biphasic development. In light of our observations, we 
propose a model for the role of PmpD, a cysteine-rich chlamydial T5AT, within the 
context of previously described knowledge on the mechanisms of T5ATs, and recent 
insight on the intricate redox biochemistry of the chlamydial membrane (Fig.4.21). 
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As the positions of paired and exposed free Cys residues likely to mediate homo- or 
hetero-oligomeric intermolecular interactions have not yet been determined, in silico 
modeling following sequence alignment of B.pertussis pertactin 69kDa passenger 
domain was implemented. The 3D molecular structure of the B.pertussis pertactin 
T5AT domain has been deposited in the PDB (Emsley et al., 1996), and in silico site 
mutagenesis of corresponding pertactin amino acid residues to Cys was performed to 
determine residues most likely to mediate intra- and intermolecular disulphide 
bonding. Despite the anticipated low sequence homology between the two passenger 
domains, secondary structural predictions for the two proteins are similar. As 
anticipated, several Cys residues were predicted to be unpaired, and protruded on 
loops outside the modular β–helix (Fig.4.22). These may be responsible for the 
formation of homo- or hetero-oligomeric complexes. However, two Cys pairs appear 
in close enough proximity to mediate intramolecular disulphide binding, likely 
indicating a complex array of redox states within PmpD. This modeling provides a 
crude template from which to employ strategic site mutagenesis of Cys residues to 
serine in vitro. It is anticipated that this may prevent intermolecular aggregation and 
facilitate the purification of soluble, homogenous monomeric rPmpD that may be 
employed in crystallization optimization studies. 
 
Importantly, our study highlights the inherent difficulties in production of Cys-rich 
chlamydial bacterial membrane proteins in E.coli, where very low yields of soluble 
protein derived from insoluble inclusion bodies are obtained. It is likely that 
expression of modular complexes in baculovirus or mammalian expression systems 
with a larger repertoire of chaperones and post-translational modifications may enable 
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higher expression levels and correct folding of recombinant proteins that mimic native 
conformation. This has been achieved for many complex eukaryotic membrane 
proteins (Bieniossek et al., 2013; Rasmussen et al., 2007). Initial cloning and 
expression would employ the established MultiBac protocol (Berger, Fitzgerald and 
Richmond, 2004). This will allow for rapid regeneration of new or modified 
constructs by homologous recombination of transfer vectors to expedite optimisation 
of protein expression in Sf21 or High FiveTM insect cells. Cloning may be conducted 
as either single or multi-gene constructs using ligation-independent in vitro Cre-
fusion.  
 
 
For mammalian expression, generation of constructs will be conducted using the 
pOPIN vector suite designed by the Oxford Protein Production Facility. The majority 
of these vectors enable tremendous flexibility of expression in different hosts - E.coli, 
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Sf9 (insect), and HEK293T (mammalian) cells as well as high-throughput screening 
and regeneration using the In-FusionTM method. Moreover, all vectors contain 
cleavable His6-tags to facilitate purification, crystallization or functional assays. 
Transient transfection protocols will offer another alternative that may enable the 
high-throughput screening of a large number of constructs in parallel to select and 
optimise rPmpD for X-ray crystallography. In addition, further validation of suitably 
folded protein structure following expression and purification may be performed 
using nuclear magnetic resonance (NMR) spectroscopy, whilst codon optimisation of 
pmpD gene fragments could be implemented to facilitate translation and prevent 
possible ribosomal arrest and potential misfolding. 
 
In conclusion, we have observed biochemical differences in the oligomeric and 
monomeric states of rPmpD, likely consistent with differential roles in biphasic 
development of the bacterium at early and late stages of infection, and have further 
proposed a model for a possible functional role of PmpD in the context of our study 
and previous investigations on the chlamydial outer membrane. The next question to 
be addressed was whether proposed roles for PmpD as a putative chlamydial adhesin 
were apparent in vitro. This is the topic of investigation in Chapter 5. 
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Chapter 5: Investigation of the putative function of PmpD as a 
chlamydial adhesin in vitro 
 
 
5.1 Introduction 
 
Knowledge of the mechanisms of attachment of Chlamydiae to host cells remains 
rudimentary. Recent studies have led to proposed models of invasion involving T3SS 
effector proteins such as CT694 and Tarp which are also thought to facilitate 
internalization, including rearrangement of the actin cytoskeleton and activation of 
signaling pathways (Carabeo et al., 2002; Coombes and Mahony, 2002). However, 
receptor-ligand interactions at the host-pathogen interface remain poorly 
characterized, especially at the molecular level. To date, within the Chlamydiaceae, 
two main adhesin-receptor interactions have been identified in Chlamydia 
pneumoniae; the OmcB-GAG interaction (Wuppermann, Hegemann and Jantos, 
2001), and the Pmp21-EGFR interaction (Molleken, Becker and Hegemann, 2013). 
However, the OmcB-GAG interaction is also thought to facilitate C.trachomatis 
adhesion (Moelleken and Hegemann, 2008). Existing knowledge on role of 
chlamydial Pmps at mediating early host cell interactions will be discussed next.  
 
5.1.1 Pmps in early host cell interactions 
Following description of the OmcB-GAG interaction, subsequent studies targeted 
elucidation of putative cellular receptors for C.pneumoniae Pmps. Chlamydial species 
possess varying numbers of Pmps. In C.pneumoniae, there are 21 members. It was 
found that the characteristic, repetitive short amino acid motifs found within these 
proteins – FXXN and GGA(I,L,V) were important for binding, and deletion 
experiments generating peptide fragments revealed that a minimum of two copies of 
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these motifs (either FXXN/FXXN or FXXN/GGA(I,L,V)) were required for adhesion 
(Molleken, Schmidt and Hegemann, 2010).  
 
In the same study, it was found that pretreatment of the mammalian HEp-2 cell line 
with Pmp6, Pmp20 and Pmp21 all reduced infectivity of C.pneumoniae, with 
antibodies specific to Pmp21 also abrogating infection in vitro. Furthermore, it is 
likely that these motifs may indeed possess critical structural or functional properties, 
given their distinct over-abundance in Pmps relative to the rest of the genome. The 
GGA(I,L,V) sequence is only found in 10 other proteins in all known chlamydial 
proteomes (only at one copy per protein), while the FXXN motifs are observed an 
average of 13.6 times in Ct Pmps and 11.3 times in Cp Pmps, with an average of 0.73 
and 0.84 times per protein (in Ct and Cp proteomes, respectively). However, no 
interactions between Pmps and GAGs were observed, as yeast cells expressing 
Pmp21 adhered equally well to GAG-expressing and GAG-deficient CHO-cell lines 
(Molleken, Schmidt and Hegemann, 2010), suggesting an alternative and potentially 
cooperative binding mechanism with Ct OmcB. 
 
If the repetitive FXXN/GGA(I,L,V) tetrapeptide motifs indeed contribute to binding, 
the presence of multiple motifs on a single Pmp could indicate a propensity for 
binding to multiple different sites on either a single or multiple receptor molecule(s), 
or may play a role in self- or hetero-oligomerisation. Incorporation of multiple 
binding sites within a single molecule, in addition to oligomerisation of individual 
monomers dramatically increases the density of binding sites on bacterial cell 
membranes, and has been observed in the 3D structural description of the Shiga-like 
toxin I (SLT-I) binding subunit of pathogenic E.coli (Ling et al., 1998). Here, 
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pentameric assemblies of monomeric subunits that contain 3 binding sites per 
molecule, lead to 15 individual trisaccharide-binding sites that likely augment 
adhesion. Importantly, this 3D structural description of the SLT-I pentamer in 
complex with carbohydrate molecules has the potential to inform rational design of 
novel sugar-based inhibitors of the toxin that may prevent host cell adhesion. 
 
The most comprehensive study identifying an invasin-receptor interaction within the 
Chlamydiae involved description of C.pneumoniae Pmp21 adhesion to HEp-2 cells 
using a plethora of cellular and biological approaches (Molleken, Becker and 
Hegemann, 2013). Pmp21-coated beads were shown to adhere to and be internalized 
by HEp-2 cells, and biochemical approaches using biotinylation of Pmp21 following 
incubation with HEp-2 cells initially revealed the EGFR-Pmp21 interaction following 
streptavidin affinity purification. Y2H screens were utilized to further confirm this 
interaction, and ectopic expression of EGFR in EGFR-negative CHO cells results in 
enhanced infectivity of EBs and Pmp21-coated bead binding, while activation of 
EGFR signaling following EB and Pmp21 binding was indirectly measured by 
recruitment of adaptor proteins Grb2 and c-Cbl (Molleken, Becker and Hegemann, 
2013). Taken together, these data suggest that at least two distinct interactions 
(involving OmcB and Pmp21) are involved at the host-pathogen interface to initiate 
C.pneumoniae adhesion, and possibly invasion. 
 
Following elucidation of Pmps as adhesins in C.pneumoniae, investigation of putative 
C.trachomatis Pmp interactions were recently carried out. Recently, all nine 
recombinant Ct Pmps (A-I) were used in competitive inhibition assays in HeLa, HEp-
2 and HUVEC cells with infectious EB bacteria (Becker and Hegemann, 2014). 
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Soluble recombinant Pmps were also found to abrogate infection in both a species- 
and tissue-dependent manner when used in neutralization assays. PmpD and PmpG 
inhibited infection of Ct but not Cp, while Pmp6, Pmp20 and Pmp21 inhibited Cp 
infection, but had no significant effect in abrogation of Ct infectivity (Becker and 
Hegemann, 2014). Differences in binding to epithelial and endothelial cells were also 
reported for different Pmp species and subtypes. For instance, Pmp21-coated beads 
showed significantly increased binding to HUVEC (primary endothelial cells) than 
HEp-2 (cultured epithelial) cell lines, while PmpD-coated beads showed the inverse 
relationship, broadly consistent with distinct environmental tropism. These 
observations may indicate a role for Pmps in influencing tissue tropism in different 
chlamydial species by binding to receptors within a specific environmental niche with 
greater avidity. 
 
Interestingly, phylogenetic analysis of PmpD across nine chlamydial species indicates 
that only C.suis shares 100% amino acid identity to C.trachomatis serovar E PmpD, 
and clusters with urogenital biovars in a phylogenetic tree of PmpD protein 
sequences, also possessing the putative RGD binding motif and nuclear localization 
sequence (Wheelhouse et al., 2012). PmpD orthologs in zoonotic pathogens that 
typically affect livestock - C.abortus, C.psittaci, C.caviae and C.felis cluster in a 
separate, phylogenetically distant clade from C.trachomatis. It is thus tempting to 
speculate that PmpD may have species-specific roles in infection or pathogenesis, and 
that the tissue type used in in vitro assays is important for studying protein function. 
These observations may further hold some degree of physiological relevance in light 
of the anatomical similarities of the reproductive tract between pigs and humans, and 
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the recent adoption of pigs as an alternative model for studying human genital Ct 
infections (Vanrompay et al., 2005).  
 
Perhaps the most biologically relevant study of Ct PmpD function in vitro and in vivo 
arose via generation of the first ever Ct null mutant (Kari et al., 2014). The study 
employed a targeted reverse genetics approach (Kari et al., 2011) to generate a pmpD 
nonsense mutation in Ct serovar D/UW3/Cx. Immunofluorescence and transmission 
electron microscopy revealed that pmpD null mutants showed aberrant inclusion 
morphology with reduced association of RBs with the inclusion membrane, but no 
obvious growth defects. Furthermore, a species-specific role for PmpD in early 
cellular interactions was identified, with null mutants showing no significant 
attenuation of infectivity in murine (McCoy and primary Bm12.4) cells and in a 
C3H/HeJ mouse model of infection, evidenced by recoverable IFU and duration of 
shedding relative to the wild-type strain (Kari et al., 2014).  
 
In contrast, the pmpD null mutant was significantly attenuated for virulence in 
immortalised human endocervical (A2EN) and conjunctival (HCjE) cells relative to 
the wild-type strain, showing a 70% reduction in its ability to infect or proliferate in 
human cells relative to the wild-type strain, evidenced by enumeration of IFU. The 
serovar D/UW3/Cx pmpD null mutant was also used in an ocular challenge model of 
cynomolgus macaques, where the initial chlamydial burden and clinical disease score 
was found to be significantly higher for the wild type strain at only two sampling time 
points over the first 2-3 weeks, but no significant differences in duration of shedding 
were observed. Peak differences in shedding were observed at 1week post infection, 
showing a 25-fold reduction in inclusion forming units for the pmpD null mutant. 
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Overall, these data suggest that PmpD may play a role in early interactions with host 
cells, possibly in adhesion and/or invasion, but also in late cycle interactions with the 
chlamydial inclusion, and that this function may be species-specific, and possibly 
fine-tuned by host-pathogen co-evolution. Indeed, the Chlamydia muridarum PmpD 
shows only 72% amino acid sequence identity to its C.trachomatis ortholog, where 
the putative RGD integrin-binding motif is substituted by a KGD motif (Kari et al., 
2014). Further experimentation is required to confirm this, and would entail the study 
of a C.muridarum pmpD null mutant. While the generation of Ct null mutants is 
incredibly labour-intensive and costly, this study showcases the utility of examination 
of endogenous chlamydial protein function that holds greater biological relevance 
than heterologous or ectopic expression studies. However, the use of a non-invasive 
urogenital Ct serovar null mutant in in vitro assays using conjunctival cells and in 
vivo ocular infection models holds limited relevance to the natural biology of the 
pathogen. Furthermore, transformation of the pmpD null mutant with a PmpD-
expressing shuttle vector was not implemented to demonstrate restoration of function, 
the gold-standard test in molecular biology.  
 
In this chapter, we provide further evidence implicating PmpD as a Ct adhesin by 
implementing adhesion assays with covalent coupling of PmpD to functionalized 
latex bead surfaces. The 65kDa PmpD passenger domain fragment used in the 
adhesion study was previously identified by mass spectrometry (Kiselev, Skinner and 
Lampe, 2009) in in vitro propagated Ct, and is hence likely to be representative of a 
proteolytic species produced during the course of natural infection. Here, we show for 
the first time that rPmpD-coated beads show significantly enhanced adhesion to Hak 
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(epithelial-like) cell lines, conventionally used to culture and study antibody 
neutralization of Ct, and that anti-rPmpD immune serum abrogates the ability of 
rPmpD-coated beads to adhere to Hak cells. As shown in previous host-pathogen 
interaction studies, we also demonstrate that soluble rPmpD competitively inhibits 
binding of rPmpD-coated latex beads from adhering to Hak cells in a dose-dependent 
fashion, providing further evidence of the importance of PmpD in early host cell 
interactions. All work carried out in subsequent adhesion assays employs the purified 
monomeric 65kDa rPmpD fragment (Fig.4.3) unless stated otherwise. 
 
5.2 Results 
5.2.1 Coating of recombinant monomeric 65kDa PmpD to carboxylate 
modified polystyrene beads 
Recombinant PmpD or BSA were covalently coupled to carboxylate modified 
polystyrene beads of different diameters (0.5µm, 1µm, 2µm) using the water-soluble 
coupling agent 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) 
(Fig.5.1(A)). This coupling method has been implemented in previous immunological 
studies (Quash et al., 1978). BSA was selected as a control due to its similar 
molecular weight (~69kDa) and pI (~5.89) to the rPmpD fragment (~65kDa, pI~4.61). 
To confirm efficient coupling of recombinant proteins to the functionalized bead 
surface, supernatants were tested for the presence of recombinant protein before and 
after the coupling reaction, and coated beads were boiled in the presence of β–ME and 
SDS and tested using SDS-PAGE (Fig.5.1(B)). Efficient coupling of both rPmpD and 
BSA were observed for 0.5µm and 2µm diameter beads, but not for 1µm polystyrene 
particles. 
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5.2.2 Adherence of rPmpD-coated polystyrene beads to Hak and McCoy cell 
lines 
Due to the ability to more easily visualize and reliably quantify the 2µm beads relative 
to the 0.5µm beads, 2µm beads were subsequently used in all adhesion assays. The 
naked, rPmpD- or BSA-coated beads were incubated with mammalian epithelial-like 
Hak and murine fibroblast McCoy cell lines. Following washing in PBS to remove 
unbound beads, methanol fixation and Giemsa staining, the number of beads attached 
to 50 cells in triplicate random fields of view was counted using phase microscopy 
(Fig.5.2-5.4). rPmpD-coated beads showed a significant increase in adhesive capacity 
to Hak cells relative to naked and BSA-coated beads. This experiment confirms that 
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rPmpD demonstrates adhesin-like properties, a finding also previously documented 
by (Becker and Hegemann, 2014). 
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5.2.3 Titration of rPmpD coating concentrations on carboxylate modified 
polystyrene beads 
Titration of rPmpD bead coating concentration from 50µg/ml to 0.25µg/ml was 
carried out, and incubation of a 1:50 dilution of a 1% solution of polystyrene beads 
with Hak cells revealed a concentration-dependent reduction in bead binding 
(Fig.5.5). A rPmpD-coating concentration as low as 2.5µg/ml still effected roughly 
four-fold greater adhesion (118±10) than beads coated with 200µg/ml of BSA control 
protein (29±11). 
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5.2.4 Analysis of infection abrogation of carboxylate modified rPmpD-coated 
polystyrene beads by mouse anti-rPmpD serum 
To further investigate whether rPmpD was essential to Hak cell adhesion, anti-rPmpD 
serum from rPmpD-immunized C57BL/6 mice was pre-incubated with rPmpD-coated 
beads. Two different dilutions of immune serum were used (1:100 and 1:50), and 
incubated with beads coated with differing concentrations of rPmpD from 50µg/ml-
2.5µg/ml (Fig.5.6). Following addition of a 1:50 dilution of a 1% solution of 
polystyrene beads to Hak cell monolayers, significant reduction in adhesion (four to 
five-fold) was observed with a 1:50 dilution of immune serum relative to the negative 
control (binding media).  
 
	 160	
5.2.5 Competitive inhibition of carboxylate modified rPmpD-coated 
polystyrene beads by soluble rPmpD 
To determine whether soluble rPmpD could block rPmpD-coated bead binding to Hak 
cells, pre-incubation of Hak cells with soluble rPmpD (50µg/ml-2.5µg/ml), was 
followed by washing and incubation with beads coated with differing concentrations 
of rPmpD (50µg/ml-2.5µg/ml). Increasing concentrations of soluble rPmpD 
competitor significantly abrogate bead adhesion relative to the negative control (pre-
incubation with BSA) (Fig.5.7).  
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This experiment indicates that binding of rPmpD to a putative cellular receptor or 
extracellular matrix component, likely competes for binding sites available for 
rPmpD-coated polystyrene bead adhesion. 
 
5.3 Discussion 
Whole-genome sequencing of bacterial genomes has elucidated an incredibly diverse 
array of putative adhesin genes in pathogenic bacteria, and it is likely that several 
routes to host cell adhesion and invasion exist (Brzuszkiewicz et al., 2006). Such 
inbuilt functional redundancy inevitably puts a large constraint on in vitro studies and 
vaccine development, and for many important bacterial pathogens such as Ct, 
elucidation of structure-function relationships and receptor-ligand interactions is 
crucial for informing therapeutic development. Moreover, our knowledge of the 
functional consequences of the expansion of Pmps in Ct and related chlamydial 
species is rudimentary.  
 
Becker and Hegemann (2014) have recently implicated all recombinant Ct Pmps as 
chlamydial adhesins, and showed tissue-specific adhesion properties of rPmpD-coated 
bead binding to epithelial-like HEp-2 and HeLa cell lines, but not endothelial HUVE 
cells. Furthermore, (Kari et al., 2014) demonstrate that infectivity of a serovar 
D/UW3/Cx pmpD null mutant is defective for adhesion in human conjunctival (HCjE) 
or endocervical (A2EN) cell lines, but not in McCoy (murine fibroblast) cell lines. 
Our data show for the first time that the 65kDa rPmpD passenger domain proteolytic 
fragment, shown to be present under physiological conditions in in vitro cultured Ct, 
possesses adhesive properties in the mammalian epithelial-like Hak cell line, widely 
used for culture and study of antibody-mediated neutralization of Ct infections in 
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vitro, due to the lack of Fc-receptor expression which may facilitate bacterial 
internalization in other cell types. The rPmpD-host cell interaction was further 
confirmed using competitive inhibition assays and anti-rPmpD mediated 
neutralization of rPmpD-coated latex bead adhesion. Both anti-rPmpD serum and 
soluble rPmpD competitor abrogate adhesion in vitro. These experiments provide 
further evidence suggesting Ct PmpD may function as a chlamydial adhesin. 
 
Possible extensions to our investigations of the function of PmpD include in vitro 
anti-rPmpD serum neutralization and soluble rPmpD competitive inhibition of live Ct 
infection. However, the identification of specific host cell interactions for adhesins 
remains a significant experimental challenge due to phase variability and differential 
expression of multiple adhesins in Ct that may also possess overlapping functions and 
binding affinities, and failure to observe abrogation of infection under such 
experimental conditions may not necessarily rule out Pmp effector function in vivo. 
For instance, Ct encodes nine different Pmps with variable expression profiles during 
biphasic development (Gomes et al., 2006; Nunes et al., 2007; Tan et al., 2010), with 
all nine proteins implicated in host cell adhesion (Becker and Hegemann, 2014). 
However, determining whether these proteins exert a cooperative effect, or act 
independently through multiple different interactions with host cell ligands will be of 
direct relevance to rational vaccine design. 
 
Although no structure of a chlamydial adhesin has yet been solved, examination of 
the structure of outer membrane proteins of Yersinia spp. has indicated diverse 
functional roles of T5ATs. In Yersinia, the structures of outer membrane 
autotransporters have been solved by X-ray crystallography. YadA is a large, modular 
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trimeric autotransporter protein that possesses a head, neck, stalk and anchor domain 
(Hoiczyk et al., 2000). This results in a lollipop-like projection that protrudes to a 
distance of ~23nm from the bacterial cell surface (Koretke et al., 2006). The 3D 
structure of the YadA head domain has been elucidated, and implicated in neutrophil 
and collagen binding, as well as auto-agglutination (Hoiczyk et al., 2000). The YadA 
head domain demonstrates self-affinity that ultimately leads to bacterial flocculation, 
a process also exemplified by the E.coli T5AT Ag43 (Klemm et al., 2004). This is 
thought to mediate bacterial resistance against host antimicrobial agents and promote 
biofilm formation.  
 
Ct PmpD may function in a similar manner, possibly mediated through Cys-Cys 
interactions or distinctive GGA(I,L,V) / FXXN tetrapeptide motifs within the 
passenger domain, and future work may involve investigating changes in adhesive 
capabilities of PmpD passenger domains with specific Cys mutations or disruptions in 
tetrapeptide motif sequences. (Molleken, Schmidt and Hegemann, 2010) demonstrate 
that at least two of these copies are required for adhesion to host cells in 
C.pneumoniae. Interestingly, YadA has also been shown to act as a scaffold for the 
T3SS injectisome (Visser, Annema and van Furth, 1995), and it is likely that PmpD, 
given its constitutive expression throughout Ct biphasic development in EB and RB 
forms (Tan et al., 2010), may play a similar role, most likely through Cys-Cys 
interactions with other Cys-rich Ct T3SS apparatus proteins such as the needle-like 
protein CdsF (Betts-Hampikian and Fields, 2011).  
 
However, perhaps the most well characterized Yersinia adhesin is invasin. This 
protein shows an inverse arrangement of the T5AT system with the β–barrel at the N-
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terminus of the protein, and is composed of a modular architecture consisting of four 
bacterial immunoglobulin-like (BIG) domains (D1-D4) and a D5 domain that 
possesses similar topology to the C-type lectins (Hamburger et al., 1999). Domains 
D4-D5 are critical and sufficient for integrin binding, as is the formation of the 
disulphide bond between Cys906 and Cys982. Importantly, invasin binds integrins with 
greater affinity than host ligand fibronectin, and structural examination of the inter-
domain interfaces reveals a larger binding interface for invasin, which likely explains 
this enhanced affinity (Hamburger et al., 1999). Invasin thus reveals a remarkable 
instance of convergent evolution of pathogenic effector molecules that not only 
mimic, but also outcompete host cell ligands for binding. Thus, structural approaches 
used to examine host-pathogen interactions are important for shedding light on 
functional interactions or guiding cell biology approaches to interrogate adhesin 
function in vitro. 
 
Ongoing and future work involves identification of putative cellular interaction 
partners for PmpD. To identify extracellular molecular targets of rPmpD, two 
approaches for identifying protein-protein interactions are currently in progress. The 
first involves fusion of PmpD 65kDa passenger domain to a constitutively active E. 
coli biotin ligase (BirA) (Roux et al., 2012). In the presence of biotin in cell culture, 
BirA biotinylates proteins in close proximity. Soluble Ct rPmpD-BirA fusion protein 
added to A2EN, HCjE or Hak cell lines will then be warmed to 37ºC in the presence 
of biotin, allowing biotinylation of proteins in close proximity. Recombinant BirA 
alone will be used to generate control samples for proteomics. Both transient and 
stable interaction partners isolated using magnetic streptavidin beads will be 
identified by on-bead tryptic digestion and analysis by 1D LC/MS/MS.  
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A caveat to the biotinylation experiment is that the rPmpD host cell interaction 
partner needs to be accessible to the BirA ligase fusion protein. If the fusion construct 
interferes with binding or results in diminished protein expression, rPmpD will be 
biotinylated in vitro using NHS-SS-biotin and incubated with respective cell lines. 
Cross-linking to receptor proteins using DTSSP will be implemented, and biotinylated 
rPmpD-receptor complexes isolated using streptavidin affinity purification following 
cell lysis and elution by DTT reduction of the disulphide bond between rPmpD and 
NHS-SS-biotin (Fig.5.8). A similar approach has been used previously to identify 
Pmp21 interaction partners in Chlamydia pneumoniae (Molleken, Becker and 
Hegemann, 2013). 
 
 
In addition, PmpD possesses a putative nuclear localization sequence, and the pmpd 
null mutant shows atypical inclusion morphology with defective RB attachment to the 
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inclusion membrane (Kari et al., 2014; Swanson et al., 2009). To identify likely 
intracellular interactions, HEK293 cells stably expressing inducible mycBirA-rPmpD 
fusion construct under an inducible Tet promoter will be generated, with endogenous 
biotinylated proteins purified using streptavidin beads upon cell lysis. Validation of 
protein-protein interactions may then further be studied using siRNA knockdowns of 
identified targets in CHO cells and complementary Y2H assays. 
 
In light of the evidence provided here, and in previous studies implicating Pmps and 
T5ATs from a diverse range of Gram-negative pathogenic bacteria in host cell 
adhesion, these chlamydial outer membrane proteins are promising antigenic 
components for the development of future chlamydial vaccines. The successful 
incorporation and N.menigitidis NadA and B.pertussis pertactin in the licensed 
Bexsero meningitis B and DPT vaccines (respectively) provides robust evidence of 
the importance of T5ATs in mediating protection against bacterial disease. The 
following chapter investigates the efficacy of Ct rPmpD as a chlamydial vaccine 
candidate in a murine model of Ct infection. 
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Chapter 6: Investigation of a novel second-generation lipid adjuvant 
(SLA) in combination with rPmpD as a preclinical Ct vaccine 
 
6.1 Introduction 
The immune response to an invading pathogen consists of two broadly characterized 
innate and adaptive phases. The innate immune system implements the initial non-
specific pro-inflammatory response through sensing of pathogen associated molecular 
patterns (PAMPs) by an array of pathogen recognition receptors (PRRs) on 
macrophages and dendritic cells (DCs), and confers generalized protection to the host 
through phagocytosis and the secretion of cytokines and chemokines which also 
facilitate the arrival of neutrophils and other innate effector cells such as NK or NKT 
cells with antimicrobial properties (Banchereau and Steinman, 1998; Creagh and 
O'Neill, 2006). This initial inflammatory response also leads to the recruitment and 
priming of cells of the adaptive immune system, which are programmed and shaped 
to recognize pathogen-specific molecules by professional antigen presenting cells 
(APCs) of the innate immune system, resulting in immunological memory (Palm and 
Medzhitov, 2009). The importance and intricacies of innate immune signaling are 
now becoming increasingly appreciated within the context of adaptive immunity, 
particularly where vaccine development is concerned (Kasturi et al., 2011; Wiley et 
al., 2011). 
 
Many live-attenuated or whole-cell vaccines now struggle to fulfill the more stringent 
regulatory requirements of safety and standardized manufacturability, and also carry 
the risk of reversion to virulent wild-type strains in vivo. Furthermore, although 
intrinsically immunogenic, these vaccines are often more costly to manufacture, and 
depending on the nature of the pathogen, may not be suitable for administration to 
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subsets of patients who are immunocompromised. Thus, for many pathogens, 
antigenic components manufactured as recombinant proteins are considered a safer, 
cheaper and more robust alternative. However, in the absence of a plethora of 
immunogenic surface-exposed PAMPs in whole-cell or live-attenuated vaccines (e.g. 
bacterial lipopeptides, lipopolysaccharides, flagellins), recombinant protein vaccines 
are weakly immunogenic. This necessitates the development of adjuvants able to 
elicit a potent and durable antigen-specific immune response. However, because the 
mode of action of even the most widely used adjuvants in currently licensed vaccines 
such as the aluminium salts and MF59 are poorly characterized (Marrack, McKee and 
Munks, 2009; O'Hagan et al., 2012), a shift in focus towards understanding and 
defining the molecular mechanisms of new adjuvants in both preclinical models and 
human trials has been identified as a crucial step to fulfilling both regulatory statutes 
and existing unmet medical needs (Reed, Orr and Fox, 2013).  
 
One of the most pressing clinical requirements for next-generation adjuvants in the 
field of infectious diseases is the development of new T cell based vaccines to combat 
intracellular pathogens that cause substantial mortality or morbidity worldwide. 
Malaria, tuberculosis and HIV are among the most widely investigated, but several 
other neglected tropical diseases such as the spectrum of leishmaniases, ocular 
trachoma and sexually transmitted chlamydial infections comprise this category. An 
array of judicious targets for novel adjuvants is represented by the wide array of 
innate immune receptors that mediate PAMP recognition within the host, and are able 
to differentially program the ensuing pro-inflammatory response through specific 
signaling cascades.  
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The family of PRRs known as Toll-like receptors (TLRs) will briefly be discussed 
below, followed by a major focus on TLR4 and the first preclinical characterization of 
a novel, rationally designed TLR4 agonist employed as an adjunct to Ct rPmpD for 
use in the development of future chlamydial vaccines. This second generation lipid 
adjuvant (SLA) was designed and formulated by the Infectious Disease Research 
Institute (IDRI), and has previously undergone preliminary characterization in in vitro 
assays through analysis of cytokine and chemokine profiles following stimulation of 
human and murine cells (IDRI, personal communication). We provide the first 
preclinical study utilizing rPmpD as a chlamydial vaccine antigen, and demonstrate 
the in vivo efficacy of the SLA-rPmpD combination in significantly enhancing both 
resistance to Ct infection and reduction in bacterial load. 
 
6.1.1 Toll-like receptors 
TLRs constitute a family of 10 transmembrane PRRs in humans, which are 
differentially expressed on variable APC subsets that also vary in population density 
at disparate anatomical sites (Ueno et al., 2011). Indeed, much attention has been 
devoted to the study of these subsets and their physiological abundance in vivo, with 
particular focus on the use of TLR-based adjuvants to target specific DC subsets for 
an optimal immune response (Reed, Orr and Fox, 2013). TLRs 1, 2 and 6 are surface-
expressed, and possess the ability to hetero-dimerize with predominant recognition of 
lipidated peptides, while TLR5 is responsible for the recognition of bacterial flagellin. 
TLRs 3, 7, 8 and 9 are expressed intracellularly, and mediate innate immune 
recognition of dsRNA (TLR3), ssRNA (TLRs 7 and 8) or unmethylated CpG DNA 
(TLR9). TLR4, perhaps the most well-characterized PRR in the field of adjuvant 
development, is also expressed on the surface of APCs, and mediates immune 
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signaling through sensing of an array of structural variants of bacterial 
lipopolysaccharides (LPS), signaling predominantly through the MyD88 and TRIF-
dependent pathways (Bowen et al., 2012). The rational design and in vivo 
characterization of a novel TLR4 agonist for use in future chlamydial vaccines will be 
the focus of this chapter. 
 
6.1.2 TLR4: an exploitable target for adjuvant development 
TLR4 is an attractive innate immune receptor upon which to base the design of next-
generation adjuvants, particularly in light of a wealth of safety and immunogenicity 
data provided by previous clinical trials using TLR4 agonists, and a detailed 
description of the molecular mechanisms of LPS interaction with the TLR4 receptor 
(Hajjar et al., 2002; Ohto et al., 2012). Indeed the only approved TLR agonist licensed 
for use in vaccine development to date is 3D-MPL, a synthetic derivative of LPS 
developed by Ribi ImmunoChem and Corixa Corporation (Baldridge et al., 2004; 
Ulrich and Myers, 1995), and now a main constituent of the AS04 adjuvant 
formulation currently in use in the HPV vaccine, Cervarix (GSK) (Didierlaurent et al., 
2009; Giannini et al., 2006). 
 
Recent studies have provided a much clearer picture of the molecular basis of TLR4 
signaling in response to activation by an array of structural variants of LPS. Indeed, 
the 3D description of the structure of the TLR4-MD2 complex through X-ray 
crystallography was a seminal discovery that has subsequently guided the rational 
design of ligands to target this molecule (Fig.6.1) (Park et al., 2009). Signaling 
through TLR4 involves loading of LPS on to the myeloid differentiation factor 2 
(MD2) molecule with the aid of the helper protein CD14 (Lu, Yeh and Ohashi, 2008). 
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This is followed by dimerization of the LPS-MD2 complex with the TLR4 receptor 
(Ohto et al., 2012). 
 
It is now widely acknowledged that TLR4 is a major transducer of intracellular 
signaling cascades that lead to the maturation of APCs and initiation of the acute 
inflammatory immune response (Beutler, 2000). Evidence for this has been provided 
in both animal models and human genome-wide studies, where hypo-responsiveness 
to LPS is observed in C3H/HeJ and C57BL/10ScCr mice with mutations in the TLR4 
gene (Poltorak et al., 1998). In contrast, mice deficient in TLR2, once implicated in 
LPS signaling, show no differences in the immune response to LPS (Hoshino et al., 
1999).  
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A main premise for the development of TLR4 ligands as innate immune adjuvants 
was the observation that pathogenic bacteria (such as Salmonella and Pseudomonas) 
altered the acylation state of their lipid A surface components in order to modulate 
host-mediated innate immune responses (Ernst et al., 1999; Guo et al., 1997). 
Importantly, subtle changes in the structure of bacterial LPS can also lead to the 
differential modulation of the inflammatory response. This was elegantly 
demonstrated in a study comparing clinical and laboratory isolates of P.aeruginosa - a 
Gram-negative pathogen of humans (Hajjar et al., 2002).  
 
Laboratory-adapted strains of P.aeruginosa possess a predominantly penta-acylated 
LPS structure, while isolates obtained from the lungs of patients affected by cystic 
fibrosis contain a hexa-acylated form of LPS that possesses additional 
aminoarabinose and palmitate residues (Ernst et al., 1999). Importantly, it was found 
that clinical but not laboratory isolates were able to stimulate a robust inflammatory 
response in human endothelial (HUVEC) cells, evidenced by the induction of pro-
inflammatory cytokines, thus providing further evidence that LPS derivatives can act 
as agonists or antagonists of the TLR4 receptor, and that this interaction may be 
governed by the acylation state of the molecule (Ernst et al., 1999; Somerville et al., 
1996). 
 
(Hajjar et al., 2002) further found that while human cells and TLR4 (hTLR4) were 
able to differentiate between penta- and hexa-acylated forms of LPS, murine cells and 
TLR4 receptors (mTLR4) were not. Because the interaction between LPS and the 
TLR4 receptor also requires coupling of the LPS molecule to MD2 via CD14, it was 
necessary to investigate which of these components contributed to differential LPS 
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recognition. Using endothelial cell leukocyte adhesion molecule (ELAM)-luciferase 
as a readout for NFκB activity in response to LPS stimulation, ectopic expression 
studies of murine and human TLR4, MD2 and CD14 components were carried out in 
transfected HEK-293 cells, demonstrating that variations between human and murine 
TLR4 receptors, and not the MD2 or CD14 components, contributed to differential 
sensitivity to LPS variation (Hajjar et al., 2002).  
 
The region of the TLR4 receptor attributable to differences in NFκB activity was 
initially identified through sequence comparisons across a range of species, revealing 
an 82 amino acid hypervariable ecto-domain that lacked leucine-rich repeat regions 
characteristic of TLRs (Hajjar et al., 2002). Furthermore, this region is contained 
within a larger 330 amino acid region in the extracellular domain, where 
polymorphisms within the human population are known to reside and are reportedly 
responsible for hypo-responsiveness of certain individuals to endotoxin (Arbour et al., 
2000).  
 
The high degree of variation within this region, evidenced by the high ratio of non-
synonymous to synonymous SNPs (Hajjar et al., 2002), suggests that this part of the 
receptor has been under species-specific environmental pressure in response to 
pathogen adaptation by LPS modifications, and may also be a contributing factor to 
inter-individual variation in disease outcome following infection by certain 
pathogenic bacteria. Furthermore, these observations highlight the caveats of using 
preclinical models to study the efficacy of LPS-based adjuvants without prior 
characterization and evaluation of immune responses in primary human cells. This is 
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of paramount importance for the future development of TLR4 agonists, where the 
degree of immunogenicity in mice may not necessarily reflect that in humans. 
 
This species-specificity of LPS recognition using P.aeruginosa as a model organism 
is further corroborated by investigation of N.meningitidis LpxL1 LPS, where hexa-
acylated but not penta-acylated structures elicit robust immune responses in human 
macrophages, whilst significant changes in the inflammatory response are 
indiscriminate between the two orthologs when administered as adjuvants in mice 
(Steeghs et al., 2008). This study was important, as the authors previously showed 
potent immune-stimulating properties of LpxL1 in murine models of N.meningitidis 
infection (Steeghs et al., 1999; van der Ley et al., 2001), evidenced by high levels of 
maturation of murine BMDCs in vitro (Fisseha et al., 2005), implying that LpxL1 
may be incorporated as a candidate adjuvant in future vaccines. However, in the 
context of what is now known about species-specific differences in the TLR4-MD2-
LPS interaction, validation of the translational potential of subsequent ‘designer’ 
adjuvants will require prior evaluation in a range of both human and murine APCs in 
vitro. 
 
The recent 3D structural description of the molecular interactions of murine TL4 with 
both LPS and Lipid IVa, a precursor of E.coli LPS, has highlighted important 
structural design principles for future LPS derivatives as novel adjuvants (Ohto et al., 
2012). It was previously shown that the lipid A moiety, with acyl chains of variable 
lengths attached to the diglucosamine backbone of LPS, was responsible for 
immunostimulatory activity (Schletter et al., 1995). In addition, the presence of two 
phosphate groups was further shown to be key for immuno-stimulatory properties, as 
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deletion of the either group diminished endotoxin potency (Rietschel et al., 1994; 
Rietschel et al., 1993).  
 
Interestingly, binding of LPS induced the formation of M-shaped TLR4-MD2-LPS 
dimers (Ohto et al., 2012). Examination of the crystal structures of the TLR4-MD2-
LPS interfaces revealed that during binding of hexa-acylated LPS, only one of the six 
acyl chains are exposed at the surface of MD2, and form hydrophobic interactions 
with phenylalanine residues of TLR4. However, the five other acyl chains of LPS 
remained buried within MD2, without changing the size of the binding pocket. This is 
in contrast to tetra-acylated LPS derivatives, where lipid IVa showed displacement of 
the di-glucosamine backbone by a 5Å upward shift towards the solvent area. It was 
further observed that this displacement aided dimerization through the formation of 
ionic interactions between the negatively charged phosphate groups and positively 
charged amino acid residues on TLR4 and MD2 (Ohto et al., 2012).  
 
Interestingly, binding of LPS induced the formation of M-shaped TLR4-MD2-LPS 
dimers (Ohto et al., 2012). Examination of the crystal structures of the TLR4-MD2-
LPS interfaces revealed that during binding of hexa-acylated LPS, only one of the six 
acyl chains are exposed at the surface of MD2, and exert hydrophobic interactions 
with phenylalanine residues of TLR4. However, the five other acyl chains of LPS 
remained buried within MD2, without changing the size of the binding pocket. This is 
in contrast to tetra-acylated LPS derivatives, where lipid IVa showed displacement of 
the di-glucosamine backbone by a 5Å upward shift towards the solvent area. It was 
further observed that this displacement aided dimerization through the formation of 
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ionic interactions between the negatively charged phosphate groups and positively 
charged amino acid residues on TLR4 and MD2 (Ohto et al., 2012).  
 
Thus, it is clear that the differential activation of hTLR4 by structural modifications in 
LPS derivatives employed by certain pathogens offers a unique opportunity to tune 
TLR signaling, and hence modulate the ensuing innate immune response. In the 
context of the 3D description of the TLR4 structure, the ability to rationally design 
and test new adjuvants holds great potential for achieving a balance of pro-
inflammatory immune signatures to initiate robust cell-mediated immunity, with 
therapeutic windows that may result in enhanced safety profiles in human clinical 
trials. This is important to avoid the risk of severe adverse events in clinical trials, as 
exposure to LPS can often amplify signaling through TLR4 resulting in localized 
inflammation or systemic septic shock (Angus et al., 2001). Importantly, these 
observations substantially guided the development of a glucopyranosyl lipid adjuvant 
(GLA) developed by IDRI, a precursor to the structurally designed second-generation 
lipid adjuvant (SLA) employed in our study. The design principles upon which these 
two adjuvants were developed will be discussed next. 
 
6.1.3 Design of glucopyranosyl lipid adjuvant (GLA) 
GLA was designed using previous knowledge on the variable potencies of different 
LPS analogues discussed above (Rietschel et al., 1993; Schletter et al., 1995). The 
structure of GLA is shown in Fig.6.2 (Coler et al., 2011). Key differences between 
GLA and naturally occurring LPS derivatives are highlighted. These include: (i) the 
removal of sugar residues from the hydroxyl group proximal to the phosphate moiety 
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(ii) the removal of the second phosphate group on GLA (iii) the engineering of acyl 
chains of defined lengths. 
 
 
 
The immunostimulatory effects of GLA were investigated using mRNA and protein 
multiplex assays, flow cytometry and microarrays on both human and murine DCs 
(Coler et al., 2011). These responses were compared with the commercially approved 
MPL agonist, currently employed as part of the AS04 adjuvant system in the Cervarix 
vaccine (Didierlaurent et al., 2009). Specifically, following stimulation by each TLR4 
agonist (GLA or MPL) formulated in an aqueous suspension, mouse bone-marrow 
derived dendritic cells (BMDCs) and human monocyte-derived DCs were assayed for 
an array of 23 genes implicated in the inflammatory response and the maturation of 
APCs, including the interleukin family (e.g. IL-1β, IL-6, IL-12p40, TNF) and an array 
of cellular expression markers (such as CD40, CD80, CD83 and CCR7) (Coler et al., 
2011). 
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Interestingly, it was found that GLA and MPL both induced similar dose- and time-
dependent immune responses in murine BMDCs. However, in human monocyte-
derived DCs, GLA was found to be 10-100 times more potent than the commercial 
MPL agonist (Coler et al., 2011). Furthermore, the authors demonstrate the in vivo 
potency of GLA when paired with the ID83 M.tuberculosis vaccine antigen in a stable 
oil-in-water emulsion (GLA-SE), where robust systemic immune responses and Th1-
bias were observed.  
 
Thus, Coler et.al (2011) elucidated likely mechanistic correlates of protection elicited 
by previous preclinical vaccines incorporating GLA as an adjuvant in disease models 
of both leishmaniasis and tuberculosis (Baldwin et al., 2009;Bertholet et al., 2009). 
GLA-SE was previously shown to be safe and well-tolerated in Phase I trials (Coler et 
al., 2010), and clinical assessment of the immunogenicity of GLA-SE in humans was 
subsequently carried out with the purpose of evaluating different antigen-adjuvant 
combinations following vaccination of 12 young (20-30 years) and 15 older (>65 
years) adults with subunit (SuV) or split-virus (SVV) influenza vaccines (Behzad et 
al., 2012). 
 
Incorporation of GLA-SE with an influenza SVV showed enhanced cytotoxic T-
lymphocyte (CTL) response to influenza virus challenge in in vitro stimulated 
PBMCs isolated from immunized subjects, evidenced by enhanced granzyme B 
(GrzB) activity, and was further associated with suppression of IL-10, as shown by 
elevated IFNγ:IL-10 ratios relative to control subjects (Behzad et al., 2012), 
indicating a Th1-biased response. Interestingly, these effects were significantly 
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enhanced when compared to GLA formulated in aqueous suspension (GLA-AF) or 
when compared to the TLR7/8 agonist R848, highlighting both the selective 
advantage of targeting TLR4 as well as the formulation-dependent variations in the 
efficacy and potency of adjuvants.  
 
Immune senescence in the elderly, particularly in response to vaccines, has been 
shown to correlate with a variety of immunological parameters, including the 
variation of TLR expression with age (Grewe, 2001), reduced antigen presentation 
and diminished memory and effector T cell function (Haynes, 2005; Zhou and 
McElhaney, 2011). Specifically, reduced sterilizing immunity to influenza has further 
been demonstrated to correlate with an age-related shift in the immune response from 
a Th1- to a Th2-type bias (Shahid et al., 2010). Thus, reversing this bias through 
tailored adjuvant-antigen combinations is considered an effective way of contributing 
to improved protection against infectious diseases in the elderly population.  
 
6.1.4 Second-generation lipid adjuvant (SLA) 
The preclinical and clinical efficacy of GLA has subsequently prompted the tailored 
development of a novel second-generation lipid adjuvant (SLA), implemented by 
IDRI (Seattle). Adjuvant design was informed by ligand docking in to the previously 
solved 3D crystal structure of the TLR4-MD2 complex (Fig.6.3(A)) (Parket al., 
2009). Molecular development in relation to the structure of GLA is shown in 
(Fig.6.3(B)).  It was hypothesised that trimming of terminal carbon atoms from acyl 
chains protruding from the MD2 binding pocket may lead to a conformational 
difference in coupling, thus possibly modulating downstream TLR4 immune 
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signaling bias, as demonstrated in previous studies using modified LPS derivatives 
(Hajjar et al., 2002).  
 
Design of SLA involved removal of methylene groups on the acyl chains of the GLA 
precursor. Although not currently determined experimentally, it was anticipated that 
overcrowding of the TLR4-MD2 interface with longer acyl chains results in energy  
 
 
penalties associated with binding, and may occur at the cost of diminished interaction 
of phosphate head groups by further upwards displacement of the molecule, that have 
previously been shown to be critical for endotoxin activity (Ohto et al., 
2012;Rietschel et al., 1993). Further, it has been suggested that molecules with shorter 
acyl chains may result in a change in signaling pathway bias between the MyD88 and 
TRIF-dependent pathways (Bowen et al., 2012). Thus, removal of four carbon atoms 
of GLA maintained as large a hydrophobic surface area as possible to facilitate 
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energetically favourable binding kinetics between the new SLA molecule and the 
TLR4 interface as determined by the Avogadro software package (Hanwell et al., 
2012). 
 
In light of the aforementioned differences in murine and human TLR4 signaling and 
the impact of formulation on adjuvant efficacy and potency, both aqueous and oil-in-
water emulsion formulations of the SLA molecule were tested in vitro in a human 
THP1 cell line and primary PBMCs isolated from healthy donors (IDRI, personal 
communication). As demonstrated in previous studies investigating TLR4-LPS 
interactions (Hajjar et al., 2002), the kinetics of NFκB activity were assessed using a 
reporter assay with GLA as a comparator. In HEK-293 cells expressing human TLR4, 
kinetics of NFκB phosphorylation were significantly enhanced with SLA relative to 
GLA, and were further found to plateau at lower concentrations than GLA, indicating 
a wider therapeutic window for SLA. SLA was also found to be 500 times more 
potent than GLA when added to transfected HEK cell lines expressing murine 
TLR4/MD2. As expected, this suggests that rational modification of TLR4 ligands 
can dramatically affect the kinetics and magnitude of inflammatory signaling 
pathways in vitro.  
 
In addition to NFκB activity, cytokine and chemokine profiles were compared 
between SLA and its predecessor GLA. It was found that SLA induced a significantly 
more biased Th1-type immune response than GLA in primary human cells, evidenced 
by significantly lower levels of IL-10. The response was also less pro-inflammatory, 
with ten-fold lower levels of IL-1β and significantly less IL-6, while Th1-biasing 
cytokine and chemokine levels (IFNγ, GM-CSF and IP-10) remained unchanged. This 
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is further indicative of the differential ability of TLR4 agonists to tune innate immune 
signaling profiles, as it is known that TLR4 can signal through both the general 
MyD88 pathway shared by all other TLR receptors, but further possesses the ability 
to signal through the TRIF-dependent pathway (Fig.6.4) (Orr et al., 2013a). Based on 
the observation of significantly lower levels of pro-inflammatory IL-1β and IL-6 from 
in vitro studies, it was proposed that the altered binding interaction of SLA with 
TLR4 elicits a bias towards TRIF-dependent signaling (IDRI, personal 
communication).  
 
 
 
However, the in vivo efficacy of SLA has not been investigated in preclinical models 
of infectious disease, and these studies form the basis of this chapter, with particular 
focus on characterizing the efficacy of SLA in future Ct vaccine development. Our 
	 183	
data demonstrate formulation-dependent differences in the magnitude of the Th1-type 
immune response elicited by SLA within and between mouse strains, outlining the 
caveats of preclinical testing of adjuvants in different preclinical models. Although no 
significant differences in the enhancement of serum rPmpD-specific humoral IgG 
responses were detected using different adjuvant formulations, the magnitude of local 
rPmpD-specific cervico-vaginal IgG titres was significantly elevated with the SLA-
SE formulation. Importantly, no correlation was observed between SLA formulation-
specific differences in the magnitudes of Th1-biased immune responses and resistance 
or clearance of urogenital Ct infection, which seemed to correlate more with elevated 
serum IgG titres, although other non-specific innate immune mechanisms cannot be 
ruled out. Thus, our study is the first to provide evidence for the crucial role of the 
efficacy of rPmpD as an antigen that mediates protection against urogenital Ct 
infections in vivo, and further demonstrates the potency of a novel, TLR4 agonist for 
the first time in vivo, illustrating the importance of the application of structural design 
principles in the field of adjuvant biology. 
 
6.2 Results 
6.2.1 In vivo immunogenicity and challenge study design 
The schematic for vaccination with monomeric 65kDa rPmpD passenger domain or 
Ct serovar E/Bour UVEBs and subsequent challenge with Ct serovar D/UW3/Cx is 
shown below (Fig.6.5). For assessment of vaccine-induced humoral and cell-mediated 
immunogenicity, mice from each group were sacrificed at day 56. For assessment of 
vaccine-induced protection, mice were administered a dose of DepoProvera 
(2.5mg/mouse) on day 56, and infected with Ct serovar D/UW3/Cx one week 
following final immunization. Bacterial shedding was monitored on days 1, 3, 7, 14 
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and 22 post challenge, and mice were sacrificed on day 104 of the study, 6 weeks post 
challenge. 
 
 
 
6.2.2 SLA in combination with rPmpD induces formulation-dependent antigen-
specific Th1-type immune responses and significantly enhances systemic 
humoral antigen-specific titres in the C57BL/6 mouse strain 
 
The magnitude and quality of systemic rPmpD-specific cellular immune responses 
elicited by each vaccine formulation were assessed in ELISpot assays to detect levels 
of IFNγ, IL-2, IL-5 and IL-10 cytokines following immunization (Fig.6.6 (A-D)). 
Very low levels of splenocytes secreting IL-5 and IL-10 were detected for all vaccine 
groups, and no significant difference in these populations relative to the control 
groups (PBS, SLA-LSQ or rPmpD only) was detected (Fig.6.6 (C-D)). In contrast, 
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mice immunized with rPmpD in combination with all SLA formulations showed 
significant increases in the populations of splenocytes secreting IFNγ and IL-2 
relative to all control groups (p≤0.01), suggesting that this antigen-adjuvant 
combination elicits a robust Th1-biased immune response in vivo in C57BL/6 mice.  
 
Interestingly, formulation-specific differences in the magnitude of the multifunctional 
T cell response were detected, with the SLA-SE formulation eliciting the most robust 
IFNγ response to rPmpD (>500 cells / 250,000) relative to the aqueous or liposomal 
formulations (SLA-AF and SLA-LSQ) (Fig.6.6 (A)). No significant difference 
between the IFNγ-secreting populations in SLA-AF-immunized (76 ± 38 cells / 
250,000) or SLA-LSQ-immunized mice (145 ± 81/ 250,000) was detected 
(p=0.1739). IL-2-secreting splenocyte populations in vaccinated mice were found to 
largely mirror the anti-rPmpD IFNγ response (Fig.6.6 (B)). 
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rPmpD-specific serum antibody responses were measured two weeks following the 
second (d35) and final (d56) boosts (Fig.6.5). The reciprocal titres at 50% maximal 
binding of anti-rPmpD IgG1 and IgG2c were measured (Fig.6.7 (A-B)). No 
detectable antigen-specific IgG was found in PBS- or SLA-LSQ only-immunized 
mice. All rPmpD-SLA formulations significantly boost systemic humoral anti-rPmpD 
IgG titres following successive boosts (d35 to d56), and no detectable differences in 
total IgG, IgG1 or IgG2c titres were observed at any time point between the three 
SLA formulations (p>0.05), despite formulation-dependent differences in the 
magnitudes of splenic Th1-biased cellular immune responses. Furthermore, no 
Figure 6.6: rPmpD in combination with SLA elicits a Th1-biased cellular immune 
response in vivo. Female C57BL/6 mice were immunized as described in the Materials 
and Methods, and splenocytes assessed for (A) IFN, (B) IL-2, (C) IL-5 and (D) IL-10 
secretion after in vitro stimulation with rPmpD in an ELISpot assay.  Data are from one 
experiment (n=5 animals per group). The mean + the standard deviation is shown for 
each group (* = p≤0.05, ** p≤0.01, ***p≤0.001 relative to vehicle-immunized mice). 
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increase in the ratio of systemic IgG2c:IgG1 titres (a surrogate measure for Th1 bias) 
was observed for any adjuvanted vaccine group, despite the significantly biased Th1-
type cellular immune response elicited by the SLA-rPmpD combination (Fig.6.6).  
 
 
 
Interestingly, rPmpD administered in the absence of SLA elicited strong systemic 
humoral immune responses, and showed detectable systemic immunoglobulin of the 
IgG1 but not IgG2c subclass. Only rPmpD in combination with SLA-AF elicited 
significantly greater total IgG and IgG1 (p≤0.001 and p=0.012, respectively) than 
rPmpD administered alone, and no detectable differences were observed in total 
systemic IgG or IgG1 titres between rPmpD alone and rPmpD in combination with 
SLA-SE (p=0.0658 and p=0.1039 respectively) and SLA-LSQ formulations (p=0.267 
and p=0.2495 respectively). These data suggest that at concentrations used in this 
study (5µg/dose), rPmpD is sufficiently immunogenic in the absence of SLA to elicit 
robust titres of systemic antigen-specific IgG that may parallel that of certain 
adjuvanted rPmpD vaccine formulations. However, the presence of robust levels of 
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systemic IgG2c in adjuvanted rPmpD combinations, but not in mice receiving rPmpD 
alone is further evidence that SLA induces a Th1-type immune response. 
 
6.2.3 SLA in combination with rPmpD enhances local cervico-vaginal mucosal 
IgG titres in a formulation-dependent manner in the C57BL/6 mouse strain 
Cervico-vaginal washes were obtained at d34 and d55 of the study (Fig.6.5). The 
reciprocal titres at 50% maximal binding of anti-rPmpD IgG1 and IgG2c were 
measured (Fig.6.8). Detectable cervico-vaginal anti-rPmpD IgG, IgG1 and IgG2c 
were observed in all groups of C57BL/6 mice immunized with SLA formulations in 
combination with rPmpD. In contrast, no detectable levels of total IgG or IgG2c were 
observed in mice immunized with rPmpD alone in cervico-vaginal lavage, and only 
one mouse in this group had detectable antigen-specific IgG1. While SLA-AF and 
SLA-LSQ formulations do not boost anti-rPmpD cervico-vaginal anti-rPmpD IgG 
titres following successive immunizations, the SLA-SE formulation significantly 
augments cervico-vaginal IgG1 titres between the penultimate and final boosts (d34 to 
d55). 
 
Interestingly, despite no significant formulation-dependent differences in systemic 
anti-rPmpD IgG titres between the vaccine groups, the SLA-SE formulation results in 
significantly elevated total anti-rPmpD IgG titres within the vaginal vault following 
the final boost (d55) relative to the control group (no detectable cervico-vaginal IgG), 
as well as SLA-AF (p=0.0425) and SLA-LSQ formulations (p=0.0386). No 
significant difference was observed in mucosal anti-rPmpD titres between SLA-AF 
and SLA-LSQ formulations combined with rPmpD (p=0.8721). As expected, no anti-
rPmpD titres were detected in PBS- or SLA-only-immunized control groups. 
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The anti-rPmpD IgG2c:IgG1 ratio within the vaginal vault was measured in cervico-
vaginal lavage fluids on d55 following the final boost (Fig.6.8 (C)). This ratio was 
found to be significantly elevated in mice immunized with rPmpD in combination 
with the SLA-SE formulation (4.5 ± 2.7) relative to both SLA-AF (1.04 ± 0.34, 
p=0.0217) and SLA-LSQ (1.25 ± 0.28, p=0.0281) formulations. Often conventionally 
measured as a loose surrogate of Th1-type immunity, this observation may be 
indicative of a localized Th1-type immune response within the mucosal tissue elicited 
by the SLA-SE formulation. Although further work is required to confirm the 
trafficking of antigen-specific T cells to the reproductive mucosa, this observation 
may imply that adjuvant formulation may influence the recruitment of CD4+ T cells to 
the reproductive tract. 
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6.2.4 Reactivity of anti-rPmpD and anti-UVEB serum in Western Blot and 
ELISA 
Mucosal washes obtained two weeks following the final boost from mice immunized 
with rPmpD in combination with SLA, were tested for reactivity against UVEBs in 
indirect ELISAs. Anti-rPmpD IgG from all rPmpD-adjuvant groups reacted with Ct 
serovar D/UW3/Cx UVEBs in ELISAs (Fig.6.9 (C)), suggesting recognition of native 
PmpD protein on Ct EB membranes, although it is possible immune recognition of 
similar motifs on other Pmps or COMC proteins may be elicited through adjuvant-
induced antibody-response broadening, and further work is required to deduce 
whether cross-reactivity is detected against an array of chlamydial Pmps. Western 
Blots were conducted using heat-inactivated serum from PBS-, rPmpD- and UVEB-
immunized mice following the final boost at day 56 (Fig.6.9 (A-B)). Anti-rPmpD 
serum recognizes rPmpD and associated proteolytic fragments, but fails to recognize 
antigens in UVEB lysates. Anti-UVEB serum does not recognize rPmpD protein, but 
shows predominant recognition of a 37kDa protein in UVEB lysates. Mass 
spectrometry of the 37kDa band confirmed this protein to be chlamydial MOMP. 
Immunodominance of MOMP in UVEB-immunized mice may preclude high-titre 
antibody responses to other antigens including PmpD, although the relatively low 
abundance of PmpD in the chlamydial outer membrane or specific conformational 
epitope recognition may also preclude recognition by anti-rPmpD serum in Western 
blots. 
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6.2.5 Vaccination with rPmpD or UV-inactivated EBs in combination with 
SLA significantly enhances resistance to Ct infection and reduces mean bacterial 
load independent of SLA formulation 
Cervico-vaginal swabs were obtained from all 11 groups of immunized and control 
mice on days 1, 3, 7, 14 and 22 following intra-vaginal inoculation (day 0) of Ct 
serovar D/UW3/Cx (4.5×108 IFU per mouse). Intensity and duration of primary lower 
genital tract infection is shown for each group, with data points representing the mean 
± standard deviations of the mean of each group of 5 mice (Fig.6.11 (A-F)). The 
Figure 6.9: Reactivity of anti-rPmpD and anti-UVEB serum. Serum from mice 
immunized with rPmpD (A) or UVEBs (B) was tested for reactivity against 
UVEBs and rPmpD antigen in western blots. (C) Anti-rPmpD serum reacts with 
UVEBs in an indirect ELISA (inset shows reactivity against rPmpD). (D) Anti-
UVEB serum failed to react with rPmpD (inset shows reactivity against UVEBs). 
Dotted lines represent the OD450 cut-off value equivalent to the mean plus two 
standard deviations of control pre-immune serum. 
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number of inclusions were visualized and enumerated on Hak cell monolayers using 
immunofluorescence (Fig.6.10). 
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For quantification of resistance to infection, recoverable IFU at the day 1 time point 
were compared across each group using a one-way ANOVA (Fig.6.12 (A)). This is in 
contrast to an array of studies that typically use day 3 as the first sampling point in 
monitoring bacterial clearance. Thus, the number of organisms that are actually 
recoverable or able to establish infection following early vaccine-mediated protection 
is often unknown in the majority of preclinical studies. No significant differences 
were observed in recoverable IFU between PBS-immunized mice and the adjuvant 
only groups (SLA-AF only, SLA-SE only, SLA-LSQ only). All antigen-adjuvant 
combinations elicited enhanced resistance to infection relative to PBS-immunized 
mice, evidenced by significantly reduced recoverable IFU/ml relative to the control 
groups (p≤0.01). There were no detectable differences in the recoverable IFU 
obtained from rPmpD- and UVEB-immunized mice for a given adjuvant formulation, 
nor any formulation-specific differences in resistance to infection for a given antigen 
(Fig.6.12 (A)). 
 
At this early time point during infection (day 1), these observations suggest pathogen-
specific antibody-mediated neutralization of Ct infection within the vaginal mucosa in 
immunized mice, as fewer bacteria are able to establish infection when cultured in 
vitro, although other mechanisms of innate immune activation within the reproductive 
tract cannot be ruled out. Furthermore, antigen-specific T cells are usually found to 
occupy the site of infection 3-5 days following challenge (Roan et al., 2006). 
Interestingly, mice immunized with rPmpD alone also show significant resistance to 
infection relative to control mice (p=0.026). 
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rPmpD administered with or without adjuvant is able to elicit high-titre systemic anti-
rPmpD antibodies (Fig.6.7 (A)). It has previously been shown that IgG in the vaginal 
Figure 6.12: Vaccine-induced protection against Ct serovar D/UW3/Cx infection. 
C57BL/6 mice were immunized with either rPmpD or UVEBs in combination 
with all SLA formulations, challenged with 4.5×108 IFU of Ct serovar D/UW3/Cx 
EBs and swabbed on day 1 following infection to determine the recoverable IFU 
(A). Bacterial shedding was monitored on days 1, 3, 7, 14 and 22 post challenge. 
Mean bacterial load was quantified for individual mice in each group using an area 
under the curve (AUC) method (B). Data are shown for individual mice derived 
from one experiment (n=5 animals per group), and were analysed using a one-way 
analysis of variance (ANOVA). Significance values depicted are relative to PBS-
immunized mice (* = p≤0.05, ** p≤0.01, ***p≤0.001) or between immunized 
groups (bars; ns=not significant). 
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vault originates from serum, likely through transudation mechanisms, and that 
protection against sexually transmitted pathogens such as SIV and HIV may be 
conferred through systemic administration of antibodies in passive protection 
experiments (Mascola et al., 2000; Mestecky, Moldoveanu and Russell, 2005). Thus, 
it is likely that circulating anti-rPmpD or anti-EB antibodies elicited by vaccination 
may mediate the observed neutralizing effects in vivo. 
 
Mean bacterial load was quantified for each mouse in the 11 vaccine groups using an 
area under the curve (AUC) method (Fig.6.12 (B)). All groups immunized with either 
rPmpD or UVEBs showed a significant reduction (p≤0.01 or p≤0.001) in recoverable 
IFU over the course of infection relative to the PBS-immunized or SLA-immunized 
control groups. No significant differences were observed in mean recoverable 
bacterial load between PBS-immunized mice and the adjuvant only groups (SLA-AF 
only, SLA-SE only, SLA-LSQ only), suggesting non-specific innate immune 
activation by the TLR4 agonist does not play a role in resistance to or eradication of 
infection. For a given SLA formulation, no significant difference in mean bacterial 
load was detected irrespective of antigen (rPmpD or UVEBs), nor was any 
statistically significant difference in bacterial burden observed between groups 
immunized with any of the three SLA formulations in combination with a given 
antigen.  
 
6.2.6 Humoral and cell-mediated immune responses following challenge of 
vaccinated mice 
Spleens from immunized mice were obtained 42 days post challenge and stimulated 
with rPmpD antigen. Mice immunized with rPmpD + SLA-SE showed a very 
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significant Th1-biased immune profile, evidenced by a substantially higher population 
of splenocytes secreting IFNγ compared to all other vaccine groups (p≤0.01) 
(Fig.6.13).  
 
 
No significant difference in the IFNγ response in rPmpD + SLA-AF or rPmpD + 
SLA-LSQ groups was detected relative to control groups. Very low levels of IL-5 and 
IL-10 secreting cells were detected, and were similar to those observed prior to 
challenge. The observed T cell responses following challenge are likely composed of 
a proliferative memory recall response from circulating rPmpD-specific T cells, as 
well as an antigen-specific systemic T cell response elicited by Ct infection. 
Furthermore, at this time point following challenge, as the infection resolves, the 
population of circulating effector T cells is likely to wane. Thus, based on these 
observations, one cannot directly draw conclusions on SLA formulation-specific 
differences in the magnitudes of the antigen-specific memory T cell response, 
although it is likely that immunization with the SLA-SE oil-in-water formulation 
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results in a significantly more robust antigen-specific T cell memory response than 
the SLA-AF or SLA-LSQ formulations. In addition, serum from C57BL/6 mice in all 
vaccine groups was obtained 42 days post challenge. Mice immunized with SLA-SE 
in combination with rPmpD showed significant enhancement of systemic rPmpD-
specific IgG1 and IgG2c titres following intra-vaginal challenge with Ct serovar 
D/UW3/Cx at this time point relative to all other groups (p≤0.05) (Fig.6.14). 
 
 
 
 
 
6.2.7 SLA in combination with rPmpD induces formulation- and strain-
dependent differences in the magnitude of the Th1-type immune response in 
different mouse strains 
It has previously been shown that differences in cytokine profiles in response to 
chlamydial infection depend on the murine strain employed in the study, and this may 
also determine outcomes of pathogenesis in vivo in different mouse strains (Darville 
et al., 2001a; Darville et al., 2001b; Yang, HayGlass and Brunham, 1996). Thus, a 
comparison of the effects of different formulations of rPmpD combined with SLA-SE 
and SLA-AF was conducted to investigate potential formulation- and strain-specific 
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differences in immunogenicity in Balb/c mice. Splenocytes were stimulated ex vivo 
with rPmpD antigen as previously described. In the Balb/c strain, all adjuvants 
elicited enhanced antigen-specific Th1-type immune responses, evidenced by 
enhanced populations of splenocytes secreting the cytokines IFNγ and IL-2. As in the 
C57BL/6 strain, levels of IL-5 and IL-10 remained very low, and not significantly 
different from control (PBS-immunized) mice (Fig.6.15). 
 
 
 
Interestingly, it was found that in the Balb/c strain, the population of IFNγ-secreting 
splenocytes was significantly lower in mice immunized with rPmpD in combination 
with SLA-SE (p≤0.001) than in the corresponding group in the C57BL/6 murine 
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strain. However, no significance difference in the numbers of IFNγ-secreting 
splenocytes between mouse strains was observed when recombinant PmpD was 
paired with SLA-AF (Fig.6.15). Importantly, these observations suggest, that in 
addition to genetically predetermined strain-specific differences in cytokine profiles 
(Yang, HayGlass and Brunham, 1996), adjuvant formulation may also play a crucial 
role in the magnitude and quality of the cellular immune response in specific mouse 
strains. Interestingly, no strain- or formulation-specific differences in the magnitude 
of the systemic humoral immune response were observed following immunization 
(Fig.6.7, Fig.6.16). 
 
 
 
6.2.8 Determination of kinetics of Ct serovar D/UW3/Cx bacterial shedding in 
the C57BL/6 and Balb/c mouse strains 
To determine strain-specific differences in the kinetics of bacterial shedding, bacterial 
load was monitored on days 3, 7 and 10 following intra-vaginal chlamydial infection 
of C57BL/6 and Balb/c mice (Fig.6.17). Mice were challenged with 4x105 IFU of Ct 
	 200	
serovar D/UW3/Cx inoculated directly into the vaginal vault. No significant 
difference in bacterial load (quantified as recoverable IFU/ml) was recorded between 
each strain at any recorded time point. This is in accordance with previously observed 
kinetics of shedding between Balb/c and C57BL/6 strains (Darville et al., 2001b). 
Thus, the window for monitoring of vaccine efficacy through measuring bacterial 
shedding is similar between the two mouse strains. 
 
 
 
6.3 Discussion 
Our study is the first to investigate the efficacy of the recombinant chlamydial vaccine 
antigen PmpD, in addition to investigation of the potency and efficacy of a novel, 
rationally designed TLR4 agonist. PmpD was selected due to its highly conserved 
sequence (>99%) across all Ct strains (Swanson et al., 2009), constitutive expression 
throughout chlamydial biphasic development (Tan et al., 2010), surface exposure and 
proposed function as a putative chlamydial adhesin (Becker and Hegemann, 2014). In 
addition, we demonstrate that this antigen elicits significantly elevated Th1-biased 
immune responses in C57BL/6 and Balb/c strains when delivered subcutaneously 
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(s.c.) in combination with a novel, rationally designed TLR4 agonist (SLA), 
suggestive of a wide array of T cell epitopes and MHC class II presentation. 
Importantly, we also demonstrate significant protection against Ct serovar D/UW3/Cx 
challenge when rPmpD is administered in the absence of adjuvant, evidenced by 
enhanced resistance to infection and reduction in mean bacterial load in rPmpD-
immunized mice relative to PBS- and SLA-only vaccinated control groups. 
 
All SLA-rPmpD formulations elicit a Th1-biased cellular immune response, 
evidenced by very low IL-5 and IL-10 cytokine-secreting cells, and high levels of 
antigen-specific splenocytes secreting IFNγ and IL-2 (Fig.6.6). No significant SLA 
formulation-specific differences in the magnitude of rPmpD-specific IFNγ responses 
were found in the Balb/c strain. Interestingly, in the C57BL/6 mouse strain, 
significant formulation-specific differences in the magnitudes of Th1-bias are 
observed, with the stable oil-in-water emulsion (SLA-SE) formulation eliciting a 
significantly greater population of IFNγ-secreting rPmpD-specific splenocytes 
relative to the aqueous (SLA-AF) and QS21-liposomal (SLA-LSQ) formulations 
(p<0.001), indicative of likely differences in two mouse strains with different MHC 
haplotypes and antigen presentation, as well as differing sensitivities to antigen 
formulation and innate immune responses.  
 
However, no correlation was observed between the relative magnitudes of the 
rPmpD-specific T cell responses elicited by the three formulations and protection 
against urogenital Ct challenge (Fig.6.12). Such observations are not uncommon, and 
the lack of correlation between distinct immunological phenotypes and protection has 
previously been documented for studies investigating vaccine development against 
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tuberculosis (TB) with a variety of antigen-adjuvant combinations. No distinct 
physico-chemical characteristics have been shown to be consistently reflective of the 
magnitude or efficacy of cell-mediated immune responses or bacterial clearance, and 
subtle differences in the type of oil in adjuvant formulations can affect the quality of 
the immune response (Fox et al., 2011), (Orr et al., 2013b).  
 
Furthermore, the species used can significantly influence the observed potency of the 
adjuvant. (Vordermeier et al., 2009) employed the use of TB antigen Rv3019c in 
combination with either a oil-in-water emulsion or cationic liposome adjuvant, and 
demonstrate the generation of two distinct immunological phenotypes in cattle but not 
in mice. The oil-in-water emulsion elicited both an effector and a central memory T 
cell response, while the cationic liposomal formulation induced only the central 
memory response. Similar to Ct infections, the optimal immune correlates of 
protection against TB infections in humans are largely unknown. Indeed, although 
robust IFNγ responses have been postulated as essential for resolution of infection, it 
has been observed that transient total or T cell subset immune responses are not 
predictive of vaccine efficacy in vivo (Mittrucker et al., 2007). This suggests that 
memory rather than transient effector T cell responses may be more representative 
immune correlates of vaccine efficacy and protection. Thus, cultured rather than 
transient ex vivo ELISpots may be a more robust immunological assay for 
investigating correlates of protective immunity, as they provide a more definitive 
reflection of central memory responses. Interestingly, the development of malarial 
vaccines has provided further evidence of this (Keating et al., 2005; Reece et al., 
2004).  
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Although formulation-specific differences in memory responses were not studied 
independent of Ct challenge in our study, it is likely that the magnitude of the rPmpD-
specific IFNγ recall response to Ct infection (measured 6 weeks post-challenge) 
(Fig.6.13), represents a waning systemic population of a pool of activated circulating 
memory cells elicited by initial immunization, in addition to systemic pathogen-
specific effector T cells following infection. Interestingly, we do observe significant 
formulation-specific differences in the recall response, with SLA-SE eliciting 
significantly higher levels of IFNγ-secreting antigen-specific splenocytes (p<0.001) in 
comparison to aqueous (SLA-AF) and liposomal (SLA-LSQ) formulations (Fig.6.13).  
 
The robust effector and memory responses elicited by SLA-SE thus showcases the 
relative potency and durability of oil-in-water emulsions, corroborated by the findings 
of (Vordermeier et al., 2009) in a preclinical TB vaccine study in cattle. Furthermore, 
we detect significantly elevated mucosal cervico-vaginal anti-rPmpD titres following 
immunization with the SLA-SE adjuvant relative to both SLA-LSQ and SLA-AF 
adjuvants (p<0.05) (Fig.6.8 (A,B)). In contrast to systemic humoral responses, where 
similar titres of IgG1 and IgG2c subtypes were measured (Fig.6.7), we observe a 
significantly elevated (P<0.05) mucosal IgG2c:IgG1 ratio (4.5 ± 2.7) in mice 
immunized with rPmpD in combination with the SLA-SE adjuvant, relative to the 
SLA-AF (1.04 ± 0.3) or SLA-LSQ-immunized groups (1.25 ± 0.3) (Fig.6.8 (C)). This 
may be indicative of a locally induced Th1-type cellular immune response, although 
interestingly, this did not correlate with enhanced protection against Ct challenge 
relative to the other vaccine groups. These observations may suggest enhanced 
mucosal recruitment of systemic Th1-type memory effector cells, although further 
experimentation is required to establish this. Because Ct is an obligate intracellular 
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mucosatropic pathogen, it is widely anticipated that robust pathogen-specific cellular 
reproductive tract immune responses are required for optimal vaccine efficacy. This is 
elegantly described in perhaps the most informative and seminal experiments 
detailing the effector mechanisms of mucosal immunity in chlamydial vaccinology. 
 
Importantly, the study by (Stary et al., 2015) elucidates the generation and 
contribution of uterine-resident Ct-specific memory T cells to protection against 
chlamydial infection. The vaccine employs intact UVEBs complemented with charge-
switching synthetic adjuvant nanoparticles (cSAPs). Important advances that have 
facilitated the dissection of pathogen-specific T cells in the murine model of Ct 
infection used in this study stemmed largely from experiments conducted by (Roanet 
al., 2006), where the generation of NR1 T cell receptor (TCR) transgenic mice with 
specificity for the highly conserved Ct CD4+ T cell antigen Cta1 were generated. 
Importantly, this enabled the tracking and differentiation of Ct-specific T cells from 
bystander T cells activated following intra-uterine infection. (Stary et al., 2015) define 
the mechanisms behind galvanization of mucosal Ct-specific effector and memory 
cellular immune responses using parabiosis experiments to track the movement and 
function of these Ct-specific CD4+ transgenic T cells.  
 
In addition, using UVEBs as antigens, they illustrate the importance of adjuvant 
selection and route of administration in the priming of tolerogenic versus 
immunogenic responses and effective T cell trafficking to the uterine mucosa. 
Interestingly, intrauterine or intranasal immunization with adjuvanted UVEB-Ct-
cSAP but not UVEBs alone, was found to elicit protective CD4+ T cell responses 
following intrauterine challenge with Ct, with time to clearance of 13 days which 
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paralleled that of live immunization (measured by recoverable IFU and qRTPCR of 
uterine bacterial load). Importantly, until now, no chlamydial vaccine study conducted 
in murine models of infection has demonstrated protective efficacy against Ct 
challenge comparable to that elicited by live Ct immunization, although the 
incorporation of native Cm MOMP as a vaccine candidate demonstrated similar 
protective efficacy to live immunization with Cm (Pal et al., 2001). UVEBs 
administered alone as a vaccine within the uterine mucosa elicited a more tolerogenic 
immune response with significantly elevated bacterial load relative to both naïve and 
UVEB-Ct-cSAP-immunized mice.  
 
The mechanisms behind these observations were elegantly addressed in a series of 
experiments investigating the degree of uptake of live, UVEB and UVEB-Ct-cSAP 
vaccines in three subsets of MHC-II+ uterine-resident antigen-presenting cells 
(APCs): F4/80 macrophages, CD11b+CD103- and CD11b-CD103+ DCs. No 
differences were observed in uptake of all three vaccines in macrophages, but 
interestingly, live Ct EB and UVEB-Ct-cSAP vaccines preferentially accumulated in 
CD11b+CD103- DCs while UVEBs accumulated in CD11b-CD103+ DCs. 
Furthermore, injection of CD11b+CD103- DCs in murine footpads caused 
proliferation of NR1 T cells in the local draining lymph node (LDLN) of naïve mice, 
indicating effective priming of Ct-specific CD4+ T cells in vivo, whereas CD11b-
CD103+ DCs did not cause proliferation but instead provoked differentiation of NR1 
cells to a regulatory (Treg) phenotype in vitro. This seminal experiment provides a 
likely rationale behind the failure of the early trachoma vaccine trials of the 1960s, 
where ocular mucosal immunization with UV-inactivated EBs in the absence of any 
adjuvant caused exacerbation and prolonged infection following subsequent live 
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challenge in nonhuman primates and in patients (where protection was often short-
lived) (Wang, Grayston and Alexander, 1967; Woolridge et al., 1967).  
 
Because the density of pathogen-specific CD4+ T cells within the genital mucosa has 
been proposed to correlate with protection against chlamydial infection (Igietseme et 
al., 1993), it is postulated that the early recruitment of T cells is likely to offer optimal 
protection against establishment and proliferation of infection. Through tracking of 
Ct-specific NR1 cells, (Stary et al., 2015) further demonstrated that mucosal 
intranasal (i.n.) or intrauterine (i.u.) immunization with UVEB-Ct-cSAP vaccines 
elicited two waves of T cells (Fig.6.18). The first wave of effector T cells peaked at 
day 7 and then contracted reaching a plateau of similar numbers within the uterine 
mucosa for both routes of administration by day 9 post-immunization. This 
established a population of resident memory T cells that persisted for at least 6 
months without the requirement for local antigen stimulation, and was postulated to 
provide early protection against subsequent challenge. The second wave of memory T 
cells was much larger, and found to reside in the blood and secondary lymphoid tissue 
(Stary et al., 2015). This circulating population is found to survey tissues for signs of 
inflammation and augment additional memory recall immune responses to pathogenic 
invasion (von Andrian and Mackay, 2000). Interestingly, systemic subcutaneous (s.c.) 
immunization elicited only the second wave of memory effector T cells, which was 
not found to correlate with enhanced protection relative to naïve mice (Stary et al., 
2015). 
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Importantly, it was further found that the vaccination route selected elicits differences 
in mucosal homing pathways of systemic effector T cells. It has recently been shown 
that CD4+ T cells require the α4β1 integrin molecule to access uterine mucosal 
surfaces (Davila, Olive and Starnbach, 2014), although the full repertoire of infection-
induced signals such as chemokines and other pro-inflammatory factors that recruit 
systemic T cells to mucosal sites is still not fully understood. Stary et al. (2015) 
showed that monoclonal antibodies to α4 integrin prevented access of NR1 and 
endogenous CD4+ T cells to the uterine mucosa following Ct challenge, correlating 
with increased chlamydial burden relative to mice that received control rat IgG. Thus, 
it is postulated that intrauterine but not systemic immunization results in ‘imprinting’ 
of homing mechanisms on effector T cells which mediate the differential trafficking 
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to these mucosal sites in response to infection. These ‘imprinting’ signals may be 
achieved by mucosal-specific APCs that are not found in skin-draining lymph nodes.  
 
Thus, optimal protection in this study was achieved through intrauterine mucosal 
immunization with UVEB-Ct-cSAP, and was dependent upon both mucosal and 
systemic waves of Ct-specific CD4+  T cells with the correct homing mechanisms that 
elicited seeding of and trafficking to the uterine mucosa. Unexpectedly, however, 
despite the generation of robust systemic Ct-specific antibodies following intrauterine 
immunization with UVEB-Ct-cSAP, (Stary et al., 2015) report no definitive role for 
antibody-mediated protection in this study, evidenced by no significant protection in 
non-vaccinated parabionts of conjoined immunized partners, as antibodies are 
expected to have fully equilibrated between individuals following immunization at the 
point of challenge.  
 
However, we show that significantly elevated anti-rPmpD IgG cervico-vaginal and 
serum titres following immunization correlate with significantly enhanced resistance 
to infections and bacterial clearance in the absence of significantly elevated rPmpD-
specific T-cell responses (Figs. 6.7, 6.8 and 6.12 (A,B)). Notably, in contrast to the 
bacterial shedding data presented by Stary et al. (2015), who demonstrate no 
difference in recoverable IFU between immunized groups and naïve mice at day 1 
post challenge, we detect significant early reduction in bacterial burden on day 1 
between all vaccine groups and the control PBS-immunized and SLA-immunized 
groups (Fig.6.12 (A)). Furthermore, we propose that this early neutralization is likely 
to be predominantly antibody-mediated, as the initiation of T cell priming occurs 
outside the genital mucosa in the absence of organized lymphoid epithelial structures 
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(e.g. Peyer’s patches) within this environment (Cain and Rank, 1995). Thus, the 
kinetics of T cell priming and trafficking likely preclude antigen-specific T cell 
mediated effector function at this early time point, and it has further been shown that 
Ct-specific NR1 activation takes about 3-4 days to occur following intra-vaginal 
chlamydial infection (Roan et al., 2006).  
 
Interestingly, we demonstrate that SLA formulation-specific differences in the 
relative magnitudes of the splenic rPmpD-specific Th1-type responses reflected by 
the population of IFNγ-secreting T cells (Fig.6.6) do not correlate with enhanced 
reduction in mean bacterial load over the 22-day period during which shedding was 
monitored, as no significant differences in reduction in bacterial load between the 
different rPmpD- or UVEB-adjuvanted groups were observed (p>0.05) (Fig.6.12 
(B)), although all groups demonstrate significantly reduced burden relative to vehicle 
and corresponding adjuvant control groups (p<0.001). Even though the magnitude of 
the rPmpD-specific IFNγ T cell component of the systemic recall response to Ct 
challenge elicited by SLA-SE is significantly more robust than the SLA-AF or SLA-
LSQ formulations (Fig.6.13), we observe no enhanced reduction in bacterial load 
between rPmpD-adjuvanted groups. Therefore, in our study, a consistently observed 
correlate of protection seems to be the sustained presence of elevated rPmpD- or 
UVEB-specific serum and cervico-vaginal antibody titres (Fig.6.7, 6.8). 
 
In light of the established importance of CD4+ T cells in resolution of primary 
chlamydial infection in mice (Morrison, Feilzer and Tumas, 1995; Perry, Feilzer and 
Caldwell, 1997; Su and Caldwell, 1995; Yu et al., 2014), the majority of preclinical 
vaccine studies in murine models of infections seek to employ immunization 
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strategies (administration routes, adjuvant classes and antigens) that elicit robust 
pathogen-specific CD4+ T cell effector responses. However, a body of evidence also 
points to a dispensable role of CD4+ T cells in resolution of primary chlamydial 
infection and protective immunity (Morrison et al., 2011;Morrison and Morrison, 
2001), and although the contribution of antibodies is often overlooked as a correlate 
of protection, accumulating evidence suggests that antibodies may play a more 
important role in the control of Ct infections than previously anticipated (Moore et al., 
2003; Morrison and Morrison, 2005a; Morrison and Morrison, 2005b; Olsen et al., 
2015). Most recently, (Olsen et al., 2015) have highlighted the importance of 
neutralizing antibodies in conferring heterotypic protection against highly prevalent 
urogenital Ct D, E and F strains, and provide a case for the importance of rational 
chlamydial vaccine design through generation of the first chimeric recombinant 
peptide vaccine. The authors revisit chlamydial MOMP as a target antigen, and focus 
on rational modifications of the VD4 region of the protein that is rich in neutralizing 
epitopes (Villeneuve et al., 1994).  
 
Because optimal protection against Ct infection using MOMP as a vaccine candidate 
is known to be both dependent on antigen conformation (Pal et al., 2001) and is 
usually serovar specific due to extensive inter- and intra-serovar recombination, the 
strategy employed by (Olsen et al., 2015) sought to design a recombinant peptide 
vaccine to make use of the non-conformational but highly conserved species-specific 
LNPTIAG epitope of MOMP embedded within the VD4 region (Baehr et al., 
1988;Stephens, Wagar and Schoolnik, 1988), that has been shown to confer 
neutralization against highly prevalent Ct serovars D, E, F and G (Su and Caldwell, 
1993). In addition, multivalency and T cell epitopes were incorporated in to the 
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peptide through fusion of extended segments (either side of the conserved LNPTIAG 
epitope) from D, E and F serovars, and this fusion construct could also be 
incorporated in to full-length recombinant MOMP, increasing the array of 
neutralizing antibody and T cell epitopes.  
 
Importantly, passive transfer of serum from chimeric peptide-immunized containing 
the extended VD4 domains from serovars D, E and F conferred early protection 
against infection, suggesting systemic neutralizing antibody is sufficient to mediate 
lower genital tract protection. Antibodies generated against this chimeric recombinant 
MOMP vaccine (CTH522) were further shown to confer significant heterologous 
neutralization of Ct serovars D, E, F and G relative to Ct recombinant MOMP in 
vitro. This is in accordance with observations in our study, where we report a 
correlation between early reduction in chlamydial load and enhanced serum antibody 
titres for rPmpD-immunized mice in both the presence (rPmpD + SLA-SE / SLA-AF 
/ SLA-LSQ) and absence (rPmpD only) of enhanced rPmpD-specific Th1-type 
cellular immunity.  
 
However, in contrast to our study, Olsen et al. (2015) utilize a simultaneous 
subcutaneous plus intranasal immunization regimen to boost local genital tract 
mucosal antibody responses. However, we demonstrate that subcutaneous 
immunization alone elicits high-titre antigen-specific systemic humoral responses that 
likely contribute to the presence of observed rPmpD-specific cervico-vaginal IgG. We 
thus postulate that significantly elevated pathogen-specific mucosal IgG titres are 
necessary and sufficient to mediate effective early neutralization against Ct challenge, 
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although the potential contribution of certain innate immune mechanisms to observed 
bacterial clearance could not be ruled out in our study. 
 
Prior to our study, only two previous studies presented robust evidence of neutralizing 
antibodies effecting protection against chlamydial infection in vivo, both employing 
MOMP as a vaccine immunogen (Olsen et al., 2015; Pal et al., 2001). In order to 
further confirm the role of neutralizing antibodies to PmpD, current and ongoing 
experiments involve the passive transfer of immune serum to naïve mice prior to 
intra-vaginal Ct challenge, as well as the investigation of in vivo neutralization of Ct 
following pre-incubation of Ct EBs with immune or pre-immune serum. 
 
Our findings illustrate the efficacy of using rPmpD as a Ct vaccine immunogen in 
vivo. rPmpD elicits significant protection against Ct serovar D/UW3/Cx challenge in 
both the presence and absence of adjuvant. While this protection correlates with the 
presence of anti-rPmpD serum IgG, further work is required to detail the 
underpinnings of other likely immunomodulatory properties of rPmpD. For instance, 
the Leishmania major hydrophilic acylated surface protein B (HASPB) elicited long-
term protection and antigen-specific CD8+ T-cells in the absence of exogenous 
adjuvant or delivery vehicle (Stager et al., 2003) and the leishmanial vaccine 
candidate antigen LeIF was shown to have inherent IL-12 stimulating capacity 
(Skeiky et al., 1995; Skeiky et al., 1998). Similar to Leishmania HASPB (Alce et al., 
1999), the passenger domains of rPmpD and a plethora of other chlamydial Pmps also 
possess highly repetitive GGA(I,L,V) and FXXN motifs (Swanson et al., 2009). 
Hence, in addition to extending the evaluation of preclinical Ct vaccine candidates to 
include antibody-mediated mechanisms of protection, our results highlight the need 
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for a more basic mechanistic understanding of vaccine antigens that may confer 
protection in the absence of Th1-bias.  
 
Further experimentation using murine and nonhuman primate in vivo challenge 
models against other highly prevalent clinical serovars (D, E and F) will reliably 
confirm the previously postulated in vitro pan-neutralising abilities of anti-PmpD 
antibodies (Crane et al., 2006), and its potential efficacy as a future chlamydial 
vaccine antigen, particularly given its surface-exposure, constitutive expression 
during Ct biphasic development, and presence of multiple T cell epitopes (Swanson et 
al., 2009;Tan et al., 2010). Our study also demonstrates the efficacy of the novel, 
rationally designed adjuvant, SLA, in combination with rPmpD, at mediating robust 
protection against Ct infection. In light of previously observed differences in 
immunogenicity and protection of different antigen-adjuvant combinations, it may be 
prudent to investigate the applicability of SLA in combination with a wider array of 
chlamydial antigens. For instance, PmpG was found to be immunodominant and 
protective in C57BL/6 mice (Yu et al., 2014) when paired with the DDA/MPL TLR4 
agonist adjuvant, but this was not found to be the case when paired with the CpG-
ODN TLR9 agonist (Yu et al., 2010). 
 
Importantly, a recently described caveat to the use of highly passaged laboratory 
strains in in vitro assays may impact future studies on Ct infection dynamics in vivo, 
as it has been demonstrated that key adaptive mechanisms occur during in vivo to in 
vitro transition following high passage of ocular, genital and LGV Ct strains (Borges 
et al., 2015). Most notably, non-invasive genital serovars were found to acquire 
inactivating CT135 mutations, not observed in ocular or LGV strains. Importantly, 
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RNA-seq analysis revealed that CT135 influences the expression of well-known 
chlamydial virulence factors such as CT694, TepP and Tarp (Borges et al., 2015), and 
such inactivating mutations are likely to lead to attenuation of virulence in vivo. 
Furthermore, (Borges et al., 2015) find that the CT166 gene, which encodes the 
putative chlamydial cytotoxin in Ct genital strains (but is truncated in ocular and LGV 
serovars), is potentially disrupted following high passage of noninvasive urogenital 
serovars. 
 
Although a direct link to alterations in pmp expression following prolonged passage 
has not yet been elucidated, it may be likely that high passage rates lead to adaptation 
mechanisms that favour expression or phase variation of a particular Pmp or subset of 
Pmps in vitro, which do not reflect infection dynamics in vivo, and that these adaptive 
mechanisms may also be serovar-specific in vitro. For instance, the pmpD null mutant 
generated by (Kari et al., 2014) was derived from a non-invasive urogenital Ct serovar 
D/UW3/Cx laboratory parental strain. However, a significant caveat to the reported 
attenuation of the null mutant virulence in vivo, was the implementation of ocular 
infection studies conducted in cynomolgus macaques, for which this genital strain has 
no natural tropism. More representative studies should investigate genital tract 
infection and clearance kinetics of this pmpD mutant in nonhuman primates, or 
employ the use of a trachoma pmpD null mutant biovar in the macaque ocular 
challenge model. Furthermore, ocular serovars have not been documented to acquire 
CT135 mutations over successive passages during cell culture in vitro, unlike 
urogenital serovars, where this and other mutations are found to lead to attenuation of 
virulence in vivo (Borges et al., 2015). 
 
	 215	
Furthermore, (Kari et al., 2014) propose that the Ct D/UW3/Cx pmpD null mutant is 
significantly attenuated in an ocular infection model of nonhuman primates, yet show 
no statistically significant difference in the mean bacterial load, rate of bacterial 
clearance or recoverable IFU at any time point two weeks post infection. These 
findings call in to question the use of laboratory adapted strains for in vivo infection, 
and suggest that the use of low passage clinical strains for in vivo studies may be 
more representative models for deriving more robust conclusions about the 
pathogenesis of clinical infections as well as vaccine efficacy. 
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Chapter 7: General Discussion 
 
7.1 Introduction 
The immune correlates of protection and resolution of sexually transmitted Ct 
infections within an outbred human population remain poorly understood. In addition, 
the ancient origins, extreme phylogenetic divergence, and obligate intracellular 
adaptation of Ct preclude straightforward inference of gene or protein function by 
comparison with a wide array of more well investigated bacterial pathogens of 
humans. Our study has sought to address key structural, biochemical and 
immunological properties of PmpD, a putative Ct adhesin. The efficacy of this highly 
conserved chlamydial antigen as a preclinical vaccine candidate has been investigated 
for the first time. In addition, we have provided the first biophysical characterization 
of CT694, a Ct-specific early T3SS effector molecule.  
 
Although no crystal structures were obtained, the importance and implications of 
adopting a structure-based approach to investigating the function of a plethora of 
chlamydial proteins will first be discussed in this chapter within the context of current 
knowledge in the field. This is followed by a brief discussion of the advantageous 
approach of structural vaccinology that may be applied to Pmps and other chlamydial 
antigens such as MOMP that display extensive inter-strain variation. With recent 
advances in the genetic manipulation of Ct as well as whole-genome sequencing, it is 
anticipated that a more rational approach may expedite the advent of a new 
chlamydial vaccine designed to elicit protection against a wider array of prevalent 
strains. 
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7.2 The impact of past and future structural biological approaches to the 
study of Chlamydia trachomatis  
Although no rPmpD or CT694 crystals have yet been obtained that are amenable to 
X-ray diffraction studies, the importance of structural biological application in the 
chlamydial field is of primary importance for several reasons. Crucially, the few 
putative virulence factors and hypothetical proteins of Chlamydia trachomatis solved 
by X-ray crystallography have unveiled key pathogen-specific mechanisms of 
survival, and this is crucial for facilitating and expediting (i) functional genomic 
annotation and the elucidation of species- and strain-specific mechanisms of 
pathogenesis (ii) the development of novel drugs and vaccines. Since complete 
sequencing of the (relatively) small (~1.14Mbp) Ct serovar D/UW3/Cx genome in 
1998 (Stephens et al., 1998), ~25% still comprises genes encoding ‘hypothetical’ 
proteins, while about 35% of the C.pneumoniae genome (another widespread and 
important pathogen of humans) still requires annotation (Kalman et al., 1999).  
 
The extreme phylogenetic distance between Chlamydiales and more widely studied 
bacterial species (E.coli, B.subtilis and S.enterica) has largely precluded 
straightforward assignment of putative gene function through primary sequence 
homology comparisons (Pace, 1997). In addition, the obligate intracellular lifestyle 
and lack of known conjugative plasmids or bacteriophages for the Chlamydiales has 
prevented the use of conventional genetic techniques typically used to interrogate 
specific gene function in genetically tractable phyla. Thus, in the absence of a fully 
tractable genetic system for Ct until 2011, structural characterization has been the 
most reliable means of revealing a number of unique aspects of Ct pathogen biology 
in hypothetical proteins with no known sequence homology to a plethora of other 
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bacterial species. Key examples are subsequently discussed in this section, 
emphasizing the importance of future work in this area. 
 
The first structure of a Ct hypothetical protein was solved in 2004, six years following 
publication of the genome. Since then, the structures of only 22 Ct proteins have been 
deposited in the PDB. A 3D description of CT610, a dimer of seven α-helical bundles, 
led to its functional assignment as CADD (Chlamydia protein associating with death 
domains) (Schwarzenbacher et al., 2004). Although CADD showed only 18% 
sequence identity with co-enzyme pyrrolo-quinoline-quinone synthesis protein C 
(PqqC) family members, the crystal structure did indicate fold similarity to heme-
oxygenase and ‘PqqC-like’ enzymes. However, CADD enzymatic active sites were 
not conserved. Furthermore, ectopic expression of Klebsiella pneumoniae PqqC failed 
to elicit apoptosis in transfected cells (Stenner-Liewen et al., 2002).  
 
This indicates the possible divergent evolution of proteins between two species 
adapted to different environmental niches, and informs subsequent study and rational 
design of inhibitors of this multi-domain ‘orphan’ protein unique to Ct pathogenesis. 
Interestingly, no orthologs of CADD were present in other Chlamydia species, further 
suggesting possible unique adaptations of Ct tailored towards host-specific 
intracellular survival. These studies emphasize important caveats inherent in genome 
annotation of pathogens that are phylogenetically distinct using sequence or even 
structural homology without a detailed examination of molecular mechanisms of 
substrate or ligand interactions. This is exemplified by the 3D molecular description 
of the CT296 hypothetical protein (Kemege et al., 2011).  
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CT296 was initially reported to display characteristics akin to that of the E.coli iron-
responsive transcriptional repressor – Fur, leading to its functional assignment as a 
metal responsive transcriptional repressor. These data were obtained through cross-
reactive antibodies, functional complementation in E.coli and electrophoretic mobility 
shift assays (Rau et al., 2005; Wyllie and Raulston, 2001). However, examination of 
the crystal structure revealed no divalent cations present within the active site, with no 
metal binding sites or DNA-binding motifs. Structural homology searches identified 
this protein as a member of the cupin superfamily of enzymes, which are known for 
their display of extensive diversity through subtle active site modifications despite the 
preservation of tertiary and quaternary structural homology (Khuri, Bakker and 
Dunwell, 2001). Proteins with structural homology to CT296 have been shown to 
possess a wide array of enzymatic functions (from halogenases to oxidoreductases), 
and despite significant structural homology to the cupin 2-oxoglutarate iron-
dependent enzyme subclass, an incomplete double-stranded β–helix fold, the lack of 
an iron- or 2-oxoglutatarate binding site and poor conservation of key residues 
required in coordinating metal ions reveal that this may not be the case.  
 
Importantly, this study showcases the utility of structural biology within the field of 
Ct research, particularly in challenging traditionally established paradigms obtained 
from established in vitro studies. Lack of experimental sensitivity, non-native growth 
conditions and other technical limitations in heterologous bacterial or ectopic 
expression systems may indeed preclude accurate functional annotation of Ct 
proteins, and hence, a structural approach for guiding functional assignment of 
‘hypothetical’ Ct genes is crucial, and will almost certainly be required as an adjunct 
to complement nascent genetic techniques as they become more established. 
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Another application of structural biology is to facilitate guidance of rational drug 
development. Although an obligate intracellular lifestyle was initially thought to 
preclude extensive lateral gene transfer and likely acquisition of antibiotic resistance, 
recent evidence shows that there are no absolute barriers to recombination within and 
between Ct serovars despite this intracellular niche (Harris et al., 2012), and that these 
bacteria do possess the ability for the transfer of tetracycline resistance in vitro 
(Suchland et al., 2009). Furthermore, treatment failure has also been documented in 
clinical settings (Hocking et al., 2015), as well as instances of antibiotic resistance 
(Somani et al., 2000). Thus, the design of novel therapeutics for treating Ct and 
related veterinary and zoonotic chlamydioses may largely depend on a molecular and 
functional description of Ct proteins.  
 
The characterization of the Ct LL-diaminopimelate aminotransferase (DAP-AT) 
epitomises evolutionary adaptation towards utilization of a broad array of substrates 
(Watanabe et al., 2011). This family of enzymes is responsible for providing an 
alternative route of lysine biosynthesis, and products of this pathway are important for 
cross-linking poly-glycan chains in the bacterial cell wall, thus maintaining structural 
integrity (van Heijenoort, 2001). However, because humans obtain lysine from their 
diet, and have no requirement for lysine biosynthesis, CtDAP offers an attractive drug 
target for the rational design of novel inhibitors using modeling within the active site 
of the crystal structure.  
 
Although the overall protein fold was found to be almost identical to that of the 
Arabidopsis thaliana AtDAP, major differences in substrate specificity were 
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observed. Crystals of AtDAP show strict substrate specificity for the L-isomer of 
DAP, whereas CtDAP also recognizes the diastereoisomer in addition to a range of 
other substrates (McCoy et al., 2006). Examination of the crystal structure of CtDAP 
revealed that the highly mobile loop lining the active site resulted due to the presence 
of the helices α10 and α11 forming a largely unstructured loop. In AtDAP, the α11 helix 
is much larger and contains a sharp turn between α10-α11 with a proline residue 
(Pro325) that reduces mobility. This results in a 9.5  Å movement of the active site loop 
in CtDAP relative to only a 3-4 Å movement typical of most DAP-ATs (Okamoto et 
al., 1994). Such insights are important in gaining insight on mechanisms of 
pathogenesis, but also in the design of novel inhibitors. 
 
Structural approaches have further shed light on metabolic flexibility of the 
Chlamydiaceae through the 3D description of hypothetical protein CT263, which has 
been classified as a 5’-methylthioadenosine nucleosidase (Barta et al., 2014). This 
study describes the biosynthesis of menaquinone through the futalosine pathway; an 
alternative to the traditional pathway employed by numerous commensals to synthesis 
lipid-soluble electron carriers which support cellular respiration (Kurosu and Begari, 
2010). Because humans do not synthesise menaquinone, this enzyme could represent 
another Chlamydia-specific candidate drug target that may be exploited for 
development using structural approaches, as it has further been hypothesized to play a 
role in the persistent state of Chlamydiaceae (Beatty, Morrison and Byrne, 1994; 
Bonner, Byrne and Jensen, 2014). Importantly, divergence in the use of metabolic 
pathways and associated enzymes utilized by pathogenic bacteria such as Ct may be 
comprise a judicious range of therapeutic targets that do not affect host commensal or 
non-pathogenic counterparts.  
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It is likely that the implementation of structure-based design of novel therapeutics will 
now need to be validated in tandem with newly emerging genetic techniques to assess 
the essential requirement of identified targets in vitro by generating and characterizing 
Ct null mutants using forward or reverse genetics approaches. However, if the target 
is essential for Ct intracellular survival, chromosomal mutagenesis resulting in loss-
of-function mutations will inevitably result in lethality in vitro, making it impossible 
to phenotypically deduce targets crucial for novel drug development. In addition, the 
expense and labour-intensive nature of generating Ct null mutants may prohibit the 
widespread use of genetic manipulation, and structural approaches may thus still 
constitute an important tool within the field of therapeutic development for Ct 
infections. 
 
7.3 Structural approaches to rational vaccinology 
While the utility of structural biology in genome annotation and the development of 
small molecule inhibitors has been addressed, another key area in which it may be 
exploited is in the development of novel, rationally designed Ct vaccines. The 
development of Bexsero is the first example of a vaccine successfully designed using 
‘reverse vaccinology’, which primarily focused on the use of genomic analysis to 
predict secreted or surface-localized proteins (Fig.7.1). Following shotgun sequencing 
of the N.meningitidis genome revealing ~2000 proteins, 91 proteins were tested for 
their potential to elicit bactericidal antibodies in mice, and further prioritized 
according to the ability of the antigens to confer broad protection following 
immunization and passive protection in infant rodent models of infection (Serruto et 
al., 2012). These selected antigens were called Genome-derived Neisseria Antigens 
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(GNA), consisting of GNA2132 (Neisserial Heparin Binding Antigen, or NHBA), 
GNA1870 (factor H binding protein, or fHbp) and GNA1994 (Neisseria adhesin A, or 
NadA), the latter of which is a trimeric T5AT. GNA2091 and GNA1030 were also 
included as fusion proteins in the final vaccine cocktail with fHbp and NHBA 
(respectively) in order to facilitate large-scale manufacturing. 
 
The design of Bexsero represents a paradigm shift in traditional vaccinology 
approaches where attenuated pathogens or recombinant antigens have conventionally 
been empirically tested for efficacy in vivo. Conjugate capsular polysaccharide 
vaccines resembling the decorated outer membrane of N.menigitidis strains were 
previously licensed against clinically prevalent serogroups A, C, W and Y, with the 
incorporation of outer membrane vesicle (OMV)-based vaccines used to combat 
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epidemic disease (Serruto et al., 2012). However, development of a similar vaccine 
against serogroup B using the same method was largely precluded by extensive 
structural similarity of the type B capsular polysaccharide to human N-CAM1 
(Nedelec et al., 1990). The α2-8 linked polysialic acid type B serogroup capsule is 
hence poorly immunogenic, and incorporation in to an adjuvanted vaccine carries the 
risk of autoimmunity (Finne et al., 1987). In addition to this, extensive strain 
polymorphism of a key meningococcal surface antigen and virulence protein known 
as factor H binding protein (fHbp) limited the breadth of protective bactericidal 
antibodies elicited by specific strains. Such similarities are paralleled in Ct by 
widespread recombination of the key protective MOMP antigen and polymorphisms 
within the Pmp family leading to antigen variation (Harris et al., 2012; Nunes et al., 
2015). 
 
Thus, rational structural design of the fHbp antigen was employed in the attempt to 
elicit a broadly neutralising antibody repertoire (Scarselli et al., 2011). Bioinformatics 
analysis of over 2000 clinical strains of N.meningitidis serogroup B revealed the 
presence of 300 polymorphic variants of fHbp. These were divided in to three 
separate clades (V1-V3), representing ~65%, ~25% and ~10% prevalence rates in the 
global population (respectively) (Beernink et al., 2007; Murphy et al., 2009). Epitope 
mapping of monoclonal antibodies directed against these three fHbp variants revealed 
distinct epitopes for strain-specific mAbs, and regions of the protein where there was 
no overlap between antibodies directed against each clade (Giuliani et al., 2005; 
Scarselli et al., 2009). It was discovered that the C-terminal β–barrel of the V1 protein 
contained most of the amino acids recognized by V2 and V3 groups. However, 
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incorporation of up to three point mutations on the V1 backbone corresponding to the 
relevant epitopes in V2/V3 groups did not result in broadly neutralising antibodies 
(Scarselli et al., 2011).  
 
Thus, a novel approach that involved the generation of a chimeric fHbp antigen based 
on the V1 group backbone that incorporated whole patches (instead of point 
mutations) of V2 and V3 group antigens was employed through examination of the 
crystal structure. Eleven partially overlapping areas that were large enough to 
incorporate at least one conformational epitope (based on the assumption that 
conformational epitopes of proteins typically range from 900 Å2 -2000 Å2 in surface 
area (Davies and Cohen, 1996; Rubinstein et al., 2008), were incorporated in to the 
V1 fHbp backbone to form chimeric antigens and used separately as vaccines in mice, 
adjuvanted with both aluminium hydroxide and IC31 (a TLR9 agonist recently used 
in clinical trials) (van Dissel et al., 2010).  
 
Serum from immunized mice was used in in vitro bactericidal assays against 7 
N.meningitidis serogroup B strains expressing divergent fHbp sequences. It was 
subsequently observed that only the engineered fHbp variant G1 elicited serum 
antibodies that killed all seven strains expressing divergent fHbp sequences. This is 
illustrated in Fig.7.2. Importantly, chimeric antigenic design also mimicked the native 
protein conformation, as verified by structural comparison to native fHbp protein, and 
was achieved without compromising the original antibody repertoire, structural 
integrity, or ability to bind factor H. 
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The design of Bexsero neatly illustrates a paradigm shift in the field of traditional 
vaccinology, especially in light of the expansion of whole genome sequences of 
multiple strains of pathogenic bacteria. Previously, efforts to develop vaccines against 
antigens with large inter-strain variability (such as Ct) have focused on enhancing 
immunogenicity against the most conserved motifs of the protein. However, these 
strategies have met with limited success (Huang et al., 2005; Wu et al., 2010). A 
possible reason for this may be the fact that natural selection has shaped these regions 
to be weakly immunogenic.  
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For N.meningitidis, antibodies play a dominant role in vaccine-mediated immunity to 
infection, so the identification and incorporation of surface-exposed membrane 
antigens through bioinformatics is likely to yield a large proportion of key adhesins 
and virulence factors that may mediate protection. However, for C.trachomatis, an 
obligate intracellular, the task becomes more complex, as a combination of antibody 
and T cell responses may be required to eradicate persistent infections and achieve 
optimal bacterial clearance. Furthermore, the identification of key intracellularly 
expressed effector proteins is less straightforward. Recent whole genome sequencing 
of 52 clinical C.trachomatis strains from a collection of temporally and 
geographically diverse populations (Harris et al., 2012) will now spur the rational 
selection and design of antigens identified through a combination of in vitro and in 
vivo approaches which assess cell-mediated as well as humoral responses to 
chlamydial components. 
 
Comparison of the 52 different ocular and urogenital strains revealed that the ompA 
gene (encoding MOMP) is an area of extensive recombination that undergoes 
replacement and chimerism, likely mechanisms for evading host immunity (Harris et 
al., 2012). Moreover, 24 recombination events were reconstructed between trachoma 
and LGV biovars, with 14 of these incorporated in to the ompA sequence. The L3 
ompA sequence was very similar to trachoma serotypes Ia, J and K. Furthermore, 
recombination events were found to be much more frequent in the trachoma biovars, 
with a high degree of ompA swapping between strains. Interestingly, 43 
recombination events were detected between ocular and urogenital branches, showing 
no absolute barriers to biovar recombination despite differences in tissue tropism. 
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MOMP comprises ~65% of the chlamydial outer membrane complex, and anti-
MOMP antibodies show strain-specific neutralization in vitro (Caldwell, Kromhout 
and Schachter, 1981; Villeneuve et al., 1994). Furthermore, the recently developed 
multivalent vaccine construct incorporating the VD4 regions and proximal conserved 
segments of serovars D, E and F showed broadly neutralising protection against the 
three urogenital serovars (Olsen et al., 2015). However, this does not encompass 
several ocular and LGV strains that are also highly prevalent worldwide. Thus, 
MOMP represents a highly attractive chlamydial vaccine candidate that, akin to 
N.meningitidis fHbp, may be amenable to rational design if a 3D structural 
description and mapping of surface-exposed epitopes from antigenically diverse 
strains becomes available. This may also be applied to the most variable surface-
exposed Pmps and antigens likely to be presented on MHC Class II and recognized by 
CD4+ T-helper cells (Karunakaran et al., 2015; Nunes et al., 2015), so that a 
multicomponent vaccine may be able to elicit protection and enhanced bacterial 
clearance through both humoral and cellular arms of the immune response.  
 
7.4 Concluding remarks 
The development of a chlamydial vaccine is multi-factorial, and likely to require an 
interdisciplinary approach involving immunologists, geneticists, clinicians, 
epidemiologists and vaccinologists. Our study investigates the preclinical efficacy of 
a novel TLR4 agonist that elicits a robust Th1-biased immune response in vivo, a 
parameter that has been the major focus of Ct vaccine development in preclinical 
models to date. However, the predominant role of T cells is based upon an array of 
often conflicting evidence in different murine models of infection, and very few 
studies focus on the role of antibodies in vaccine-mediated protection in vivo. Indeed, 
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the only robust evidence provided thus far, highlighting the dominant role of 
antibodies in protection against Ct infection in vivo focuses on the antigenically 
variable MOMP antigen (Olsen et al., 2015). 
 
We demonstrate that the highly conserved Ct rPmpD is a potent vaccine immunogen 
in vivo, eliciting high titre serum and cervico-vaginal mucosal antibodies that 
correlate with both resistance to Ct challenge and enhanced bacterial clearance in 
vivo. No correlation with the magnitude of the rPmpD-specific cellular immune 
response to resistance or bacterial load is observed. However, other mechanisms of 
vaccine-induced protection such as synergism between B cells and CD4+ T cells or 
innate immune responses stimulated by rPmpD independent of adjuvant cannot be 
ruled out. To further confirm the role of antibody-mediated protection, future 
experimentation will implement passive transfer of anti-rPmpD serum in vivo to 
assess levels of protection. In corroboration with the recent study by (Olsen et al., 
2015), we propose that future preclinical vaccine studies focus more widely on the 
role of antibody-mediated protection mechanisms in vivo.  
 
As mentioned previously, clinical studies investigating potential correlates of 
protective immunity in human urogenital chlamydial infections are scarce (Batteiger 
et al., 2010; Gottlieb et al., 2010; Kimani et al., 1996). A particularly pertinent 
question in the context of infection within the human population is how much time 
the host requires to clear or control natural infection, and whether genetic differences 
determine the resolution or pathogenesis of chlamydial infection. In several 
preclinical models such as mice and guinea pigs, clearance is typically achieved 
within a few weeks, although in humans, this can range from months to years.  
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Studies documenting Ct infections within the human population are limited. A long-
term study of up to four years in women with untreated Ct cervical infections revealed 
that 54% spontaneously cleared infection within one year, 82% at two years and 95% 
at four years (Molano et al., 2005; Morre et al., 2002). However, without serotyping 
of strains, it is difficult to deduce whether the observed longer-term durations were 
due to unresolved infections or re-infection with different serovars. Typically, studies 
of natural infection and transmission within the human population are both ethically 
and logistically difficult to implement, but are nonetheless an important prerequisite 
to understanding immune correlates of protection and pathogenesis to guide 
development of safe and effective vaccines. 
 
Moreover, a prospective vaccine would need to be readily synchronized with existing 
immunization regimens, in addition to fulfilling regulatory requirements and 
standardized, reproducible good manufacturing practice stipulations. These stringent 
regulatory hurdles generally preclude the straightforward incorporation of whole-cell 
or live-attenuated vaccines, and this is further complicated by the obligate 
intracellular life cycle of Ct and the associated labour-intensive maintenance and costs 
of bacterial culture. Thus, it is likely that a multicomponent subunit vaccine may be 
the most likely future candidate for development.  
 
Ideally, a successful Ct vaccine would achieve sterilizing immunity while offering 
protection against adverse pathological sequelae. To date, no preclinical vaccine study 
conducted in any animal model of infection has demonstrated sterilizing immunity 
following challenge. If this is not achievable, potential strategies may include 
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targeting antigens that are constitutively expressed during the ‘persistent’ phase of 
infection to treat pathology associated with prolonged infection. However, it may be 
difficult to measure the efficacy of such therapeutic vaccines in clinical trials, as 
clinical endpoints of upper genital tract pathology may be subjective and difficult to 
assess practically.  
 
Clinical trials of novel trachoma vaccines may thus prove useful surrogates of 
assessing clinical pathology, and knowledge gained in this setting may possibly be 
translated to the development of urogenital Ct vaccines. It is thought that the 
pathogenesis of urogenital chlamydial infections broadly mimics that of ocular 
infection, with the development of lymphoid follicles at infection sites and the 
subsequent initiation of fibrosis (Darville and Hiltke, 2010; Hu, Holland and Burton, 
2013). Furthermore, ocular and genital serovars of Ct share >99% genetic identity 
(Carlson et al., 2005). Thus, because the natural history of infection, sampling and 
pathology are easier to examine in trachoma patients, it has been proposed that the 
study of trachoma may offer a more feasible means of obtaining more robust and 
geographically diverse, large-scale patient cohort data on links between chlamydial 
disease and the host immune response and genetics, which may subsequently be 
applied to the study of sexually transmitted urogenital infections. 
 
Given the unique Cys-rich, disulphide linked complexity of the Ct COMC, it is likely 
that a key prerequisite to efficacious recombinant subunit vaccine development and 
structure-function relationships will be optimizing the expression and folding of 
antigenic components to mimic native conformation. In light of the phylogenetic 
divergence between Chlamydiales and more well-characterized Proteobacteria such as 
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E.coli, optimum production may necessitate the use of higher order baculovirus or 
mammalian expression systems that are able to more reliably incorporate a much 
wider array of intricate post-translational modifications, with an enhanced repertoire 
of chaperones that may facilitate correct folding of membrane proteins. Indeed, yeast 
and baculovirus expression systems have been used in the synthesis of virus-like 
particles in the manufacture of the licensed Cervarix (GSK) and Gardasil (Merck) 
vaccines (respectively), currently employed as prophylactic vaccines against a subset 
of HPV strains in women (Schiller, Day and Kines, 2010;Schiller and Lowy, 2012). 
 
Crucially, following elucidation of widespread recombination within Ct in the human 
population (Harris et al., 2012), the design of a vaccine that is able to elicit immunity 
against a broad range of strains is perhaps most desirable. One way of achieving this 
may be the rational design of immunogenic and protective antigens such as a 
consensus MOMP or Pmp-based vaccine that may be guided by structural biological 
approaches. More emphasis must also be placed on elucidating the adhesion 
mechanisms of Ct to host cells, in order to identify putative adhesins that may be 
targeted as vaccine antigens. Finally, perhaps most importantly, recent novel advances 
in genetic manipulation of Ct will further help to interrogate the contribution of 
specific chlamydial virulence factors in in vitro and in vivo infection models, which 
will significantly enhance our knowledge of the infection biology of this obligate 
intracellular bacterium, and expedite the development of vaccines and novel 
therapeutics. 
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8. Appendix 
 
I: DNA sequencing of 65kDa pmpD-encoding plasmid from T7 promoter 
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II: DNA sequencing of 65kDa pmpD-encoding plasmid from T7 terminator 
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III: E.coli rare codon usage for 65kDa PmpD fragment 
 
gta gat ctt cat gct gga gga cag tct gta aat gag ctg gta tat gta ggc cct caa gcg gtt tta ttg 
tta gac caa att CGA gat CTA ttc gtt ggg tct aaa gat agt cag gct gaa gga cag tat AGG 
tta att gta gga gat cca agt tct ttc caa gag aaa gat gcg gat act ctt CCC ggt aag gta gag 
caa agt act ttg ttc tca gta acc aat CCC gta gtt ttc caa ggt gtg gac caa cag gat caa gtc tct 
tcc caa ggg tta att tgt agt ttt acg agc agc aac ctt gat tct cct cgt gac gga gaa tct ttt tta ggt 
att gct ttt gtt ggg gat agt agt aag gct gga atc aca tta act gac gtg aaa gct tct ttg tct gga 
gcg gct tta tat tct aca gaa gat ctt atc ttt gaa aag att aag ggt gga ttg gaa ttt gca tca tgt tct 
tct CTA gaa cag ggg gga gct tgt gca gct caa agt att ttg att cat gat tgt caa gga ttg cag gtt 
aaa cac tgt act aca gcc gtg aat gct gag ggg tct agt gcg aat gat cat ctt gga ttt gga gga ggc 
gct ttc ttt gtt acg ggt tct ctt tct gga gag aaa agt ctc tat atg cct gca gga gat atg gta gtt gcg 
aat tgt gat ggg gct ATA tct ttt gaa gga aac agc gcg aac ttt gct aat gga gga gcg att gct 
gcc tct ggg aaa gtg ctt ttt gtc gct aat gat aaa aag act tct ttt ATA gag aac CGA gct ttg 
tct gga gga gcg att gca gcc tct tct gat att gcc ttt caa aac tgc gca gaa CTA gtt ttc aaa ggc 
aat tgt gca att gga aca gag gat aaa ggt tct tta ggt gga ggg gct ATA tct tct CTA ggc acc 
gtt ctt ttg caa ggg aat cac ggg ATA act tgt gat aag aat gag tct gct tcg caa gga ggc gcc 
att ttt ggc aaa aat tgt cag att tct gac aac gag ggg cca gtg gtt ttc AGA gat agt aca gct tgc 
tta gga gga ggc gct att gca gct caa gaa att gtt tct att cag aac aat cag gct ggg att tcc ttc 
gag gga ggt aag gct agt ttc gga gga ggt att gcg tgt gaa tct ttt tct tcc gca ggt ggt gct tct 
gtt tta ggg gct att gat att tcg aag aat tta ggc gcg att tcg ttc tct cgt act tta tgt acg acc tca 
gat tta gga caa atg gag tac cag gga gga gga gct CTA ttt ggt gaa aat att tct ctt tct gag aat 
gct ggt gtg ctc acc ttt aaa gac aac att gtg aag act ttt gct tcg aat ggg aaa att ctg gga gga 
gga gcg att tta gct act ggt aag gtg gaa att acc aat aat tcc gga gga att tct ttt aca gga aat 
gcg AGA gct cca caa gct ctt cca act caa gag gag ttt cct tta ttc agc aaa aaa gaa ggg cgg 
cca ctc tct tca gga tat tct ggg gga gga gcg att tta gga AGA gaa gta gct att ctc cac aac 
gct gca gta gta ttt gag caa aat cgt ttg cag tgc agc gaa gaa gaa gcg aca tta tta ggt tgt tgt 
gga gga ggc gct gtt cat ggg atg gat agc act tcg att gtt ggc aac tct tca gta AGA ttt ggt 
aat aat tac gca atg gga caa gga gtc tca gga gga gct ctt tta tct aaa aca gtg cag tta gct gga 
aat gga agc gtc gat ttt tct CGA aat att gct agt ttg gga gga gga gct ctt caa gct tct gaa gga 
aat tgt gag CTA gtt gat aac ggc tat gtg CTA ttc AGA gat aat CGA ggg AGG gtt tat 
ggg ggt gct att tct tgc tta cgt 
 
Red = rare Arg codons AGG, AGA, CGA  
Green = rare Leu codon CTA  
Blue = rare Ile codon ATA  
Orange = rare Pro codon CCC 
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9. Abbreviations 
4SP 0.4M sucrose-phosphate buffer 
ANOVA analysis of variance 
APC antigen presenting cell 
BCG Bacille-Calmette-Guerin 
BMDC bone-marrow derived dendritic cell 
BSA bovine serum albumin 
CADD Chlamydia protein associating with death domains 
CCR CC chemokine receptor 
CD circular dichroism 
CD(X) cluster of differentiation (X) 
CHO Chinese hamster ovary cell line 
Cm Chlamydia muridarum 
COMC chlamydial outer membrane complex 
Cp Chlamydia pneumoniae 
CPAF chlamydial protease-like activity factor 
CRP cysteine-rich protein 
cSAPs charge switching adjuvant particles 
Ct Chlamydia trachomatis 
CTB Cholera toxin B 
CTL cytotoxic T-lymphocytes 
Cys cysteine 
DAP di-amino palmitoyltransferase 
DAPI 4', 6-diamino-2-phenylindole 
DC dendritic cell 
DDA dimethyl-dioctadecyl-ammonium bromide 
DMEM Dulbecco's modified Eagle's medium 
DMPC Dimyristoyl phosphatidylcholine 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DOPC Dioleoyl phosphatidylcholine 
DPPC Dipalmitoyl phosphatidylcholine 
DPT Diphtheria-pertussis-tetanus (vaccine) 
Dsb disulphide-bonding enzyme 
dsRNA double stranded ribonucleic acid 
DTNB 5,5'-dithiobis[2-nitrobenzoic acid] 
DTT dithiothreitol 
EB elementary body 
EDAC N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide  
EDTA ethylenediaminetetraacetate 
EGFR endothelial growth factor receptor 
ELAM endothelial cell leukocyte adhesion molecule 
ELISA enzyme-linked immunosorbent assay 
ELISpot enzyme-linked immunospot 
FA Freund's adjuvant 
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FCS fetal calf serum 
fHbp Factor H binding protein 
FPLC fast protein liquid chromatography 
FRT female reproductive tract 
GAG glycosaminoglycan 
GAP GTPase activating protein 
GNA Genome-derived Neisserial antigen 
HBM heparin binding motif 
HIV human immunodeficiency virus 
HPV human pappilomavirus 
HRP horseradish peroxidase 
HUVEC lymphogranuloma venereum 
i.n. intranasal 
i.u. intrauterine 
IDRI Infectious Disease Research Institute 
IFA Incomplete Freund's adjuvant 
IFN interferon 
IFU inclusion forming units 
Ig immunoglobulin 
IL interleukin 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
IRF interferon regulatory factor 
IRG interferon regulated gene 
LAL Limulus Amebocyte Lysate 
LDLN local draining lymph node 
LGV lymphogranuloma venereum 
LPS lipopolysaccharide 
MALDI-MS matrix-assisted laser desorption ionization mass spectrometry 
MALT mucosa-associated lymphoid tissue 
MD2 myeloid differentiation factor 2 
MHC major histocompatibility complex 
MIP macrophage inflammatory protein 
MLD membrane localization domain 
MOMP major outer membrane protein 
MPL monophosphoryl lipid 
MSM men who have sex with men 
Mtb Mycobacterium tuberculosis 
MYPT myosin light chain phosphatase 
N-CAM1 Neural cell adhesion molecule 1 
NLS nuclear localization sequence 
OMV outer-membrane vesicle 
pAb polyclonal antibody 
Pam3CSK4 N-palmitoyl-S-[2,3-bis (palmitoyl)-(2RS)-propyl]-(R)cysteinyl-alanyl-glycine 
PAMP pathogen associated mmolecular pattern 
PBMC peripheral blood mononuclear cell 
PBS phosphate buffered saline 
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PCR polymerase chain reaction 
PDB Protein Data Bank 
PDI protein disulphide isomerase 
PDI polydispersity index 
Pet plasmid encoded toxin 
PID pelvic inflammatory disease 
Pmp polymorphic membrane protein 
PMSF phenylmethylsulfonyl fluoride 
PRR pathogen recognition receptor 
qPCR quantitative polymerase chain reaction 
RB reticulate body 
RGD arginine-glycine-aspartic acid 
RNA ribonucleic acid 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute 
s.c. subcutaneous 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
sIgA secretory immunoglobulin A 
SIV simian immunodeficiency virus 
SLA second-generation lipid adjuvant 
SLT Shiga-like toxin 
SNP single nucleotide polymorphism 
SPATE serine protease autotransporter of the Enterobacteriaceae 
ssRNA single-stranded ribonucleic acid 
SuV subunit vaccine 
SVV split viral vaccine 
T3SS type three secretion system 
T5AT type five autotransporter 
TB tuberculosis 
TCEP tris(2-carboxyethyl)phosphine 
TCR T-cell receptor 
tg transgenic 
Th T-helper cell 
TLR Toll-like receptor 
TMB 3,3',5,5'-tetramethylbenzidine 
TNF tumour necrosis factor 
Treg regulatory T-cell 
TRIF TIR-domain-containing adapter-inducing interferon-β  
UVEB UV-inactivated elementary bodies 
VCG Vibrio cholerae ghost 
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